var title_f24_62_25568="AIP ERCP";
var content_f24_62_25568=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    Autoimmune pancreatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic retrograde cholangiopancreatography in a patient with autoimmune pancreatitis. The left panel shows a stricture in the common bile duct due to the surrounding enlarged pancreas (long arrow). The right panel shows a stent that has been inserted across the narrowed segment (short arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter Banks, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_62_25568=[""].join("\n");
var outline_f24_62_25568=null;
var title_f24_62_25569="Swan Ganz lung zones";
var content_f24_62_25569=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Effect of lung zones on pulmonary artery catheter monitoring",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lung can be divided into three physiologic zones, based on the relationship of alveolar pressure (P",
"    <sub>",
"     A",
"    </sub>",
"    ), mean pulmonary artery pressure (P",
"    <sub>",
"     a",
"    </sub>",
"    ), and pulmonary capillary wedge pressure (P",
"    <sub>",
"     c",
"    </sub>",
"    ). Pulmonary capillary wedge pressure approximates left atrial pressure (P",
"    <sub>",
"     LA",
"    </sub>",
"    ) under zone three conditions, when vascular pressures exceed alveolar pressure. If the pulmonary artery catheter is wedged under non-zone three conditions, alveolar pressure swings interfere with accurate assessment of pulmonary capillary wedge pressure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_62_25569=[""].join("\n");
var outline_f24_62_25569=null;
var title_f24_62_25570="Calculator: Cardiac Output";
var content_f24_62_25570=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"CardiacOutput_form\" name=\"CardiacOutput_form\" onkeydown=\"clrResults();\" onkeyup=\"CardiacOutput_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Cardiac Output",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         CaO2 = ( Hgb * 13.4 * O2Sat / 100 ) + ( PaO2 * 0.031 )",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         CvO2 = ( Hgb * 13.4 * O2vSat / 100 ) + ( PvO2 * 0.031 )",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         CO = O2Consumption / (CaO2 - CvO2)",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"      <tr>",
"       <td align=\"right\" width=\"50%\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Input:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             O2 Consumption",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"O2_Consumption_param\" onblur=\"CardiacOutput_fx(); minMaxCheck();\" onchange=\"CardiacOutput_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"O2_Consumption_unit\" onchange=\"CardiacOutput_fx();\" style=\"width:105px;\">",
"             <option value=\"1000|0|L/min\">",
"              L/min",
"             </option>",
"             <option value=\"60000|0|L/sec\">",
"              L/sec",
"             </option>",
"             <option value=\"0.01666666667|0|mL/hr\">",
"              mL/hr",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|mL/min\">",
"              mL/min",
"             </option>",
"             <option value=\"60|0|mL/sec\">",
"              mL/sec",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Hgb",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Hgb_param\" onblur=\"CardiacOutput_fx(); minMaxCheck();\" onchange=\"CardiacOutput_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Hgb_unit\" onchange=\"CardiacOutput_fx();\" style=\"width:105px;\">",
"             <option value=\"0.1|0|gm/L\">",
"              gm/L",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|gm/dL\">",
"              gm/dL",
"             </option>",
"             <option value=\"1e-06|0|mcg/dL\">",
"              mcg/dL",
"             </option>",
"             <option value=\"0.001|0|mg%\">",
"              mg%",
"             </option>",
"             <option value=\"0.001|0|mg/dL\">",
"              mg/dL",
"             </option>",
"             <option value=\"0.1|0|mg/mL\">",
"              mg/mL",
"             </option>",
"             <option value=\"1e-07|0|ng/mL\">",
"              ng/mL",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             O2Sat",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"O2Sat_param\" onblur=\"CardiacOutput_fx(); minMaxCheck();\" onchange=\"CardiacOutput_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"O2Sat_unit\" onchange=\"CardiacOutput_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|%\">",
"              %",
"             </option>",
"             <option value=\"100|0|fraction\">",
"              fraction",
"             </option>",
"             <option value=\"100|0|ratio\">",
"              ratio",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             PaO2",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"PaO2_param\" onblur=\"CardiacOutput_fx(); minMaxCheck();\" onchange=\"CardiacOutput_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"PaO2_unit\" onchange=\"CardiacOutput_fx();\" style=\"width:105px;\">",
"             <option value=\"0.00750063755419211|0|Pascal\">",
"              Pascal",
"             </option>",
"             <option value=\"760.002100178515|0|atm\">",
"              atm",
"             </option>",
"             <option value=\"750.063755419211|0|bar\">",
"              bar",
"             </option>",
"             <option value=\"0.735561538478802|0|cmH2O\">",
"              cmH2O",
"             </option>",
"             <option value=\"10|0|cmHg\">",
"              cmHg",
"             </option>",
"             <option value=\"22.4199156928339|0|ftH2O\">",
"              ftH2O",
"             </option>",
"             <option value=\"0.735561538478802|0|gm/sqcm\">",
"              gm/sqcm",
"             </option>",
"             <option value=\"1.86832630773616|0|inH2O\">",
"              inH2O",
"             </option>",
"             <option value=\"25.4000840071406|0|inHg\">",
"              inHg",
"             </option>",
"             <option value=\"7.50063755419211|0|kPa\">",
"              kPa",
"             </option>",
"             <option value=\"0.750063755419211|0|mbar\">",
"              mbar",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|mmHg\">",
"              mmHg",
"             </option>",
"             <option value=\"51.7150957831416|0|psi\">",
"              psi",
"             </option>",
"             <option value=\"1|0|torr\">",
"              torr",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             O2vSat",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"O2vSat_param\" onblur=\"CardiacOutput_fx(); minMaxCheck();\" onchange=\"CardiacOutput_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"O2vSat_unit\" onchange=\"CardiacOutput_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|%\">",
"              %",
"             </option>",
"             <option value=\"100|0|fraction\">",
"              fraction",
"             </option>",
"             <option value=\"100|0|ratio\">",
"              ratio",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             PvO2",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"PvO2_param\" onblur=\"CardiacOutput_fx(); minMaxCheck();\" onchange=\"CardiacOutput_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"PvO2_unit\" onchange=\"CardiacOutput_fx();\" style=\"width:105px;\">",
"             <option value=\"0.00750063755419211|0|Pascal\">",
"              Pascal",
"             </option>",
"             <option value=\"760.002100178515|0|atm\">",
"              atm",
"             </option>",
"             <option value=\"750.063755419211|0|bar\">",
"              bar",
"             </option>",
"             <option value=\"0.735561538478802|0|cmH2O\">",
"              cmH2O",
"             </option>",
"             <option value=\"10|0|cmHg\">",
"              cmHg",
"             </option>",
"             <option value=\"22.4199156928339|0|ftH2O\">",
"              ftH2O",
"             </option>",
"             <option value=\"0.735561538478802|0|gm/sqcm\">",
"              gm/sqcm",
"             </option>",
"             <option value=\"1.86832630773616|0|inH2O\">",
"              inH2O",
"             </option>",
"             <option value=\"25.4000840071406|0|inHg\">",
"              inHg",
"             </option>",
"             <option value=\"7.50063755419211|0|kPa\">",
"              kPa",
"             </option>",
"             <option value=\"0.750063755419211|0|mbar\">",
"              mbar",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|mmHg\">",
"              mmHg",
"             </option>",
"             <option value=\"51.7150957831416|0|psi\">",
"              psi",
"             </option>",
"             <option value=\"1|0|torr\">",
"              torr",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Results:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             CaO2",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"CaO2_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <select class=\"medCalcFontSelect\" name=\"CaO2_unit\" onchange=\"CardiacOutput_fx();\" style=\"width:105px;\">",
"              <option value=\"10|0|Vol%\">",
"               Vol%",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mL/L\">",
"               mL/L",
"              </option>",
"              <option value=\"10|0|mL/dL\">",
"               mL/dL",
"              </option>",
"             </select>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             CvO2",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"CvO2_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <select class=\"medCalcFontSelect\" name=\"CvO2_unit\" onchange=\"CardiacOutput_fx();\" style=\"width:105px;\">",
"              <option value=\"10|0|Vol%\">",
"               Vol%",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mL/L\">",
"               mL/L",
"              </option>",
"              <option value=\"10|0|mL/dL\">",
"               mL/dL",
"              </option>",
"             </select>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             CO",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"CO_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <select class=\"medCalcFontSelect\" name=\"CO_unit\" onchange=\"CardiacOutput_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|L/min\">",
"               L/min",
"              </option>",
"              <option value=\"60|0|L/sec\">",
"               L/sec",
"              </option>",
"              <option value=\"1.666666667e-05|0|mL/hr\">",
"               mL/hr",
"              </option>",
"              <option value=\"0.001|0|mL/min\">",
"               mL/min",
"              </option>",
"              <option value=\"0.06|0|mL/sec\">",
"               mL/sec",
"              </option>",
"             </select>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"3\">",
"            &nbsp;",
"            <br/>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"center\" colspan=\"3\">",
"            <span class=\"medCalcFontOneBold\">",
"             Decimal Precision:",
"            </span>",
"            <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"CardiacOutput_fx();\">",
"             <option>",
"              0",
"             </option>",
"             <option>",
"              1",
"             </option>",
"             <option selected=\"selected\">",
"              2",
"             </option>",
"             <option>",
"              3",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontOne\">",
"     In this calculation, arterial oxygen content",
"     <b>",
"      CaO2",
"     </b>",
"     and venous oxygen content",
"     <b>",
"      CvO2",
"     </b>",
"     are",
"calculated by using both oxygen saturation and oxygen tension of both blood samples.",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <b>",
"      O2 Consumption",
"     </b>",
"     may be determined by",
"    </span>",
"    <ul class=\"medCalcFontOne\">",
"     <li>",
"      Separate calculation",
"     </li>",
"     <li>",
"      Machine measurement",
"     </li>",
"     <li>",
"      Estimation/assumption of approximately 250cc/min in a healthy person",
"     </li>",
"    </ul>",
"   </form>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_62_25570=[" /* <![CDATA[ */",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function CardiacOutput_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.CardiacOutput_form){",
"",
"",
"doCalc = true;",
"if (O2_Consumption_param.value.indexOf(',') >= 0){ O2_Consumption_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(O2_Consumption_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = O2_Consumption_unit.options[O2_Consumption_unit.selectedIndex].value.split('|');",
"O2_Consumption = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Hgb_param.value.indexOf(',') >= 0){ Hgb_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Hgb_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Hgb_unit.options[Hgb_unit.selectedIndex].value.split('|');",
"Hgb = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (O2Sat_param.value.indexOf(',') >= 0){ O2Sat_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(O2Sat_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = O2Sat_unit.options[O2Sat_unit.selectedIndex].value.split('|');",
"O2Sat = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (PaO2_param.value.indexOf(',') >= 0){ PaO2_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(PaO2_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = PaO2_unit.options[PaO2_unit.selectedIndex].value.split('|');",
"PaO2 = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (O2vSat_param.value.indexOf(',') >= 0){ O2vSat_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(O2vSat_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = O2vSat_unit.options[O2vSat_unit.selectedIndex].value.split('|');",
"O2vSat = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (PvO2_param.value.indexOf(',') >= 0){ PvO2_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(PvO2_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = PvO2_unit.options[PvO2_unit.selectedIndex].value.split('|');",
"PvO2 = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"CaO2 =  ( Hgb * 13.4 * O2Sat / 100 ) + ( PaO2 * 0.031 );",
"",
"unit_parts = CaO2_unit.options[CaO2_unit.selectedIndex].value.split('|');",
"if (doCalc) CaO2_param.value = fixDP((CaO2 - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"CvO2 =  ( Hgb * 13.4 * O2vSat / 100 ) + ( PvO2 * 0.031 );",
"",
"unit_parts = CvO2_unit.options[CvO2_unit.selectedIndex].value.split('|');",
"if (doCalc) CvO2_param.value = fixDP((CvO2 - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"CO =  O2_Consumption / (CaO2 - CvO2);",
"",
"unit_parts = CO_unit.options[CO_unit.selectedIndex].value.split('|');",
"if (doCalc) CO_param.value = fixDP((CO - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.CardiacOutput_form){",
"",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.CardiacOutput_form){",
"",
"CaO2_param.value = '';",
"CvO2_param.value = '';",
"CO_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"/* ]]> */"].join("\n");
var outline_f24_62_25570=null;
var title_f24_62_25571="Protamine sulfate: Patient drug information";
var content_f24_62_25571=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Protamine sulfate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/9/11413?source=see_link\">",
"     see \"Protamine sulfate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/18/18724?source=see_link\">",
"     see \"Protamine sulfate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10204221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700213",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10204244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2749141",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat heparin overdose.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10204222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2749139",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to protamine, seafood, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10204224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10204246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10204226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10204223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695944",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10204227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10204228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15561 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-199.231.185.123-23AA9155C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_62_25571=[""].join("\n");
var outline_f24_62_25571=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10204221\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10204244\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10204222\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10204224\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10204246\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10204226\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10204223\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10204227\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10204228\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/9/11413?source=related_link\">",
"      Protamine sulfate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/18/18724?source=related_link\">",
"      Protamine sulfate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_62_25572="Indications for splenectomy in Felty's syndrome";
var content_f24_62_25572=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Indications for splenectomy in Felty's syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/62/25572/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/62/25572/contributors\">",
"     Jonathan Kay, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/62/25572/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/62/25572/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/62/25572/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/62/25572/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/62/25572/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Felty&rsquo;s syndrome (FS) is an uncommon but severe subset of seropositive rheumatoid arthritis (RA) complicated by granulocytopenia and splenomegaly. The granulocytopenia in FS may improve when RA is treated with disease-modifying antirheumatic drugs (DMARDs), presumably because these drugs reverse underlying abnormalities in the immune and reticuloendothelial systems. Other therapies for FS increase circulating neutrophils by mechanisms which are not disease specific.",
"   </p>",
"   <p>",
"    The goal in the treatment of granulocytopenia in FS is to prevent recurrent infections and to facilitate the resolution of ongoing bacterial infections. This may be accomplished by interventions that raise the granulocyte count, including the use of DMARDs, growth factors, other medications, and by splenectomy, although infections may also result from granulocyte dysfunction and other disease-related factors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25572/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will discuss the role of splenectomy in the treatment of FS. The clinical manifestations and diagnosis of FS and drug therapy for this disorder are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4247?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Felty's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18695?source=see_link\">",
"     \"Drug therapy in Felty's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179494842\">",
"    <span class=\"h1\">",
"     RATIONALE FOR SPLENECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenectomy has been an important component of therapy in Felty&rsquo;s syndrome (FS) for many years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25572/abstract/5\">",
"     5",
"    </a>",
"    ]. The enlarged spleen in this disorder appears to play an important pathogenetic role in the development of granulocytopenia. How this occurs is incompletely understood as both granulocyte sequestration within the spleen and production of antibodies or other factors that inhibit granulopoiesis may contribute [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25572/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4247?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Felty's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The old observation that splenic arterial blood contains a far greater number of granulocytes than splenic venous blood is compatible with an important role for sequestration [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25572/abstract/6\">",
"     6",
"    </a>",
"    ]. However, subsequent studies suggest that other factors play a more significant role in the pathogenesis of granulocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25572/abstract/7\">",
"     7",
"    </a>",
"    ]. Regardless of the mechanism, splenectomy leads to an increase in granulocytes in the peripheral blood within minutes or hours in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25572/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For many years, splenectomy was the principal therapy for FS. However, this modality has now been replaced by medications and biological agents, and the indications for splenectomy are more limited. The hospitalization rate for splenectomy was 71 percent lower in 1998 to 2001 than in 1983 to 1987 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25572/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18695?source=see_link\">",
"     \"Drug therapy in Felty's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6734301\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR SPLENECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main setting in which splenectomy should be considered is in the patient with severe granulocytopenia",
"    <span class=\"nowrap\">",
"     (&lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    and recurrent infections despite therapy with drugs and biologic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25572/abstract/10\">",
"     10",
"    </a>",
"    ]. Even in this group, however, the benefit of splenectomy is unproven. As a result, every effort should be made to reduce the susceptibility to infection before resorting to surgery. These measures might include reduction in steroid dose, local treatment of skin ulcerations, and physical therapy to avoid prolonged immobility.",
"   </p>",
"   <p>",
"    Survival is reduced in severe rheumatoid arthritis, including patients with FS. However, the main cause of death is cardiovascular disease rather than infection. Neither infection nor splenectomy change long-term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25572/abstract/11\">",
"     11",
"    </a>",
"    ]. This observation, plus the unpredictable effect of splenectomy and the availability of medical therapies, has limited the indications for this procedure. Prophylactic splenectomy cannot be justified in patients who do not become infected, even in the presence of marked granulocytopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFECTS OF SPLENECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenectomy is followed by a short-term increase in the absolute granulocyte count, often to the normal range, in more than 80 percent of patients with FS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25572/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. The granulocytopenia recurs in at least one-quarter of cases, but the granulocyte count usually remains above the pre-splenectomy level.",
"   </p>",
"   <p>",
"    The degree of granulocytopenia appears to be an important determinant of risk as there is an increased frequency of infection when the absolute granulocyte count is below",
"    <span class=\"nowrap\">",
"     1000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25572/abstract/10\">",
"     10",
"    </a>",
"    ]. However, the value of splenectomy in preventing serious infection and in improving survival is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25572/abstract/5\">",
"     5",
"    </a>",
"    ]. There have been no randomized trials, and this issue may never be resolved satisfactorily. Most reports conclude that patients without recurrent infection prior to splenectomy are likely to remain free of infection afterward [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25572/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. Furthermore, ongoing infections may resolve dramatically in the postoperative period as the granulocyte count rises [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25572/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, patients who have experienced recurrent infections prior to surgery usually continue to do so after splenectomy, even though the hematologic response has been adequate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25572/abstract/2,5,11,12\">",
"     2,5,11,12",
"    </a>",
"    ]. This observation indicates that factors in addition to granulocytopenia play an important role in the pathogenesis of infection. As an example, several granulocyte functions are impaired, including chemotaxis, phagocytosis, and intracellular killing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25572/abstract/3,10,13\">",
"     3,10,13",
"    </a>",
"    ]. Severe disability, skin ulcers, glucocorticoid therapy, and hypocomplementemia are other risk factors for infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Thrombocytopenia and anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenectomy has beneficial effects in FS other than resolution of granulocytopenia. Concurrent thrombocytopenia usually improves after splenectomy, but it is seldom severe enough in FS to result in spontaneous bleeding. There may also be some improvement in anemia; the degree of improvement is determined by the degree to which red cell survival has been shortened by splenomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25572/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179495323\">",
"    <span class=\"h2\">",
"     Nonhematologic changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three nonhematologic problems also may improve after splenectomy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improvement in synovitis has been observed, but it is often temporary and does not occur in most patients [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25572/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Healing of chronic, refractory leg ulcers may occur after splenectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25572/abstract/1,8\">",
"       1,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Esophageal varices and portal hypertension, which occur infrequently in patients with FS in the setting of both splenomegaly and hepatic nodular regenerative hyperplasia, may resolve after splenectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25572/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the role of splenectomy is difficult to evaluate in this setting, since the course of these problems is variable and since other therapies have often been given concurrently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Large granular lymphocyte syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large granular lymphocyte (LGL) syndrome, a disorder associated with the clonal expansion of atypical lymphocytes, is immunogenetically and clinically related to FS. Although information on the response to splenectomy in this group of patients is limited, it has been reported that failures may be more likely than in FS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25572/abstract/16\">",
"     16",
"    </a>",
"    ]; the number of LGL in peripheral blood may increase after splenectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5095?source=see_link\">",
"     \"Large granular lymphocyte leukemia in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical morbidity and mortality following splenectomy may be increased in this group of immunosuppressed, disabled patients, but the issue has not been specifically studied. The risk is probably higher if splenectomy is performed in the presence of serious systemic infection or extraarticular manifestations of rheumatoid arthritis, such as vasculitis. Splenectomy for any reason is also associated with a long-term increase in susceptibility to bacterial infection.",
"   </p>",
"   <p>",
"    Laparoscopic splenectomy may reduce the risk of intraoperative and postoperative complications, as appears to be the case when this technique has been employed to treat immune thrombocytopenia (ITP); however, an insufficient number of patients with FS have been reported to adequately assess this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25572/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment with a granulopoietic growth factor such as G-CSF may lead to short-term improvement in granulocytopenia and may facilitate control of perioperative infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18695?source=see_link\">",
"     \"Drug therapy in Felty's syndrome\"",
"    </a>",
"    .) In addition, an alternative to splenectomy, partial splenic embolization, has been proposed for high-risk patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25572/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179494735\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In FS, the enlarged spleen appears have an important but only partially understood role in the pathogenesis of granulocytopenia and related risk of infection. Splenectomy usually leads to a rapid increase in granulocytes in the peripheral blood within minutes or hours. However, neither infection nor splenectomy associated with FS change long-term survival, the effects of splenectomy are difficult to predict, and randomized trials have not been performed to document its benefit. (See",
"      <a class=\"local\" href=\"#H179494842\">",
"       'Rationale for splenectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6734301\">",
"       'Indications for splenectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main setting in which splenectomy should be considered is in the patient with severe granulocytopenia",
"      <span class=\"nowrap\">",
"       (&lt;1000/mm",
"       <sup>",
"        3",
"       </sup>",
"       )",
"      </span>",
"      and recurrent infections despite therapy with drugs and biologic agents and despite other measures to reduce risk of infection. Prophylactic splenectomy is not justified in patients who do not become infected, even in the presence of marked granulocytopenia. (See",
"      <a class=\"local\" href=\"#H6734301\">",
"       'Indications for splenectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Splenectomy is followed by a short-term increase in the absolute granulocyte count in more than 80 percent of patients with FS, but granulocytopenia recurs in at least one-quarter of cases, usually above the pre-splenectomy level. Thrombocytopenia and anemia also typically improve, and some patients experience improvement in chronic leg ulcers and in synovitis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Effects of splenectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Thrombocytopenia and anemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a potential risk of increased surgical morbidity and mortality following splenectomy for FS, particularly in patients with systemic infection, because of the degree of immunosuppression and other comorbidities associated with severe RA and its treatment. Additionally, splenectomy for any reason is also associated with a long-term increase in susceptibility to bacterial infection. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53011506\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editors of UpToDate, Inc. would like to acknowledge Robert S Pinals, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25572/abstract/1\">",
"      Laszlo J, Jones R, Silberman HR, Banks PM. Splenectomy for Felty's syndrome. Clinicopathological study of 27 patients. Arch Intern Med 1978; 138:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25572/abstract/2\">",
"      Ruderman M, Miller LM, Pinals RS. Clinical and serologic observations on 27 patients with Felty's syndrome. Arthritis Rheum 1968; 11:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25572/abstract/3\">",
"      Breedveld FC, Fibbe WE, Cats A. Neutropenia and infections in Felty's syndrome. Br J Rheumatol 1988; 27:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25572/abstract/4\">",
"      Dillon AM, Luthra HS, Conn DL, Ferguson RH. Parenteral gold therapy in the Felty syndrome. Experience with 20 patients. Medicine (Baltimore) 1986; 65:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25572/abstract/5\">",
"      Goldberg J, Pinals RS. Felty syndrome. Semin Arthritis Rheum 1980; 10:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25572/abstract/6\">",
"      WRIGHT CS, DOAN CA, BOURONCLE BA, ZOLLINGER RM. Direct splenic arterial and venous blood studies in the hypersplenic syndromes before and after epinephrine. Blood 1951; 6:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25572/abstract/7\">",
"      Burks EJ, Loughran TP Jr. Pathogenesis of neutropenia in large granular lymphocyte leukemia and Felty syndrome. Blood Rev 2006; 20:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25572/abstract/8\">",
"      DE GRUCHY GC, LANGLEY GR. Felty's syndrome. Australas Ann Med 1961; 10:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25572/abstract/9\">",
"      Ward MM. Decreases in rates of hospitalizations for manifestations of severe rheumatoid arthritis, 1983-2001. Arthritis Rheum 2004; 50:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25572/abstract/10\">",
"      Breedveld FC, Fibbe WE, Hermans J, et al. Factors influencing the incidence of infections in Felty's syndrome. Arch Intern Med 1987; 147:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25572/abstract/11\">",
"      Sibley JT, Haga M, Visram DA, Mitchell DM. The clinical course of Felty's syndrome compared to matched controls. J Rheumatol 1991; 18:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25572/abstract/12\">",
"      Campion G, Maddison PJ, Goulding N, et al. The Felty syndrome: a case-matched study of clinical manifestations and outcome, serologic features, and immunogenetic associations. Medicine (Baltimore) 1990; 69:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25572/abstract/13\">",
"      Breedveld FC, van den Barselaar MT, Leigh PC, et al. Phagocytosis and intracellular killing by polymorphonuclear cells from patients with rheumatoid arthritis and Felty's syndrome. Arthritis Rheum 1985; 28:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25572/abstract/14\">",
"      Khan MA, Kushner I. Improvement of rheumatoid arthritis following splenectomy for Felty syndrome. JAMA 1977; 237:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25572/abstract/15\">",
"      Stock H, Kadry Z, Smith JP. Surgical management of portal hypertension in Felty's syndrome: A case report and literature review. J Hepatol 2009; 50:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25572/abstract/16\">",
"      Loughran TP Jr, Starkebaum G, Clark E, et al. Evaluation of splenectomy in large granular lymphocyte leukaemia. Br J Haematol 1987; 67:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25572/abstract/17\">",
"      Rosen M, Brody F, Walsh RM, et al. Outcome of laparoscopic splenectomy based on hematologic indication. Surg Endosc 2002; 16:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25572/abstract/18\">",
"      Nakamura H, Ohishi A, Asano K, et al. Partial splenic embolization for Felty's syndrome: a 10-year followup. J Rheumatol 1994; 21:1964.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7485 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-61.234.146.186-EA4EE1DDAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_62_25572=[""].join("\n");
var outline_f24_62_25572=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H179494735\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179494842\">",
"      RATIONALE FOR SPLENECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6734301\">",
"      INDICATIONS FOR SPLENECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFECTS OF SPLENECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Thrombocytopenia and anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179495323\">",
"      Nonhematologic changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Large granular lymphocyte syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179494735\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H53011506\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4247?source=related_link\">",
"      Clinical manifestations and diagnosis of Felty's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18695?source=related_link\">",
"      Drug therapy in Felty's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5095?source=related_link\">",
"      Large granular lymphocyte leukemia in rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_62_25573="Keratoderma blennorrhagicum";
var content_f24_62_25573=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Keratoderma blennorrhagicum in reactive arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDw2Tc7ooGRn5hmrVsGjkJUFs8Efj0qC2iMTEu2d2CF9ParqsFdn2kqOo6Yri8kaXLNtN85QfL2OQKt23l+a0cgJJ4yPSqJhaSHzMEc7sjrVjDIUdNxjx8wx+tNJWF5GhZQSRWzbGUIWzhxk4ovoPMtPLaQiRj/AHu3rUJuTAxVUYxk7lAHT2q1DKZws20uc8Ajpjtis5IrRl/TNqoPOJ3qNmSeM1On7m8YQ/uon698EdfzqvYCRY1PlhySWb1+lRRXkEt7HArfMrF2ycD8RTs7F3S0NF1hlmGNzcHewOOKPJEVwqyOcA5yVzhe3FEe9DIXJA5yFPX2wKtWEZmIdoyAwA46ml0sWt9SwigbHaNTk/54psp8ybap8wJzkfKMdqmnMhjeOLAVSSeOT+NVIZJhIRlQCDnA5A9M1jJWZ1RehPFIsaASKxHO5CcE+n4VI8jbQjgooGQisMA+/wBKpoVWQKzfVsc/iaS2KSv84byx134x1oi9SraCSSI4dWQlMZXcep9KjEYkQxESBcFuoUH/AOtVwuhuCQoWLgjC+nalRDdzkmM884b7oH9KpLUzkZ0UKqvy8hv4s9/TFWVgkA5UhBj5c5OfWrf2VpGCpGuwcvIy4Htj29qmitfmYZdjj5pegz6gU+TsCZVWNjIAAI9oyN3GPekdN5ZUU7QPvkd/WtEWUxIfZthHTzTkuaRoH3j98wbssa8VdrbkvUotb5QAEMSMZA5NRPZ5Ktn5znC5FaBjCBkLSO5+9700QGNSZv3YH3R1J/Cm12FYzNhjYjYCTxytMLLIgww655PT8a1hFvBBUKmOCrfe+tVbizUE7IwM8cHp9RU2JaMq4iB3Pw4bjcKqzQFMMjArnOMfw1pvAUKhAVwO/AqC4hIZiMMOx60loTJGFcgkHHAJ54qgwIUjlj2bHStmZlHVsk9Djp71n3JXYWIx29cmqTMJIgjkZduVbjqQaewywMaEk8nihVw2AQqnkMak5U7Wfk9s1dyALArtKAA9/wClJuOBgA+nPUVNgOGfjI7VE0YkYED5sZAPGKluwIaGGORjPSps7UHAx3BP9KNgTc2489KAEfGFBwOex/CknYpagVRo9xA4/Sk+43zHg9zTggzkN8vcYpDACC3OB0z2q4tEtNEJB+bnrxQd8Z+78uKcxDdAVOfzqUIGbhWBJPWtIzcNUzOUFLdEfmI/Q9ulRvyMd+lPeHChlxk8n2p9k8QukFxkDPB7V20q8anuy0OWdFx1Rr6FpJJEknJIzz2rZu40toizED0q1atEkIKsOmdx6VzXiXUxLM0cRyo46da9O0acdDl3Zi6rcGeVgp4zxjsKrQw55OMfSnpHluQT61HeXS20RAx61yOXU0XZEd9dLAhAPIrjNZ1JpXIRuvvS6vqjSuyo2fesQkk5JrCc76HVSpW1YE5OaKAM1ctLFp2HXFZG7divBC8zBVFb2m6STgspxWlpOj7MNiuihtljUL/OocjGU77Gdb2KxIuFPSpvLA5I5q7tAzmojgntU3M7lbAop+3JOVNAAJ9Ka3Azf3pbKoHHByOKnsnknCfaFCR5LBeufrUzlfKMcW/zOASOoqxGnAwWCqMba5rncyeAbMMBlT1A7e9WpUSSMMW2NjBAB598VVtnjmnkVl2Mo/i44p21hdxxLypGWx6elLqNIvQxOY1D43rzk8cVb8jzCu1gDgZ5/Oq6hUb5WyDwV64q5aO0blQNsRPDgZ/A03ruVYrJbXk0m4SmNIzxGD1Hrmrw022hjGcFnAyzD5s/5xU1rIjyyiRAwyMMTj8P61ozRYbO3zVbuxzg+1SzVRRmQI9lhZF/dyfxeuK24EkwxXJ9OeAPYVlTK8k0Qig3fNnnJA45q7AZrWRQjCSVgOCeFH0qUVHctBH3MkDbgp3MFGPwqJn8qH5nGwjJPAye9Mt5J5HZn+fB25zwT61ZFuAGZCpIXA+bg460nG5vEqTTQlNwjd5HblsdvWolDKTGcYJzjHT8KnMCo+5toGMlVPNWRFM6bTGVDc9McevNQo2LQyKKSbCRMAF/i7VaWIbChysYPJ3cufWrFna+YPKRlAQZLHofyqwIEhQAKTKTyQOn0rRImSuU5YhCmJpUUsOEB5xUsbmSAMkaRoOAd2457D2NTpaRSFXmQNIf4Cev1NOl+XYqHYin7sYHSrS7CK0COsYDKzOw4DN1b1PFWYFklby4VUE/xD9Rk1LDaAsJ75mSJuQFXl/p7e9SSBHddkWyP+FEb9T601EVrldoFj37GjZhhWkx8oz2B7/WopbfZjzcuxGRgA1rRxo5R5VYN/CG7/hinOrbSRC0S9iCNxNUDiY4hbYu/aFY8cYx+FV7kOxISPco4+7tz+Nbf2eKV9qRuHA5fIbB9KoTorbogCqjqWB4/LqahglYy7iNnjIUx5X5TGRwD7GsidAjunBlU8ELjiuhutjDy4Pkfbu3bsgY9fesie3LR5TGxTyzH5vbH+NQ9CeW5zt6obMihSuOWAwV9sVmuDkqqZIHUnj/APXWzfQKu0t8qEAsnTB7/Wsu42xZiY5QnJXuKRhNNFIKzHPykD72alUoH25BA5BNOIBViTgHoAOtSwRIGBYAA9QO31qk+5gxqqjjIAA64A5NSGNNmdp4HHNKVdNy8sqnkjt70bsksNmQMe1VZMSImVd4VywXsT3qSRdpGAScYXHekw0pBjyxA+Y0sYymCpGf7vGazLiDoSy84/2QaVXcnBOAOeOppAm6MsGXOeeual2Kr7nb5sZB7GjYorOrbiCoLOeDUmPL27lY+oz0pSjODtYZxnJNR8sN2Rx2xVJisKsB3MFcbsdP6U2a3aQgHaQeCM8ip2xGwBJbdzyeRUKMDkAlc8+mapMloI7i5t4WSInZ0IJzVLksWerzbWUfMwPtUMiApyCfeuiniJR0exzzoRkZ97drBG3QEelcXrGqNKxRGrq9a0o3cDGCUq49OlcHf2FzZSFbmNh/tdjXS6qnsZ06PK7sqkknJ5NFAGTgVs6PpT3LqWHBP6Vm3Y3bSINKsWnlBKnH0rt9M01URcjBPc1f0vR0hThRWgwEeUA6Vm5Poc0p3ZAsQjUbccVC5APHFPklHQVVdsmkSOlYE8VF0pcHNSJASRwaGMRITIRkHFSSQFFzitXT7LfjIPFTahbhE544qoaslnPrGuxsH9asKisOEUoAM4Peq4Lfd4PQ8jge1WCEt3Jf5S4+8ORXIehchvM+TvbKsgJxjp9faotOklJDzfKW59OO2KkmAuGEJ2Hc2SQeQK0Y4o3UMA644GRjJpjASB5fKGYkf5kLfxHvWjaPHGHEmU8th1+6eO1QW8YlYLKhYDnB55+tW7C3heebYQXRtqkc7R9KdxpMvQRGa2ZyyAnkKec+lWywjfcUOFULgjj3OBToGRFKTROHb2wceopTHHIQIwGBPd8H6mpcTpTsVJbponCIuZWJbcf4BViNBcSB32quzk4Jy1IbRQTIqCSduMg5BFTW5lAVGKIU5LYBJPpQnYEiS3UByIY9+wBvQHgZ4qxJGZIkVcLg5bbxj8aicmNAJi7KFw2zPIPSrcJWSIfuyOcbd3SlY0joVZYpI2QlAWHXZyB9as3EJKASOm8j5gzdPYCpLlYvIHlBpJM7SAcii0gl2/Kig7f4j09OtLlLuSW8kbKiCWTgcbVq9C0cc/lpHLJK3948A/hVFQLTP2eVTN0D4zye3SprdQVVPOYvwSqLt6n1p69RovRmRmAggTaeCx9fXJqzDbRxJmWNZG7EYwDVZAn71IeAAV8wtnr6VaOFkZYeRgcseKpSsVyolWAXDZMYaUnueAKZ5PksQAit3AxmnCU7AC/yE4AHQ02VQj78qm3qc8CrTJsNQxxg+bvc9Ax601hsG7HLnpnnPpiiBhlS4YqoyWH8VJdyRp++b51JA3dCCe1DdkFhkbkMLeAAI/XHBHv9TSNCGgy29I1PzKCASPU+tPtT5bOJHw5GNzdwegBqw0clxEWkG4R9QR2/+vWY2jn7iFSH2jGBkRsvXnqKz51UzoY/9WhB/wBX09vpXSvCZbYK6lASxz/h6ViGKVFDbwyD5gAMsfbjvihkXMHWIkZyBskzyo9Pb6VhXUABLllLng8/pXSXaos0kNsrEM/3jzxisW5tc/vFLOU5B6EH0NZX1MZxurmYY1fDjLE4Un0qBScBTtc5IODwoq+8YDBRneGyXx1/CoPL3bXclADxx96qTMJRERAFJZhkDketAURrvbaZDwAO1OCMzlX+Q/3u1JtCbmIPy/xe9VcmwkoIjDNg5HIWhdrZBLAjoCKkAHDYG7sQc0SoQzcg8fMP/r0gSsCxEgE7cZ6r3FGFBA2Bs88jkfSniHjJAXHQZzQ6hmLSMORxk80iiJYjuO7JXrmkLMCUyCCflI/rTwDvBkAZF6DNNdw5CZVPQ5ppARlSC/mYyM/dOaRShQuVzjrg0spXDbSMnu5pYo8qqhgSevQVaRDZGT5n32I9h3pgQ7f4gT1z6U94pGycliPTtTFiJyM5fvk80ySLYNxAHB6+9QXEKSpsdY2XuGHSrQVt2CPpmopBu24frwapMVk9znJvDUCzh4NwPXaelb+jWkUSqAVBp8g278nJA4poCqoBbOe9aOTMpU2zbZ1RQBxWbeSZY471US4cBlDMx9/SonlLEnBxQmZOmxzMSKVF3c9qRFJ75q7bW+7kcmquTZiWtuXZfeum03SDJwAOeKrWNjhQxXFdbp21YgO9VFBYo/2d9mBBFYniHCqCB2rsLhwQen41xviNgN2Og5xVxVpWJehzluWcjIIDfwngHHvVuBRKpCptHo3WqtirKFZiGjJGVbtWkkRcsYkG7PPfA9K4VqehYiVI4iSUBGOeKi+0qpVYgSOuO1X3gJ/cuOnOAc5FZ8zCJSQmW6hRxiiwaokjvGjlCtEwaQ4Qg8Z966GzhNvbpG6oXxksp6e+awLTE6qgDbmbMrvxtHoK30RI7fy1uHZOqqc4x9aDSN2SJdM16LTIlkdRh92QBnpV1bZY2Cxl3ViQdy4xUVh5dzdsgtiuxQT5Yxj/AOvV51dVAKhpVzjqTz9Ks0SaGOBDhPLJVhkMc/kKWO1FupaMYTGTkHcfepV85p/tBk2pEB+6Y4Jp5VpZAXljVNoLbn+6O4xWVjW4ipMdvmsY2LA/Pz+YqE7ZJmJlZ1XkleFzVmKRhu+zRGYscMxPIHpTANyxhFijiJ3nODn8PWn0GkyeM+dtQJ5SKQQd2OanRUkKKiH5sgknJBNU40eS58/c7xn7u7oOev5VqWBk8tjB+9U8LIWI59getItEkkQjGxYMbuCzMcIKHVIhGVWJMkkkDk/UVAsRRzvljMpGSSS36etWIIoXYzSPKykdAuDx2plokhBJKxbEwvDAA59qlWOV33fMyAbQCKje4BKxRnySc4G3B9qAH8pWkdioOeTgmmimy1+8ZcqqIvoe1SptCMWKkNn7vNZ8O3fidyQxO0Ad/rVxZ7dD5YyxXggDv6mm12ENYpJgoWGOpPWhQHcYJZx8xXHX3pGLGQvCgxnqx4pVkEb7XYKQednO2puVYUkrKpwoY/dxyPf6U873ZmbzFXhzjkNUqvkIrYEZzt7ceopjlSvySghRkKB1xSBoqeWJVcpnyj/CB+p71TvngeY20SsjLz5igZ+laSDywnlRYd8hju4H09Ky9RVTIqRBvlJZ2VsFz0/GlsQ43Zi3VtEUkQylQh29Oc/hWPPbJI2FlG8jIABAPr+NdQ9s0nmCOPK5BwwyF+p9azbvTJI4JDMFZkwwbrj6VDT6IiUTnWicMCwUGIlSwOTn0qpcqckOSydiB1/wrYvIZDN80DHcFIIB+YjqaqfZk2+YpKxk8bm/Sixg1YzZ42UZLHA9ORmiMSCLlf4eA3ANTNFudj9zvtPQ+4qAQtJIZDtKYAwpIzVGbQqYkZVVTv64BxipoyF34whXnDLnNJECGUEYcnIZhj9aZO/OwMS3Q45/yKCbDcMxLdCp6KOMUwplt8g+XnHNXIwoQAhg3TA603aBESzgsfl6cj3zTCzKpcOcNncDxjigK8inG3YTyTyRVhrdg28pkZ+8Tj8qfJC2zccOCdoGOQR3qkJlNrfy2G4D35yfypjDEhBbBHfGKs7N0pz9/I6fNRLI4VVOx8cKAtOwiowPQEnHPsajEp3FsZx0qWSNpH3MpAxnC/40wwlzt3hPTb3ouS11IZ5txJJIIqOR24Khdx4G4VYZBGQIwd/f396bJH3LZPXA607isQqpwRlfcAdKUAc8AMPWpUiUKQqkE/MS55H4UqojKCAxI/iHOaLhYiztKjBwetJsVlw3LE9qlEbqcuOD0wKiJRpMqCCCO9UmJiCLZGRtOD70R+ZE2Y2ZT6UMyhQQ2c9M96UfPk4wAM5LVVyLGhbavdQAgASLnoR1rWtvE8ajbJCysf7vauaiiwGKliQfWnNt3nj8/WrTaJ5EdpBrllcqVWba2OQ3WsLxBMj7tpBrD+badyAEdqQPuXkEjvjoKqM7O7IlSvsFm2/cC+ADk5HatNXkkjRQDHgdV6GseyZcbtrbuAcHj2rdikyuVUgj1OMn61xxZ22JUBO0YKbhgBR8xFNCDcysBIqtjr096lQOqllkBUjlgP0qxAUWIkhVjI5+Xk1aBxuSRQxqkTxwEupzIWOB+A61LJ5k0zSQrGA2ASASR7D3qSFnCkAKDkEuwwB9as253xtJdzr5RO0FDnJ7Yq7lD7GJ7dfMjDjeSZJJOvT1HH4VbhB/eFZlKkZPX/x2q4RkUoJGYEDCHoKlhG4fK4RguCg/hAoNVsIhM0zoYSPl+XJ5PHoaWHyvPKTqg3DgJ1I96fH+8aMvb4KA4JODn1z1NV57cH97CWkRZNw2t0OMfjWTV9SrluSAo6/Z0REc7iS5wo9Ke8sZCNGhcN91YxjkdDmo7V3eJ/tYaQqd+E4G0etBkuCxZyY4CQgTGCO4oRVy5bOxQSSxxRRxpjBPU57DPWrqSlAFhjARAS3AyO+axorhUdv3ZcbgqKo4Hv8A/rrSgCqAz2zO5GAoYknHc4p2KTLrBZAnmsoZxkoByfT6cUxowkhBlfywuAqpzj8ajRZyvmiMxEAjjgnnuTSLcp5Dusi+cx2lnbgfh6000ikWDOcFY49zEgNuOSP8DT3QJEsvlNJIOdoJ4/GqcaWxQu0sj5PCKuMn15qxDHIoKgOFPd3yR+XFJFpjXnkY7ltSTuGGwePrUyxSREF2iU8kM2BSxI7K29lmZvl4PFMFvbRhlkUlmPCr8w4oYyYoZY2Ms0SkEEAt+tJE8Ur7FDLNkhgqjHTg01dk0f3ZHxjIVdoH4mojKiP59sMkgo7NySD9KhlFy1ZCzhd7EMc4wSPbH51PNEwlDom07MhOnGe9VUbyQ7GVUhbk+VxgioJZdyGRCWJOF7Z+uaLjZfMUm0hZFTzeXYc/hiqNzEvlybZRhztVieQR2H+FOS+Q2xeBd8u3LMOzegqtBIwl8pG3fNkD1OOWPpijS5LJXjW2iD3LsSfmZRlWJ/Cslw4uN8BYBmKOgYrjPetm4jW3G+TMkrLxznJ9c1g64l0bHAhIjY5VEyuW9fetYw5jnqTsihd36pbzA3Es0mMDsG9h61zK3EcxwwCp1KseAR15rZt9Ku72dpL63c2oJQrC2GJUZ2/Qd8Vk+JdAbQZhJHIJYXAkYICQgPfPpyPpWjw0mrnE8Qr2JlGACTxKcbS3IA9R/hTJAUkKbdxIyBtPHNVbS43wRoxyemAPmB9Qa1/s0s1oko5CHYeeeff6VzSTTNl7xms7SSAB2DZ6dR+tOCsjHaFO8fWrO1Wc+WpWJej9/wA6a1usMjnDcp8rK2T161KDlI7jzo/lVSGbBJPYVG8ReQZcYySOfmqw6HhZA5LHLAcnHuKlMKMWlU7D2HO36DPeqFYqR/NE3mKcZwFUcmppJgyhVCIuMHjrR5eQGl2schkUnkjPNOn8sO+4AuBknGQlF7BYhmG6A+WqqRyC4qiI0jBeR8g9dvTP0rRkUEhGZXlXBBPYUyWBpbksjLuP3iDnB9KerJKCMyMQ+G7gD0+lLgBwxO3AOAq8n61orCquylyHx8zYyAfeqz2YeZsEmMHl/wC+fanFEtFRiY3baeMdQfWo4lLZ8rbuxjnj8hV2SMghVhwB03DaWqt5RVzlmyThUUcH1qrAiMRbCOC57huTTlUfO7ZUHoB0qRLeVSB0YMcjtj3p7IhV9zfd5JPAP0qXoHKmVnClRubIPVVPNQiMr9wKV/ugVoRwPIFMUYUD+93pskQ83hiO5UDG2mmJxZRWDHOBu7Zoa3OOSdo7k9KuFG3Heu7qfTNQiIglTuG7puNMlpkLK0aja4zjqBnP1p8K5zuOe+KftEZBHDLySKR/mBMTkZOeKpSZHKI4jclgwVR3qJogVLK3I5NT7F5G1Bx0PJNG3dg4AbGMk/yquYOVmZZKu0iUcgcYNb9pGoiAcJ833Qx4rmbCVfNUsGb6eldLabQp2jcDzz2NYLc26Fu3ty7b8YC9lJ6etWAwJVTLgOeXC5IHpRDKjfOziPnAHOKt24C/6wkSdVATd+narirlDobZZ1TCyOitlw4+Zv16VZFtsZg+6MEjaEGR6io1ly4MkgwRzEo5P1q6sskylA0b+XwEgO0Ae57mtNBxCwRvJWMJ5bHk4+9x71dlUk/K8aMFyxGATx7VRw0h8vaqP0+Y7m2/UdBRdwyhBJZGV3+6VA25A6kDvQn3NBsagZJ2OuQqh87z+dSxwtEAk8qNG52hQRhSfYdabCrlEkmZEjB+YJ8zDHrmpYjEbjzIFkLqc8nIPuR61DArzvBb4DSOZZVKhcEAr/SnQRtO7MQGB+UAcbB681LPatMyTSKoYAnauAf1PSkkMkIMssu19uEQNkqPp6ms1uXbsPju1W4eOGRlOMsxGAMenrmr1ntiBaaRpGJIIDkMQfbpVONn8ncseOQSzjLenB7U4XDFjsnLSONhAP3fYVoCLu13CssEmcYHmHO3P4Uv2IhSzwMpZs4UZOP6U5YrhFhMiM7qfmKsWwD9aswwiNf9IYlgegb73/1ql2W5omRKLj58ohTAAGCBj61NBcR+XuCq8h42K2QKa8kbSZe4Pl5428KD3qdUaXakSPGByOgyKRaRJMpkZlkZgPSPAAFUzBGY2cttjU5Bwf0xVpI1VmCIGYEjOcLx61A4Mx2yPvI/hGR+RobNFcHGDt83Zbg5G7Jz9aW1BSHNsn7zkswHDc/d9qJNzFdrrl+AEGcfhUNtA8UrxNKVKtkt2GewqdyrIS8uSjLFbuN2MtkDBb0FNNzOyBIjuYDltg2+46frTLpSm2SFFdXJ92C9zxTtPAkizcSfMchFI4x6470rCZHLOgTej7lKgnnBVqmtpZxZAtECpjJHAXp2P/16zpfKW5iEEZk3H5hJwG7g7atlZLi9a3mJBUb2bOFwOcY7UJmb0LMAJOJ5CZGGBGjZGPSoL63eR/8ARzmTOGJyVRf7op63RFu7LtTPVj39h6UxZp7a98po1SOSLcM5Kn3+tdNKVjnqK5VitshLaeJ/L80SBoZDE8R6Fh68dqwfE8aGL+ztJF7IsylJp7uQOAmc8Y6dK66ORZ5FLIsZTn5j145PvxWPrYMce1EK3V1wOc7UHQn0rqlVi46bnG6LvocZpkAiuv8ARU3urY3Ec59fb6VvSBZZhY25bDYWRhzyDyKmt4kiQ6Xp0a+eAPOnOeOOpPrWlahIoliso1Z4iD5hH3mHU1wcjbOmNomVdL5FiwQeWmdgBP8ASq9wiLLEArABQqAEfNx70zV3uLFnlmhkljB3PIq5Vcnoak0m4YtFJcoQ7nKY7D6VLi1uO5Ebc/6SzJl2w2P6UjwSSWRmZFJBGExyo9a0rgTT3fkogHmYL/L90dh170slp9+GMNjgMUP3c/zFNroFkZF0rExSFEdscsPTHpVaEJKmyJyBnO4A4981d1CJYsQwkGIsC0vvz8o+tSWtq62ql4JFaQ/KpGOOvFEVdmbHL+7BDbTKW+ViAN3riiW3FsP3at5h7E859afPH5U+ZCWOMJxkA1YlBuYchVM235lyePpWySJ2OevHkhIURfeOMKcKD7mnQ3aoRGrcjoSOCfao9R0iHULjfJcSI4OWIbgAdh71R1C0u49Mu78yQwQwMAkMxG+QEHkH146CrVPqYyqWdjaFwoZTGGklPGGHFNdWikeWcbs4yU7ewrD0i9aS38wxsYjyQ5wR64Nb1qkzwxPMf3G4lVXnn398UrFLUrSIzovysIS3Gf5GnNFDKxwM44B/hFaV3GRexFGQKFLMV9MeneqqWaySlyWhQciM9HNZyVjRFQoXbcirGvqT1/ClChSB8wDjGxec+v0q1CUlgl3Dy4QceY3Wn2Kxsww20Z6v1P41ny3GUxanyjLKrjnDDOQfYVGsIXaXAwf75yV9K045Ukikj3gMJCRnr+BpUgDOolUM5+6QcYrTk7CdjFe3GCMbMcknpimC2YriFsZ6ZHDfSto2UiSNhVY4J2uMd/1qBofs7BGUOT6dCfT2o5GRZGTLCyf60kZ4ORg08RqoGVAB6H096utE0UMhL+ZtBLRvyV/wqIQ+YMRMMYyYy2SaOViclscfp7geXj7uMdM/nXRWjO0a7SUU4LECuW0Zd7ozHgDketdhppWOAbvmJH61k1qWjRtPmYt8wVx95vSrZ8vJWJ9qgYLbvmY9+ajtoty7ZAyptwSvP5Cp7SO3kkEalGlUcebkbfw961ihliGFd7fZtoKrwm7IPtxWhDt8pk/dvuGRGvH1z71XiimaPy8RqMZLOCFwD2HFWLc4uWJWVpX+X5CAPrVpFIsuIyVME6q4ADKi4B+tRyJthIllRCD8qhuW56c0gf7JKPtMrIzcbVUfhuxReCIx7tk8skg+Xa36j0qblogUQrJIyrtQDjzBtAPeorOMl/MZmkbjDK20L1qxcIJBGphLEYJbfu2j37UkSsQq3LFIUbrJgZ+mKVr7jd1oSZ80hoUzcK5Cbv4j9PSlCLD5jXeARkMkY3EGpE2PMqtIxJJAEYKjH9allSDyQ+7yB0IYc4Pc0rW1KWpWiuFaAyLCzKCCHJySe3A/Wn2E8u9PK2CTJ3bFAwPfHf60AxlFigikCYyE6Bven7ngHlwAgPhiFXAHtVJia1LiqJGIkeRjuOMKSoPv71ajVY0ysTFd3JdiAc9cD1qGFUaLYXZpcjaOwFWYoZvNHmqFHQDB6ewqZmsPMURiZWKpDtUZCj1Pc0qGNZCGZnOOAnb8TT5VAb5SyyIDkr0Hp9aktGjKsEUjd96RjtH4VJqnYasjify4YlErntycY9aqTNvuk8rLsAw5PX1xjir8qoFIT5IyDuZn5YH9aiugrQpFGduP9WY16fjWb0e5otStAWSU4KRQMOWY4bn0pZgifvolaULkbiO+OnvTZY1jlikdw8gODkZ49zU8cJeVxG5xzuB4GKH2AzbeNfPbaVxImdwHK+35VVhuYoRMkkjjeCoYrnByMn8qtsiedMAxjhb524zjPao9TtYyu8EqVTIBbnOeM+9R7wMPIVIGaE7i2FUsMnA9PaoGt1CrJH5gTByxHLt3zV+JluJELfMAgZhjAzTXiXl1JS0zvwinLH0GatESGLJHLschmBOApG0g/SoNVZVkhlRc+U43ZbLHPt2FMYyictcjcSSQW4wKbd+XPZOFBVeMybuSPb0rZO6OaZakdLe7WWZNsSMpGDxuPGM9v5UzUUFutzqMhieQn90rHcfQKMdKpzkXuno87SCO3iILHqcd+Kfp8kepw2x25tYkUsQeS3eiMtdiOUNKsQsTLmUvJ800vIJbuBntV9I0jvk2BSPLIw3r6nFWGlMRBV1KEAEbRtB9SDTQudTUlSkhXaQPmXHrWlxW7lbULRJN8EpZlmxuGOABz9KypI0tfOubgY29B0OPQe9bmCzSyHAx8o5xtJrIt4n1O6e4mJW0i+4cY3kdTVT95akuyDS0BZ53ibfIc4Ycgegz2qW7lkg8tYlBWY52gfdx3P8AKrZc24JLcbTsUnn2xVVpoop4GuJGkZwWO1c7VHbH9ahxsi1qZlxZql6IVUsPlkZsdD2ytWJppJJwvlmVEJYnOMccDil09naSSZk5+4jNx8oJwe+Tg1dMQjTZ+6HB2grnd+PrURd9UDjYzjEqEElzHjBDjINNjtnd5I2O1DyrDOB6Va8iWXzJLlVAbhY+mfrUkzLIsaeW5RugU8VrEzfkUL+wiVMMoZVGVHb8e9Zlzp8d9AIbiKT5SWGchRzx+Q55rUM7vO8W9VAb5+2D2H6e9PubmW5maKJgSGy0hGO3861jKKRlKHMzmPsaNqMMO0w2uQHVM4Cj3rUEiyXzojKEBGHJwGA9qv3MSrCojP8Aq3G8qO+eeeueao3cnkBvLDK68YxkEnsPespzad0NRsW5kR5I3Vu2Cp569hj3qi1rcJGk927xqg3bSO3v6UxAUtzJcZEycgL1U9ufWtG5SS4mWNFZkJBkbd0BGdp9frWcpKWppFMzUQTxx3Tp/oik4Ujhj6/T0qwmWkEbQeTbPj94V6+49ua2mhmEbQRss0cYCiIY+U+uPSkskVd8E0HyT85DcDjIGO2aFTsNox0tZFR4QNqCQgliCfbBptsryTmGGIBV+bc2DitoRxrO0ILNHKMrlclWHpTksEjTEW1lJO8qc4z2IrTkd9BWXQzvKNwky/Pv7vnrz3/+tVZopLZiVlMhHDEngj0rXSyk8pyGXy9pU7hyOeMeprK1hkt3bfEXVQMqG5J9/rVxg2Zy0KMyNOkmwhR1bcefz7iscaXceeZluge/lkg4+lbi6ddGK3KWUpNyvmxoXydo/QfnT0tmDIsUbRXbblaIuME8kYJ4zx0rT2F9zndVdDy7Q5GAjbcMlemK7HTgojZmb5j1/wDrVwWjMTBHgjcQOtd7ozAKo2b349jk1x63NkbtmGuI9ttEwDdXkzwB3FbVrbsilY5FUnGX2gsfWq1m6KViuN77uSi8fTj0960WlEm5U3DYMbEbaSPUnGa1gu5toxvkqY15MznhVYZK/jTREY1DQRrFMDt3Y3L/APXqZGdrdIrPywwOWYx4yO3Jp1vHKUKG4MgycgArsPcAYqrDGJBMruk0aNJnJ3RhQffJ61LHtLqZLkK+0gGAZB9sCoVbyifPuXlZQcbuM/iajhkRBMryRKv/ACzSPhzn3rO2paJRiRFS1JjbPzMRjOPaoJYI7mUZgkkReWBwF3YqbcqkRpHtGAxklfLZ9/WlNo24vJcgRljlUHy49elJjJWePygzjLxj5gG4X8qEnaWV0WOPGMfOM49+apz3SbsWyPNH93cAMZ9x3FWURp4GhYs7xjcGAKjb6fWs5NlRHv8AakQm3+Zj8ok8sbR644/WpbQ3EUivIAGc8KT3PpTbdwjgXDFRuHCDdnjpUk9xDFP5qqPP28BhnAz1wO/tQtEUzYtVaMxSyXMWxsAgnnI9OKneVJm2BjJtJ5GePp3rE0oma4eWVJ2WP/nodnTvx0re84ypHLAsdurY2shyFz3Pc5rqjDmjczVRJlTyZZC7cooYFVBxgAUskMbhG3ZCA5DZJqxJG8pUysvlb+/b3/GnTR483YytkZcDlT7fWsJQdzeLuVzEpBXAPsp/maiEoD7nYKF4CDJANSKBHbqYiXKtg5GDn/Ch2RJf3b4Xj5TtJyfeuaSOiJWmjklEkgRwgxk8DJ7VJCxWBopGKurfMCpzjqBk/jVuKEqrmdlKpg5I7+lU5FdpDvJZjkttHqc5B/SmDIo3+03IyEjVQWwBkjA64pkefIkklC73CkMR2zjB96uKsaxP5W2Jvus7HnB6/jVK4wsgd3O4HMa5wBx1P+FNxshNoXTocqLaJgd7HcSMnrwM9hTr9QrkxEiKHgMrHr3Pv6AU+1mMESyQgebLwvHH1Ipl1MURjcIud2FXGCR6UU420Mpsy7mWWUEuS2FJAKj/AD60+AC5sRti8yLsSMc/59at2ixSM+xXBY7lOccelNhRcSRROA2dwXaQPxz3rdKxzy1My4ybX7GBseRtrsw+UL6ZFWPDUCxPNbkEYOV44PUevSo5Vj8uWSYkNgLhuQMdP61NYrvKld2edvBG72+mKm/vCS0LV6siiQbVZNueuaytGuATdyOsqpFxnJ47gA1pXjCJBMq7YX+XpnA71zMe9tTa3ikkEcoDBWbJc5IH0/8ArVUnZ8zFbU0pribUUaC3YqpJaQgAfhmrFnA9uyxQvvVccsCQcjHFWYrcL8xjQFhnLetS280bJHIDKsgH3FGQcHtnFNXvqwsh7QKXDjdyMHHJ/D0rN02IXFxPOFL7iVRT1wOOtXNWumgsX8uHZLKfL+bg/MOue3FRhIUhDhNuFyBuGB6USSbsgvYSBXgkvDEoCybcA9VJ7Yp7R4PmEnzG+XeVyBj09KdpY2MruyKG+UeYT1xTrzfKytt/dKCWDHliP5UKNkJu5TvMCNXQ/eOAobk+nXp3zVR5ZYLdE8pfObCqUPvjJqwoFyy3JXau3Kg9vw7Gs7VmzKFRt7twmTjBz1qr2VxNEa4eMW8bkHG6aRlGSfoR1q2oiSPzEaQM3RiuRzSabZx2kCiQuZGPzccUl3cKiHy8KGYsFbPX19wfSpSshGdeXEsERaFC6jp16jnnHf61oNYpJNG8p23LklVQ8KccsT2+nvWfKZZnNtEuWfAwBjCgnniteNB5fmRkBwVWUt3OP88U0S0Y+sW0sMfkRyKZpccgHJ9f5ZzWhauEihSIStuBRWbAZiOpIFWCCJGlEZkwoVIxyoBxnj15pPDUAkgu7rI3yTfIkgyxHQ7R9c1UYa6CvbcuxQYtpXeR/MjfBcjbxjjHeudu9bhaVrfzlWdcg7vlY4/T9a68wyRXeGDbLiMx8tkB+oGK5DxPpKTtA9wHRojlSV+Y88D168e9bOHu6EczuaNjdebbrKhjW6jALBujY7j0966B7VlkVkj2hx0PA49fzrAh05kiWSR9tyBvjXg7frnqa7DSpTcWEDsvDqoDHpkdTnrTjFPRjuylHD5hdQoyPlK/eGcDkVm6ro/mIHiZcD/WArkqPb/GulnMKxu6pIChEY8s5P5VCYZJHRZfllXGCykbgex7V0xp2IlJPRnFNo2qLeQgTTG1jkCwKASOoOxfU+3vVvVfDyW13M0GpXWJNpliuo8t5mOV9ucYr0K5t4dQ02yiS+itGtgUKyZADZzvUjqTWX4oSO91BZI5ZHWGFUMpODIwGC2D3NC80cyjrofKHhqb90qvzgfLx0NeiaNKwCmMkvxkgV5l4WmCMwkGVGcY616N4elLKu4+WPQ9TXnSXvG8Tq7NZi8j4MeF+d+49s1p2snlwcs5ZvlRFGS3sTVG1gQgvcZEPAK56n1xXR2dsoVvsUE7SlcBiccevPSqUToT0K1ukUcv+kiRyOkZwCv1qy6TTWrf6OIRn5QJME+44yakgtijFZpytwuNqZ3Z68nHJqPMPnsD5s87Nt3bivHtnpVPRFJFO6tJAFM2nwu3USPLkj3x2pn2dBaPLLcD7Ox+YMmec9uO1aN4EAC2JVZjkFsFvwHbrVZ7OSEeZKIHwRkxkKVPc/Ws35FmelvGU3WxMyxtuyxAH/Ae4/GpbZ3lZ1uS0so4XYoIUe/4Ve8+KKP955ciSDJ81cbRz7VRtdwJXf5sOSWEa8AenWoloUloKoMCyFGhij39EXp796nmdmCLG4mYnaDu2gj+lUHu3MnlwsFiZcHaefpVi3A87Czv5QGTEV5/T1qOZNWRSVi3CZ2U4RkCA7FU52n+tMCqSqTRFN4B3sD17f5FSQlCd0KyIpPyktgYHPT1rQlji2xgnhhkHqfrmqiuom2TW9ussP2YTlMr1DYbd296e4RiQWkiZWwQhz5jfyqlBcMFeMKTGG+VzkZGO5q3alTdeV0kVctGpzj6VtKtFpJERpO9y1GXdWbPLchSMkf0qwZWX7ylSCMn8O9R5kFwVQNGFznBBzx3qOZuguH2t0DFsLXHKdnds7YohUs8jzKocEYwOC3OKcsX2ZA0ql8tnHcevPpUm5WsRkq0hxnB5A9ahsGaWQ7yCo7s3P8A9esnJG1kPlYssayFivMueoAHCjH1pAplTzS5AHTDYpRMrtK8I3uG24PTA6VWmcOSmGznJbI546CkpW3BpC3E0cUMG5Cz792w9F9MmqkjRtKxVE4Us6sN2PfPrVi7VViiUo3yjexbjOT/APWrHv7sxWzyWuEyOW7YHbP15qkzOSsXotVdgscqLEFUKAnBIqDBmZnXB74AziuUsdT1YFp7gCOM5KMWGT9a2LDxDHcSLbi8i8znciEdfSuilHm3OSdRJ6GzZxSqxbBCNnIXOM/Q9aeyPDdK0mCkvy429PciiFknZmdwcDoQQRV2aLMTNNlSgLZ3dOK1cF0IUr6mHqETS3kNptdoxmWZ19PTHatMPtcEgsEGzCDGPf3qtpczzO08bMbpmzIpPAA6HGKuRiaa53AxhVyrIF5J9jmpjFWuNlRomlluFbbuQgFc4T8MdazI4ZP7fbJTyxEGyVGQQf8APNdHMlubYIokSRRjCLn645zWJbJFdanjdKgVOjKWzz3pTTdhIsyZUPGqb2U535xg/wCc1LaHcWcqS44yDjPfgUIiYfe8pCqNvy4Axxj3puozRLbFpYpBIQPKwwI3HgcCqStqwKtyqX+p+QpASJMtuyACavXNtEqoxDEEEBQQVFSaRaRWkXSVnZTvY9CTyaNTJMJMUI56ADJzjrz3FVFJK4r6le2ti0jpG4YYAx39cmk1syy6e0kahyWCYUc56ZFJbNIPlnZiwxwP61HftGJrDfHnfKAVI4PfmmrNCYt9bi3Ysz7AgDY69M81n2VlJK8t7cxyLk4j3PtODz0q20L3l08oKLAgPBOd56bsemR0rTaHIHmMyjALMVJwetOyZLbM90ba4Rl24wC2Pm49DWLdlmm8jb5coGI41BO4Yzn09q0r0I4Ai8pixJxyDj8ay44lKrucJIrbW65wcYI9M/Spk09CXfcswWz24QtulkUhZGQcY6dfQA9KktlkeW9jB2o4STcF3bcHBx71WuLiRYlFuDIB/qwhOAT1B9an8i4swrXG5rh+JSDwGOcDHcAkGnZNom46WGS7KWdsrRGUsXbqAB3z6nt9atWUYime2RZEWAALhsbR65+tY9/dyaHEZJIN2/COQ5JGRwOD0HGKmspEktmd0fzJBkhD0PatOZRdkSk2jZ1O8mWz80kySQSBo3XGHI7EVamtjf7NRGwqTut0c4x/tY9s1z0227mFmIt1uB5jqh4AHvnrmrk13LHCNPZCfMK+QAfuKSMr+FWqi2YJdDXsbaSTzdzRMAA0kg5wfT610Wlqq6c9tFCFWIlgTwMHvx7nmqmlZgsvsybZhH96QjGW7n+VWbQvvdkJS3cFGjPO8E5wPatKclcpx0Kt9fy2Sf6L9mjn2YD4LEtn5cDvzzXJ6p4mvZLS8iubuUT2qCRCoK+aM4dD7iug12OaK7DGJDChDqWYjO0+o6Y7VzHhvT2fVrvWNShZ7SElY7WX7soPBLZ7An9K6Zp6KJxO6ep6J4Q1y+1LwxpM9lJbRF7fM8ckiCVHyeWBz1GKr6z5s2oD7dIrTMoy4YFcdunFYtxrmk6bfNt8NafA8WGl/d4kRcYV+PvL0HtVqbUxcTi48i3SBsBhACMfh36isDSktdUfI3h6QRXMnI2+uK9N0N5CEWABmPKkgcV5NpLlbsKP4jzXpXhKZ8KU3Ek8jFcU17xSPTNCsZiFk1GTzD1KxjJI9z2roAP3ilXURkfJGHPH1xVHRABDCWWTYAFZipAJ9AO9a7zQJIqRANkbmeRTlvYAVqo2R0R2Kv2eMziSRJZ5CCNyjGPXkUsEqWseZfOELMflWL+tMjnuJWYJC6ImeGOFX6KP61nQ2968sj+VMkQIY5Ysmee3asW2mbRWhevp4VjBb7RkgBFLduufWskzdDBLFaSg7g7jBb2PFST211hZhYRpIg3CSNhkjtxmh7r7TADdSwJlc58kkn1B61nKbd2jRRILi4ubiFppZVA5UlG3bfXt0pkGJFDwXS7z1jRduT79qmS7ZYALe6BRhgHyAeemCTT2lkiQNcRy7m/iiIKn3OKylI0jEjeEzg/KTIMACYDbj61KLZdwe4ZVZeFaMcj8e4q8XjMEb3CwCJhlXLbsfUVEEuD5awXCuM4QR4XH581Oj8xtNsz47gOCI4nWROSUPUetb9vdRhhEgG0jJVnwQT0H/wBesm5sbhSs6tvnXdvGcZGadFGZY1nDKj9FY4JwPWhuUNGCSkaDsZAEXK9Tgc8+mRTrGVnUopOV/jB5H51RIkReHBV/mUr+tatrChCK75kC7t2Mke1JNydjRLQle5ZYJoLlBESQfM7PUfkvguVPK5wSDn2B7Vblt0UxCSPLAYDE5z+NNj8v7sUo8sfwk5Gc0pKxpBFSJ2ceQ+5to3Ngc49KljiUcqRgn5c8njjipby2AjaZEfK5GB9OtQwMUjDToFccBhzgY7D1rFo0uOeMLG0UYwcfM2MZxUCyorKisc46Acf/AK6eIlwB5j5A5GDg05rfC7gw3jJB2f49alJ3C5HqV0Z0k2Bti/J05OOv9TXE6/PJBFItujGSU4Qc8nIHT8q7KS2cBoo1LsV3E/xZrJksWnlBESNOjpPAGO0F0IO0fXpXTThzSSXU5a8uWLZT/wCEJ+06ZOJLy7uLyHh0jZYojg/MEyCTg8ckZrn5fD1toFnZ36ySLN5hIOzIYA+vrzXooOtXEdw2nX6R6fdMzfMqbwGJLA+hGSM1ofZ7D7HFZmOKbywdz5LIXIHQnsAByK9n2EUtjxYzk5HP6W93NeqjQyRwFQUfOc+4P+NbV7IEhihCKkspK9ePxq6lqYoUjVVXK7VXuMHikWHMrl+VUE7RwVrnmkup3w21MK5s5ILu1lBb7OD5cgRtuR/XB7VtRwyuxKKVQHAYjBA9zSLaGaF5JUYEAFFznZxVpYGnsUWRmBIAxyfbmoUUti2yjJARhnkjbaCwA69f061jxCFtRaaVd7ADIX5WNdJNbOsJRItjLjaRjgdqwhbEuJVQhifvKDxk9v8AGpkmugcwyZNjP5wkVC26M/eC/wC9jvVFoft2q+SjIY4edzfLuYjP6Z6fSr2u+bDabXUbsEqWHBPtinaDZ+RbqrgmcjDFh1Y9/wBKzau7D8zSW32Rc52H5RnvTvJMkBE2P9gg4AHoas28eCzKWUtxu7U64dlgZGkX/f2jC/54rYloxJVKFPkQP0LgdfQVQHmXWsxxRLmGEbmYjkMQQAP1zWnfPKsUksSCbyeCg+8fQj86NJsBbrztkkJLysOu4nkA/kKVuZ2IsV5YljuI7VU4K5BUkcjrz+NJcu+I41TIxgKW5AHJ/r1q/JGZFXCs2CCCRxkZqtczRSMSEwz4Ea7gdxOef06VfLYTZgXIVUlnkLBN5DbsEqOMce/FVBZsjvO8jiFF8wMW469Rn+VXZZmdsTeUkSklkVRgEcjJ60/7H/aLr5mRAOQSOGGRgc96hxvsRchsNm6W7uCNsrFY8gbQo7/jQPmv4nBV7aKVT5RbnJ9D7enetGSKNYXO3bIpKBAOAPp+dZ12wFtFDHEHumZV+9t3OTjP4YBq9UKxYNpDrJu5Aga2icopHy/P/wDW/KqSWTWsUkSO424VcAZJ+n5dK3ZUW0t4YlGEt8LIwAAIz8xI7+v40yKKMRG+n3QO6/uQwJODkFiO2abhzsOaxh2z2tgjr5mLx2LyhOAB0A5q34fnnutfWZo0QpE6g7QQW6/yrD1y0F1cxXi3Qd0UrhRnA9fetvwuxs73TXaT5XY78jJBYED6cYqEmpa7DumjobS4W9k861ikSOOTZKG6lu+D3Ga2Yp9zSI22M42rg4A46isWFpLOSW4t18xSxi8ocdDycfrW5AIUtklVQysuSW7+oq4tmqjdDbwLNG5R9jCZQ7MMjkDB/PvWHbW9sNKle5voY704SZHy6Lnkgqfp1rqGQC3WORWTzIzuEoyOuQSe1c7qmjWVytxFqkLTuwCiRHyQvQAkc9K71O8VY4Z02mc7HNceKNYEltp8/CtAJF+7JGBgj3J44/GrkVvFFHDZAXlrPCMXAuXyScchRgbeQMc9K7vSUtYdHt0tkmgaztjaRoI2aOPd1kDD1H41wHxDi1bU/FmnHSWxBEqwmVvlaUr952B7dua5ak+T3rXHRg5StsfKFsQJ1PPH869Z8AInlq6qzv7nAAryWB/LmDYB7YNeo+BB5pATlB9/njHoKwno0I9hsdThhjjjlxJPjr/Cg9Caulrqd2dmZtoG3YwRRWBYtHNaRtChZywVVC5HuT61sGCaU7VuCFON2EyB3z9apyb0R1RSsKthFcID5rygfOShIAPuc806OBBCImgeJRxkkkN79hUymYMYftEjrnKqoCg498VFND58GJJkjdCM7ZCdufxyTUS09TVFNLd7SZRbu6seDsQnv6mo9RsZpLgGaBpP4fMDiM4+oqQlDuCXP2x4zghzg/QEnIpVsd8edkPIJzvzj61zy95WNUZBSCBXdfOBY4be4YHHY/41Na5eBJbSSEgD50wxU/4VavbIPHulVVfZwRk5/Gqa3d1Y24EtmACOpOVNc7i1uXFovCytbpMwq9rMQd2zlffrVa6tGtXjkVxP6+UcMD9P8KrHUXlTKSLDxhk24yc9eanS7KBknQlw24hQMY9sVLcHozTUSK8AdsYZh8u3GDz7Hn8qs3NhNpwiBWSASDcsbHcpPv3FNuFa4gBSSM5OQHTaw/Gp47hwhF5C5Rl2lmfdx6jvTUu4rPoWIIvtIVQAJF4fB7etaNtOI8RM8gH8LHuKz9NnWKEpGFdOgz98D3qe733MYlRTiPggc496m9lzGsYmmtxtf90ofCk5LfxZ7VVDK7RyTrtdBxu603TrmKYhg/XKhum0f0odm8yQNjC9W68Cpk76lpElzPCICoABPG7PBzUcMrLE0XbPyrnp+FMC/IhHzb/mOR/U1ZiiQSlpC2xVOCe9Te+jHYqoZFjUqzO4bDKcfLVppSdquvyg/wAajJH/AOuoYAVaWNIyE7kfez1qWCGJLhn3uSq/wjkNVxiKWiCaONpt7MFYqOVGf5/SnfZXmcNAweTHIJyVPrzwKsiVJJR5MYaQHOe/5etRzT+XMql5JGfPy4yF9ckV30YrmucdXUj062eWIv5bGSLjHpyeRWjZ26gLuwDgYOTnNZMWq2kV15AuYVmZ+AGCkHsMHn8a6S3m8zawYOCMfMAc+w/Gu5SbRyWSZXnhUfMr42kcdAfrRDCGuHVoT5akZJP3vb86ulmIVXiwRyCO34UsSqIgoZWIY8dazszS+gxyquduEPQgf4+lVYoGSacy52HDDaSf854q35YEm+TjjaD+PAx+dJdF4ZChePGQQGXPIPJ/lTSuJuyKsiyzRbVUqOQ5bvnHb8qSVD5KrHHkbMAn8unp2qnd6iyy5tUJTJOAfuj1GP51UfUS9zIJABn5tpOSuc+vvTsRzakF9/pNwsG4NHHgsB0bJxt54/8A1VoW8RgkeNgRtXK8en04pLG2jlke4cBA3O5u3AGPp/jVmO0P2lf3uxh/Eeg/+v0NY8vU1TC3ki8sgofM4wAR16/yNSPGDny0wwzkEdT/APXGasfZQucFQy4bjsOhH17Uxle4kcxSYZeWcfTH9B+dXboFzHMCyXaYiWSGFhkk5y3b64BNa0qssYUAL2UjuOoqOdY4oR5cPC9v7xHOfqc1fMKuGVhlFTGQc/w/n1xTgtbImRzc90kzMBMehxhs+4P8xVHUTGYpkwqARlVIH3TtBwPx/nXPzx3tn4slZVEdnN8yqchVGQT+WM5rU1CNbh49issUyAgnnAx/9cc+1QqndEuNmch4fguLm7f7YHlgVyEjbjaepz/sjmu504NBY/bb08RAohAwBgcnPpk1TgsA1wkduQqsygYPOO5z+JrdvwZtPltbdkjjZApB5A/2v5mlSSQpI5vX9St4oI7kNuTcAWzn0P8AU0mhOL7U4XxkW0Zm3sP4iMA+nc/nWedJH2T7Jdu0sMIOH+6oHPX15x+daGlxSaToQf5llvGyAf4YgePfBJz+Ip3ble2iIk0tC6ITf3PlT5EKkPK6nPy/3T9arapcy/bJLSWMyIAV2p8oAK5A3ewrWsQINNaBSY52IkkG3JJxgAds4A61j3q+bJpj3AZLO5kUSBzuIYADr24BraC+9mcmeZpJeaTNJLcGUWjkKGZC20Z5zxxXU6drLXcqXImIg8xTjpkKRwfyp3iK6kkvFtxGVtY225EeIw3UoAeGBBzzXI3Drol3f29tl4I7p4lU9gDx+OOa56r5dnoKm7nuTS+XqQdwkaSEfMDkHgY/wrRsUQ3zyS7/ALMWxgnA8ztj+tcUspnSyDTCJ2gV3IbAwFH5k8fjXdaJJ9sspXuY1MAG1UA+7gdv61Sd5HXBuxc1lfliMpGxCMnB6HjHuOlY9wNsUhCuAz5+bouewArRmDf2VIspwsQZo245Xt17iuQ/4SqzuJ40hm3O2Nq7OF7tznGa3V7XZEtzv9K2SaX9niuYVtxbNE0TN5Z80vndz2Iqjr0YvtQdY5kOIFSWQdHIHODUsFzMdOsvsemW9+sqfNJ5IbD7jlWx0wMcnrV7WxCtjdNNDb28UHlhGjGCJD95Djg44rKT0M6dlK58ARcyqPevVvAEGFYsCFPHXHNeVQjMy49a9m8GRltIRY/ml3jHpg+tKS1Od72PS9JshDHGVYbQwwowBz3rdCYXzIYlRCNpY8c1naJZ7YlLkSS8KzE8A47fSrN5DtlWOMPJwAcNnP1+tVstjrRHfeezQeSVm5x5ZGEJxzUUkRG3zZFjcZPJwD64ouryTTQfMSNWPIQAsUFYV3q8jooSyjVAQrF8kufr6VzzlFfEzaPkT3F9Z2jODC85GSjD5VZvfvgVWeaW6t0e2j292VHGD+marzEuhfYjIeMg5AzTIGa0d0gVR0J4+8BXHKq5aLRG6jpdksUsqygrmF2JwVbr9asjU7idGjn+ZgON/Qj8KiuJ2JRoZA5IHDIMdO9ZV5cDeA0QRgclk+voO1ZNtdS1ZluS5ErLuiRhjbgev8qssqw7fKVjGOhYZxVZFh2iVBuyOrE4B9gKWK7l+yywP5hUdORUy7stPsbdpIrRlm3eW+OgHy1cuRtjKqQVP8SDkf8A1qyNMubYxGP5hNkY3N8v0NbcAMo3+UiJtIZQc5P17fSri9BdTLR43lbarbuFG3nn8K0LC7Z2Kj/V9CApBOCeSKy5pY+YwBGTxkr09qdpsjW96u0yuWGWTAUE+x9KzSaZopFuNJIJ/ORANzE7GBGRV+K4huA6sQpxuOflP4Ui3BVVkWIIxHOGyf8A9dZ7xKkyuzKVY5JJyM+/pTatohp33NHKySDB2IOeATx3qysqP5ShsBhgs4JB5OBxVGJAHQlnGT8pKk5/AVciikikZpGEcJ+UqCMsfb/9VaRi2JySJ4JFbckbYk3cEcnPT+tPmgNvctJldzNtKHkuP6fjT4VSOZtmSjryMBQTj8+oqWRyYhs2KjcnI/ma3jBdTJybFUwIF8uNNrD6nHvj+Vc54ouGsrNpolkbaCypnCjHIJH4V0kEAEAkRwVY5ZcY57den1FVNY01LqxnZz5YmxGVwCyg9cD6cV2QWlkcs2ePfYLiXTZNSOnTPL5nnCfeMDHoOuAe4FeqeC74XVrBMSwWaIMUJHysf/rg8ir02k2UOivaSWqtNHEY7ebPzYYnK/Tk1W8PaOLG3htw5BBJwTnIPUfQVtGm6ZyxbbZ19tsMasWZlPzZI5B9/wDGiYQxnfISR1OOm3v0/nUVu5WQKMgLj5QvUd+asSTBUYhvmAGFHAJ/+uKJM2QsUcxhMhQbPu7mI456/wCfWqeotMlt5ULqPMcHK46jnn261o5kmhX5lZVX5uNucjAHXnqKiuLQfYZgVCM2CrjJGR/X2oiJ6mFBbR3Wpx2qS+XbeW8krAnPynrjv34FZWo27XU7W9vmRUG6N3+VuvBP1xV3VLFzciSOVoJR0Yc7SDkfnnFS2VkYCZlhz53G4k+2AP0rVtWMVCTdxdOIe3hz+8xyXboccgfiCRUiGNnZmjVkYYYg4B64Ge3Uj8BVm1CW6yttHlbcqG6HA3cY9RkfhUFuzM2xEKQMCoTqc+v5c/hWTN4qxM0wmkRYnyWUhjjkZBxn/PaiVJVjxbjYRwD1JB5/nUywiNmRiQzggqOCT1A+lUNbRpLO4W2LrI42D5OQCeuPz49qErajuSKnmAEbSwJJBbgdGHP5ilnkW2RZGlg2IOSDz+Xpg81iaIZdO0BWvziZS2QoGcqxP6/NUdtI2otqNvIjpZxAwvcRkbl3jK4B65XaacdNSZS6EyRJdSSyAnLJt80YZT7+/IAx70yeGFoo4412iFiGY85Jw/5DgfSsnRrmWz0+OKOYrKGZCcfewR27c4rctS0wM1yBIikZJAJYryF47Vi9Ra3KFna+VcrM5dZ1O0RcdCvt2zip70LbSkN8kYGeO59c/iKs3JV1LAGNzncSc7uf04IrK1OfYEhTLFz5aKD1OMcH0ziod4otkUVrFq2qrHcSFdPEbzTtx90YwD7kgiuP8Xa5LH4ttLiM7kRguwDbhMDAx6D+lehxWUem2DWClTdSnfcyKc72wcgew6Vx2q+FPtGpx3iMgmkOdm8dFIUZx2xyfrTqOXKlEyS11LeqX0tppSuSGlVcOjc4BPHTr0qayUalpT2zR/MW3qsjfKeMlDxx61JHZgWQBaNsKAuFPyrznnvk1ZtbWNIWJkRHABJA4yevPbvVxk+fUbS5TgvE91q8jRwPpwaS3w/moSBuAGJCmcFuOv6VnaLok8kEz6m+wbvMZpDyx5JPfnpXpUQElu8yKsk8rN5jFjlFzx7baw7glzdeW+5Qiwjjcx59vrzUzjF7szhFo3dCtD9ktPlJcwoqyEcgfwgD8a7ewQWJht2YM6ryRyH46+1UfDdpHZPGzKHdYgiqflCEgc+5pL6SWa7+zRN+8lGwc9PU57Yx1oStZs6Y7D7wPeaBeQop8yMkrtGC3vn6dq850DwtDf288k/mokHmGUxj5sA8YyOPf616fHMI1a25LIAockDzOetcLrdvfW8d/daNqLWcouBKJQCQiMMN7EcV0NJ2uc87tM2/BMFpoMqaXLb3tzdy6c2ptcG4ZFcByPKAHGQAM+9X/E04F8kFtEVtpoUuCpJOyMjLE5PXqK5vwtcWWn/2O02q6/qV9drJexSwlPJQsxVlG7v8vI6fnW34juUlNw1s080kmBI82C7nso2jAA7AVyc3u2RVCL5rs+L4eZk/3hXv/wAMkMVtCjL7ZPSvALf/AF6YGeRx619E+DIPIsLXajZ2cgHI3d63bszmSu0d7atIzbE2henTjFQa3rEWn2ZW3+WYHY20fN+fase71gQoY4Hdn+6XC8qP9kf161lLfRzKw8xhtXODkk47YrJ1b6Lc69ESzsXPnOXfed7jdwfxrIOWvgUkZZRkqGbj6Z6UkGoK1x5ZjBKcZJK7s9vpS3SM7ExpmTnGw5GPWuWcebVlKpYux3JEZ+zgAgfMo+79arLfBuUjPmL95jyCPQCqluqxxpub960mTt5Ax0Gau2yXE0vzxtIzLnCjIznvUJX2Kc2hbf7WCZSmQ/TgD8/8BT4l3DzCrseMjb+tX7S1zKyynzPLcloUb5d3oW/wqe3smeTasjSQkny0HQ/l6fjTeHZSqIbGWe33LGF8sYLY6ex9TWWrSNMzIrdPnLD5QaualMdOjaO8VPLUgqCeB7MR1PtWVYXkdxCHSdJJlyQoB29ec9h/9enKgpNIft1E1440ERaTezHgnGFq0v2iPasMzD+4O1OfzJIk+z2hfbjzPMJ3IT0yP/rVpRjaMvm4dGUYiXO3pn8OaPq2o1iItFeWKRbJWdQkg+Y7lyDz296oW9woDxtneM4+ntXRSwySqWDIke3dk5P4YrBu7a3SQkeY5Rs8Dbknr+H4Up0rfCaRqJmvbMxh3AloUGAF+Yn0GBVhogbZAGVGGcbOSfxrPslZpokjXyFTjmQZP49a0ooJoCzJC5XAAZQTjPf0zTjTvoN1S3ZjawWN4wy+h+YHOODjp3xxTbiJFuFGwKrjDOcjJ7Z9Kkil2xY/cQopO+SZwvA6r/8AWpZ7mG4DwMrzjy8gkhVP06mtnS0M/a6l6FcwhMjuvbg1ZMBaBTJGzDlcZFULGVUtPKljMRUZR1O/b/s4PaprJD5CmKUh24ff/DgDJx+XNaRhoL2g+FY1KAO6hhlkAGKuyQxXAVY0Z1GCHUjr/k1DfTNFGpaQdAQeSp/TpSWF5FGH8mWMl8llVcAEY5z6n+lbRXKZt3JXtkSRNn3U5OMgH15p7RHdG3AIG3cDwR/TvVkTrJH8rAoPX0PXFRwTgxsrueCegPA78/jmtHN2FZDYd0J3KQR0IHTH1p75dxyo5GWY44H/AOv9Kjl4BBClNvIxngsMH8KY3CgJ8rKdu49TnnJ7df0NRuPYvLcqPLZ1DAdAcYGDxn+X0NXJRKsKNt2Fjkf7J7f4fQ1gRbxIGG4qDjB57dD+o/AVuCRhbxnJGAAVYdT6/XGPyoRLKkUJkJGNx4IJI+X6n8T+VLNalQUVWkOAOOADnI59cgj8qkhdWkkjdQSwww3YwT7fU/rVeUwxzokjNtH3mPIB6E57cj86bQxPs4iJA+ZlKnDDIALYOMdRhqgto3kkJYr5nHze4OAB/KnGWNnJToejEgEZ+U9OwIqYBXILDJPJPTGRgj8/5VF7MqxheJ9XWzVJ0wR90g9wM/0yKhija7iXEmFI2hj+YI/KjXtMW8dmBwCM4xjJzvAP4hhT7S2e22xJkhD9zkjIwV+vGaXO+Z9inFWDxDazXmmrHaxjLbec4A9QPocVysd3d6EbqO1mjWe7iDkOQwUoR2J6g5H0xXcTWypEQ7yKpygI47Efz21y2paILjUUuL6UlCWxGOGOVXA9uTTqSsrrcyUE9GUNHt728Wa7uZMyKz7pOzMXbjH1HauhicbEVEIVNqLuPpwenemRo8ipEiARqSIwAQMkc9e/yn65qy4EcLqONxI9MZGf51mmUoajpWaFlEjqwK8ZwD6f1/Ss3TYFW6n1KZh5SNsiUnGXI5Yewz+dDLNeyx2sMqb5HyXHDRLxkn2wD+Yq7fRxosFvaqEht/lUcdBjJpXT1Dl6GbazSO7KAJPMPHU8HGSf1q3c4eR5SiMseEjwMA4H/wBaqb4yJlXKow2YPJ7DHp1qXUk+z6cI4iRdRRmSQEfx9Tg5q6abInpqIkLSq4cFQBtLNxkAjis+6aMWZSFkWWVwOOctnH5YNZR8T6etxsWeQzZGFLkDGQM475yK1bRBPfNO5jMdshccYBY8YwfTP6Up26ERdyzPGYFWKMLKYUCgjIBAPT378VTsdPW41C2jEm/zplLR8ZCgbj+HFa0bN5C7CEJHI7gc8mk0RXTXzOwZHggY5JGBzj+tS0nYtG75wEjsvCux5HPt+v8ASqt5u05RLLLuupk/eAn/AFY9Pr61KLyIzPdsriVMiFCpATjlvfvis2ZpZ5G835SASC5PfitJa7FEkUqSq5LNnbuTjGPpz6VSAa5vRbM4VLqNo3yeMDq2Pbn86tW/DRsXUqBjIBJYj69qTSo1bW3vJgksXluqxyE4bBGTx+FEZMTSZvadZPp+i6fBoV9Y6fbKrB4XZQS24nflgTk1A9pdJMb3VLqC8lwFgkiI2seuTgAcfzqxpd7DqM8wn0mzWOAkO4Zvwx71V1y9SaTdEiwhV2rHnA49P0qJJBSptPb8j4ksImkuoeuC4GR619E6LKbTRlbeI8pjpjPH5k18/wDhv/kOWZIyA4yK9jhnuboGGKVFxwQFyT6gU6jd9DjjuX5Lt2wIVw6rkMxzknqT6VRaC4vrksS5iO1d0alRk9/f0+tbOk6JLJtM0ZKOeWl4UnA/GupTS7chYoZoIYw+B5UbEsR7noKI0rotPU5TTdEla+zJE8USkgPIRjj+XH41fk0fEkhhWSWMLkJyBu6Y98YNb8b6UzLDLNPMI1PyhcZwOvJ57CtCPT7TIltIpmMa5+ZOcknkY9TVqkloWm7nIWOmAwvF9lMrvkgs5A3Y4bPfk9K17PRo/swM0svmAbE3fKM5zwOvX1rrDpTxmSW/YxyR4k8pCHbk5ORzgdB+dMiu7yD7sUVl82+RpU3yDr0J6cd+nNVClFbg5N7GWuk3RRAtu0URdlZi+OQAckn1xj8altreC3VIGusy5CbbaPP1AI4HOO/SnvHNIZnuZJbjfIRIHOcAdgpznp275oFrKuxo1aPDAjCjKtzyewzitFyp3RDvsc/rfg5fEV3HKrTpHtLsJCFL5C4OSeAOffiqn9i6X4GhW5li+23UxMccKncDJxwB7fjXUi0nubwtJLJI6k/LKeM54xngHrwPSs+4jSHWki1aFYra5gaMvFHuNpJgfOB2+vrTSivetqZS5n1PPtW8VeITqkcN9bSW0cmGih27FZT0IxjP411uiXcyXSpfPHbxNgKFO5lIIGBjnHI6mjW9K+3X9law/aJbDTYzHHNONk0zEAs2euOR2xgV0unaQsM7meBRvwQMfKDgZxnqfl6+9SoSvqwgNkm+wJ5a2bzTtyvmHBx64z0rMuJ7ZFUtcRRTOxfHmbgR+AP+TVXxpPfW8H2Sy3PJJwX4DD/ZHp6cZFS+Cra4t7W4udS8r93naAvy9Bn6HH6ms5JSny2OhOyuI97p8GoLaT3pe4AAaOOI8scH1447YrSsFZZTHmPy8EKzOchvp6UxfC8S3sd0AzMRuLnDc8kL9R1zVp51idFTy2Zvvsq4IHU4HPX3pRg0/eNefTQwdeyt1MbKKaWXaqIF+fLHgbccn3PpWWv9uabEt/qYzBkJJHHIHeH03L/CDxz+ddXcQz6XremalBAfs6OWbMpJwcjA+gP4mrHiW3huo7uWOa3kS5hWJEjQmQgsCpZccYIBq3Rvqc86jIJHeKzSS1WSVpDzEBlm56be3uT0q54XdriAmVHt+WJI5AIHRTj8Ku6eixWobygX8vdnJH8I5z9ePwq5YyRQWMUMaZBZnUbvXOavkV73NYyfKYeq639jKI0SvKV53fLtXP5Uml6i9yheCQA8qe4BHXOPfB+hqfU1Wcq8Vzb2sobEpeMHcpGFIJzgZGDisGbR57Wea8hs4/skrqWdHKJ5m7HBHc/MMfSnYn2h2JvSERW8otuIwMHjOD+HSrYl8wlUk+UHbjueMfqKyNELBVklRZBsDKX6q5+TBI7cc1oQIqorvEV2qpO1s9Dn/wDXSLTuWk5LBkIGB5ZY/fUjp9f6iqs2oW9tKI5drBiBnHIHQE+npWqrQOvmqCN3Y9F7E/gRXI+MbS8eOW3s4I5Y5fvODgr6/mDUvSNy46uxvwlGYySZ8plJAB9en49q2ZZligwkbMMEncSfRhkDr/8AXFc7piSxWMcF4wd0QBx33YxyO2eK3kJKbXCMMbVPIHTgD14JH4Ci42rnL399Da38Duu+MkxyIwI49+/QEZqo2pSXlzdxagkqW8QICQqQzDkbW7HoB3yQK3r3R4ftP2gLtGAVHBLd+B9AfzqY6WrsokCqdvyk5yemO/f5T9Qaz1b1LaiYOgrNJNteKRUw27Lc4Pb6HH610+0kKJD8jgAOvPB/r0P51DBaBzsaNkkIIZ8YCjPOfoQPzNW96sRGoBRQCAVyQGPzfr/MU0hehnTKxTAA3k7sMMbT1H6g/nVRpHadVCs0vGAOenQdP7p/StOfzFiURqpkYFhk5HXOfxypqkXWBiiZYKMyuPQHH8iR+FQXfQbIY4CDdSmV9o3HqEwcHHryBVU7mdGmQEHruHBGNp/ocVleJTefYDLYl2milEbBeScjaeP++TV2xDiPMpzEVCZfgAkgNn8ganmu+UfL7tyfZmIrEjhMfIccgjcBx+AqtqkkK27ABQM7lOOfvAjjvkHFaUkywDcGAGc7exGRzj8TxVY25txHcyj/AEkDEcbAfL8pG4++B0ptaEGfDa/2YjMWAvLlf3mBzEvICfyJqks7SxldqhnzuPU+v+NX5x57SNKd7Hlsjr/nFZuoMETMYUsvyj2Xnj61k32GT2ISWaMoDthUyOM5DdAv47h+lZviCYrb3LEOTsckY/i6g8fWtvT4hBYIcASSnLY5+UdBWdqdt5yBXiZ02kFVBxjHGcdhitItoymrI8Uv0ik1KBrZNsibQ2G447f59K9hhgEGi263Ij+0zYllOT8nZV/SsK28PWs2uRWyFFXcJppMY/djk8+hyB0711N6ImKvLINrYxtYfL6D+uKVOm9ZGd7aFmIhDlmXLjCqD8uPcjn2pkXlrp947Pl5H8tT3+Xrj8e9Z39qLBZo8rLFzgKRk9cdM5/HFPkv447SCIOgLYYjnJc4J4PQ81pZIqMkXYjKY1zJluGHsM57e1SR5iNyX3BAAMgcgDOffrSRuAQS+0uoJBPQYFU5bgo8kkhYBRn5c/MT0H/1u9JKyKlNvUWET3Vwlpal+RuMoydq9yfT8a3LIBdWt4xD5sKRmPAOzfjqfYd6g0u2fT7G4BdftV0uZEIHyL2Gfx5p9lPsvkjBJKxEMVHLcfy4ppWWoWvqdTb20X2TztP0UPG2cH7Ts3dj1+nWuT19SNR+xLbCCZ9oMIk83bnuW7Vti+ils4IZI7iKKSFrMsF4bPKlPVgT0rnriZW8YOU8z/RbJI2Mq7XkccbmHY81MlfQzpyfMfL3w20uS+1OeWNMiJMBiOFJ/SvYvB9rFdTA27KI4yd8jdAQDnb6A1X8O+FTpnhZLGxjBnlTNxLggu3PH+e1eg+HPD8GmWtuhLfdfdGgBY8YBJ6Yq3H3rmEIt6jrG3jNkjSl5E6eZJxnAyAQeg6Uy+s52jEVuskkpIWLy4yQpx0z0wM8ntWyt26QyGOCJ1ZwVAXIB9/QHGOabcrfvKohVoI8eXmNxkE9R/sitdGjSxj6RoN3pDGTUZorNMkPvZXLrk+mSfpxWxBqcgsfJhL3e1QDJJlExg52qOw9+ait9NhhdzJOJThPmmbJIHXJ/Xkc1daKFIVea4w2VLNEpJJGeo6Djv6mmtFZB6lG2W28lx5RDON7hVLZYYBBPftVtrRwUKmMochpJM9OwIHan3UsqQKbWJoI3fJLEEK2M5Y9M1mC/SS4O2VZJFyRh+HYckHjnuQOO9W3pqC8jQEwcApJG8pARpDyFx69M9/yqhdGL5hdFnYnnYBj149fwqxHcqQ6G1iU/ddl7kj35APX8Kbcwq+/C+cz4Cycgbs9/pmpdug0rhZXYj2rBYySqw+RX6HHUkn1x1q8hivPNkmKJl/4SCf9oDvjFZ7wXU0xHyxkKQTGcA89yPfn8KcbT+zwpuJ5S7nKxAcnjjkdOOR7mnGZMoJkk9pbJGzvOpQjAwDtB4IJ4x07e9QZieIDbMYSABnIwAeTjv8AjVXXNZFqtuvlGMkFFRU4J6bvc5xUVjqMV0GSIbWDYDKCd3TIPp1/CplVV9BwpmldQ20m1jM23Py7k5ZT0IHTGQB261PbzJbRAQxM1mgJCykHk9FIA5zk5A9KikTy7RVJaIqBuUDBGcD17jHT0qNgu0yPtjYrkDnBIB9OhoVR7FulYamsQT3wtkn2zADcm0gAegI6DoR+tV72BftDTkHO0jHOSOvHrTZrCzSZLgPDHPnzFyBv2/7OPTHIrVtGjWNEeRSQQwdSSADyP8/hScW1qEUR2QkkhmiEhQbe3Vh2b/64qGKzwSYridkULhPlQ47nPtUsqtbzJMn70HO/YTg9M4x/KtVIbc2iSFuNxIymQB2z75/nVRloOUEZ8geCMpK7N15xuDH6+hrQjjaNClu+VRAueqqAM/Njk+lMdY5vKZlxvyCo42A9R/nsantkQoVR2Lt85R1GD0x9PelF6kuNlYx9Rt7aS3MUMWSf744OBkfTjNZEPmyRxWtxcB4opdykZLsAeB6H5tp9txNP8TQTWySPEJTcTSr80T4THGB784/CrmhKb4m+mgVNjBRuIAYEYJx2+X9Vq209CXHqXtPtVjgYttjuZGeR9vKoxYsR9QQPzqR3BMokOEYkNtxggkA8/QGpJlMdi6q7Km0u7uSu89A6/wCeprjv7eX+04Y5FMIfMhBI/eNg4Az3IPI9cVnOSSLpps9Bs0jkVI2aTbhiNnILDgqPTPWrNxDC0qb8nKDaeCSexPqOMfXFZOlFZp2OcA8jcMEEKMt6Z2kH8K1p96SMGi3LzvCNznuB+Iz+NJuxaWpQgtovtquZF2lh8zjJYY7j1BOK0HkkEYVUAEZKZ28DgZb3wevpVVUEkoV1IJGW4wc/dOPqNtW87rheHf8A29pOT055752n14NTzIti4ha3BwFbBPXn5cfKM/iPoaI7dFkLbC8YQlthDDAPH44yMe1TvFHEVJJdQ3G4hVyBjBPUEgjP0qjq0/k27SQEEqyZMbcDGck/y/4FSbtqJXloh88iKGCD5XO12OSM/dPHoeD7GmTKVDF1G9j8wxn5jjIHP1/75qjpD3V9CFmSVN4KiTJ2DoP5gZ+taeJnheMM6BuRwRjK8AH6gjPvU819SvhdiGZUXeu7aX4lwOFXuB+Jb8qoSWxnGCMdS34/Kefrj86uO4JJZHjLneFJyMcHn3ILVAYZGkEjAurLywJAyeB/LNK1w8yjJaps3oFMkuGJYd8cgevI6+1NSJPIwqfuvug54zz/AIrV262IxEgJyScEdM4Yjr6MfyqFFRyjqC25dxRRxk/4fLTabHcqQxoj73KuTuKKOAMjIb8xgUtzc/aLdRIUJIz1+Ydyf1YUXcYlikYEbgARkEnGdyj26EVn3TiG1d4xyudy55x82P6cUrNDIpXeQFXcNGCT14Vcg5/nVKbzbuWKKDIZgAADtxjHJP51Ba3U9xA7SIyhmLZJ69cD0PUVesFdYvNyGf7nUEqODnHbqKhJS2JlKxaVBFG4BYIqhOT2x2/n+NQg5uZAAJI8ZLKfr+XWniRYoQ8jBV+8MDjOPU9uc1VllWYBbKJpIZMBnjI25zjI/EfrVxjqZSlciMZhSe4RMmfKqGOMIoPU+hIrgvFuqz3Or3VlbymCKMkS444B5K/mOPau6ubmFgvmLKiDKhSvPTse4Oa8z8UXcEV5cXJicTtISiyHcGBVWB9+uKKt+XRmTkrmJdtqWnPayTLIs0oEyMTkkc4P412Wiaumo/ZzKEN9vDFWYljnAyR246fhWXd3CavBbX5i2W0H7vbIMjzDj7vsAMYqTRbJrTxWHR2VhEJJWcAFeOn6CsV7stNmSm+p6LLN9mXa4CiIYfuRxwc/jWro1sABfX52ybP3ET544I3sO3t9ai0Owa6VtT1BcxgZijPR/Rj+NSXVx/pDuz7XfJBY8+v+NdfwsuKuSrIr23mSKN8jZy54VT2xWbcT7btFiLfMpBMXGc//AF6dqF1DANucoi4ZuvT/APXWZol9M+qPPYnGwYEp6R+hH4VOjdinJpHSybNW07T4pb9rSe1TynR43KnBJ3qV7njP0rPvdTs5tcu3SV2EdvDbtJKpWSUrn5yD6561t32qQ6Tp+npNr9/a+dH5ipHAr4XOM+wrn/FOheZJe6rHq1zqM8UUJlMsYXdE4JQoRww9qTWtkc6nZ6mhZxBIzsUoudqhcBgxHfrnjNXLS3muFd2lCBhsd8cJjpzk+nT36U21gcrEzMSvT5cZzjpg/X6fWrMxSF0PnLtQAqoQjBz85YcDPP4Vo23vsdSXKrBEFthcNCbiR0jG8FBwcenXr36/yqwIcwu9wkjOw37WyOAcbvU9B/WoLaJVZU3OZW3MrMcEg8gjB6f/AFzV+aJ2jcIJFnZsKQ2CEPOfcEjp/jQmQ0cN4j1mPT7xLeOJjJnbGzICzA54IHGau6CbiaGFmDShnwEVhjHGTz78cdKkufDkUt759wzMUJUMkZYZ29WbPGSeg7Ac1swwLbWgjRPlUAbj0yB7D0+lRG/NdlNXWhQ8U2076c4j3o0vLANwvy84I7jHNc9ofh+a3kaSZp5pZ3ZBLIxwvHX6BepJ4PFd0xjkkcSwPGrYKP8A3iMAcYwTz+J+lRTLAA8MTqNpBKliQR0BHt3568mqkk5cwRVkQrarsCorFVABKjO4D+I98movKLyuSq7QoIKrnGD09u+etaCQ5VnYxpg/KAwUHIOPz7fXNTvdRwhELmPgANGhyR1+nQYz3+goGtDPaGdW3xyNHGpBQuBkH7p57dT+Ap8iwE/vZIxxkAKRnPGf0A/A0rLJMJRvQ2zA7WYYIHPbnHcZrE1q4a2tSw2eUFKAEBucnA7ZGTk88Yp81tRO7ZLeR2l2xOFaMH5g5w+McrgdMnH5VJaWKpLmDBEuMhSGwex/MVkaFMbg+dKSuBuAbncFPJH4nuTwK07aOVLjMRKjcF4zzgjnHbqen1pOS3KSNCZVjZVKFpgcqcfcyO/rz+VUdUj3pmNdoxgtIOPrx6GrE7mKzkDLK8kaeX5aMCRn3/CmafJ9u5dJCGyMCPbzjDAD34OO+KFa5Um7HKQTXpu5HTIycIe24D5hz3OD7dq6aOISGOPYgYEKBt5G5dwA/H1qxe2btDHGqhNwDbgM47hgOvBHP1pCvlGQEKFLAtjG9MDnn2OCD6UuWwrlkG1WL5tyKzAuV5Cg8A8eh4PtV6CT7QAoOC5K9SQTn1+g+vSqMUTJI+BnaSu2RMgEnOM+nXH1FMad441cKsKHHygbceuT0BBJ/SqSJk2W51AI5DqMPkjnHQH27ipURSvmdCpyCo3becHn0PFZcOsRSXix3CDBD4UYA4/hPpkYP45rWXyzIfLlwu5dpOCducDI74bg+1O3Yad0RyxysyJKsgdRiPywM5zjB+nB57VWt4JERyy738zJ2g/KT06ejAg+1XNYhaOKFRI2JFZD/CQ4Jwfw6Y965+21Em7kw5jVGVXGejBTu+vQE/nSc+V2YnC+qNC5eSPa5j/eKfN2PkAHvkdMZ4/EVxLaPcXWqQSmVzbi5LxoFBwpG5HH4Fhz/dFd9HdzmMwyHehAU5HmLuJ+UH2O4H/gNZN9N5dnPPbW7LHEi5VQeQF5UjtgjOe2QaU4Ke4RbWxq6QVW2CuxUyqABnK4GQAR6nkE+4raSXyom3wkgN8u4/xAYzz1P3T+NcP4Tv7ie6kt2E4hVty5UcuWHB9ujHjq1dldsv8AZ7yFGdYWxiQgKhGQSTnPf36ZppqavETunqS3M0Yw80YhCNkgEEZ4IB9iMflUkcgCosUchOFKbzyG6D2/2fyrz651SYs0cZV41G4AsQflzhD7kMQPcV2WjX63EEfm8IRuYnqvGOeeCcjj1FQpKTLkrI1onjLMInAAxwzZBH9368n8hUNxp6SZjXCxgj5QM5I5z6jnr7EU947drlgkrxyLIG2Y3AHPf8c/pUNtbIsTl7tTGZGBI4Oemfz4xRLsJO2qZDcWQtdjPcOC4KhUT5enGOegG367aZFO0ksJt4cr1GX7khhk9hnp9aXXrSa+slWN0iZ24+YYVcgg59Qf6isvT4Jo5GgUlWI/dqWHrkZyOijA+pqG+WVkUtVds1cyIWYyExHJUcNhT0+n3iD9KzLy+ltji4cIMiQBgRjBOVwOmeTU7SJ5Rto1DMzlThx83HOfp835iuc1HUYvtVql8D9kVvMcKpBIKllx6jII/GrbS3A0mumEa7GaUruYMpHzDoM/kala82rMZ0IBGQgP3lGcgHP0NcpojLHNcfKTE8irGrnGF+YZ29cZrpWgkGnjfIrQ7Crup+VRsOCMc/w/rSUrq4ttDLg16yM7RK7l2IT5U+4QoHP/AH0a57UvEQW4h8gM0LkAhv4Rk9vXgf8AfQqI2kt3rEspyTIWO2PgtgfeI6KOBU50qD7UJkSNGgcMhUnaqj1H4D9a5lUnNWRpJRizSt0aeZTJIiIV3KsXA2/L19+DxV15AkUaQEk8ZXkcfKTz6VViFvHOUgl8zGOQOG6E/jkEVZZZIld5ZVORnJ4CkA8A9ulbRukYyaOY8aXKLZSQLcY3vGH2g5AJI/l2rltK1e5t9OS2tXSGdt7M/c7eQF7Dof0rr/FOlHUo2MaO8kJACKeJSGznP0aue0zwxBLagzTCNI2OIpgQM84zj1NTJTdTRGUnZFeHxLHsjGo3M73BHETgqDnGBu9sD61LeW9pqoiUKrSOAVWMH5eDx6EVzHiKG5udTknngZS0hCsqnG0dMDpx0+tb3hNfstl51yAzn93GcEkdckY/CiLbfJLYyfc0L7TLa5trS1EhSJIz5MK57scsR69K2/CPhy3nmEs6E2UXMkvTz3xkL9M9avabo6X8v2eBSJGIM0qnHlIDnp6ntzWvfXyWlqLO1Ty4oVChAMbSB39c4zW/JFe8y4psmkvHeU/MqRA7QAMgAdqx5bqJZt2XcR5PPQnB7+lZ97qZDbN435wqg/LjH6U/SLKe5O4hfJ4aSUE85Hb1NC97YpySK0izXd00duFDnIJzwOvJJq5OEtYBBYldqj523ZLHHJOKnukgt/3cJ2xAbiVHLZ9Se9VFlSMM7RkQIBgAfe69aSjyslyOg0+WzttEspfF1xpIiIY2f2qBpHVM55KkfKSDgGsTV/FNymr6joVyY2Fx5dxFdQhQskJUGML2CAfjnNZ/iLWfD+paFZwa/b3LS2wzD9kuRE0iBjgPkEDGTjvWXqUbSa2JrhbWLfYQLY20LmQR22392Nx5J65J7mm5OLSSOdK8tTv0v/s8crXRMe07UYkDKDg569MHmrumSotgx8xQWjby3VshcthhwOM8fl6VjWlnLqVqwWWRklbBA44z+GFx+fPSpLmGZryOBbj5Ik25j53Yzw3HGeMY96hNnouKZs6WlxbPKks0LLHKAisSWGAGI54OP/156VfNyty8jYPB3rxkZyfmPP6etQpIZ4UEzOr5UKZFyDnPAPUDH096llEiwxpAixDGSRg7vQEden8qpBZMa8Ukt4hlbC5GA/Y4JyQO3vV23Tyg4wscJ+VlP3WXB6nnHJyfUnFVbALDGjzjy7gx5B5+XjoR3AxnB/HrUcl3unKZlLKCoiSQbWPTaeOvOM+pOOlPzKaurItG4OABEzxy5AywBGCcHgcDjn8vWqL2puo0MmMN1eUldwx8pPqe3qeBwKu2TZYlJmaORdoH3AVB4weeBg446D3qMROHjCsxcsZFXGCHyACMfl+ZpvUErElsjxQsZNhDg7d5x8pHcjjtz6A1FfIsRWW4SPzViaQZ5RsEEZzyM4B9hgd6lcbdwtcSLlV2yNnOf4hkY2k7mPrx2qlqqM1tIGPzvgMobIA7ZA65yWPUYxQLl1KAdpo2W33fOxbMYOSc528+hwff6VLqECXgUyqpTZtVSwJCr8vPoOpJ96z9OUm4RICJUMhCl8blGd2D6DHOB/8AWrfjQW8CeSrbyqkH+Fs9h/eGTk0kFislrHZlkjO0nMZ+bcPug5HcHjpUsioxVk2opz5btwCR1/HqD9afcNC8j7HO5Qc8j5jgDv8A5xVwx+XDNIFZVY7wAwwMjC/TpihsqKMgp9nfzIR5OBhgp3A9iORirUcny8r5YQruKAAj0II/SrItdsLsM7lPIPJBA+vPH51nwzgTeTtkilyFYMQRtyQD6Y5HFJNopxuWgUCn+8GIZy25QCMcjsM4/GqrAB3cFQw4PPDYDAgn6Hj61dPzQCZkBjRMsGO3GeHXHfBGahlTy0kjcBmyMsAPkYdCPY8ZpsmxFE/G1jvTywCGXll/2T3PQ/hTruKOa1Kblck7VbpuJA4P1GPxFRhGncpGgCgD5R7/ADDHp359arXbyypthHmSSNtYcIQRyCPywffFNMmSMPy44J5iqyxxlAw7kZ+Qnn0IGfYmt3TshwJgpkbIfZwqngOufZtp/GqT2jSXauJ02PMsnKgDb1LEdPVT9RV7Tk8z/VIUiELndghiykqwzk8kYx/u1C3EdBHbi5t8S+azIfM3bA2WVQGXPv1rLlso7GaSTdsLkqzHGN+35Tz/ALIIJ9a0oZV81GWTYGcfMqnBUgZIz0yC34is/Xi6wMLaPdcj99hAPmCMQQPXcCT+dXdLcWpzWka9cSPNFGBui5JZPmVUUMMgcFskj6CukS/SdHluoEkhkbeXiOQwc4+vKnr7VxVxaJJqcQQfZ9jFX8tSwYgqUB9flYg47Zro7ACKCP5S0TKwhIwVdHJ49lHH0qYSd9wcVa5r2b28ZjkV2jjbtEuctkhjz3JUc1buZbdUKSJJIA2THt6kcYB78H8ifSqlvJHBG+/e0kDLlwuSm3BJC+gJwfwNZ3im4u4EWeyt5W2Izs3QllOSR74Y49qtuyuZuLvoS3djp8bytG0aNuwpAychQQWPcADP1ot7edQjwMHDKfLw2cZIBLfkevqK5zwz58qJHPIypIytvznKEfKR64AAI+tdfBMixLNIrqg3MWY9B/uj0DDH1FZxalqlY11iXYoZ0a4R2JEpRgxIIZQvzcducGnrpk4tdqsruGMv7o5xgHGPQk/qKisZftF4VRW2om7LHaSecnJ9fX3rQiuJJpGVSoi27hIWBBbHBwOwwD+dU4pkOUkU7h5I7QvI8oSNwrIFLMRznA9OT9cVUVYluJLhfM8xQB90qSSWAGeQOcZzSXmpXNjNLDPHLODGDv2dy2STjoBuIzVSC9gkG24dBbhTJLIT1HBDcHjsQO/NS7IabaMa71j/AEqS1hKyAuWjDJsbbnkEenr/ALh9avvp5S2DXBSZxH+8ZjkKWHCjjrkEZ7Z96SOw0n7Ys9m6744hIrPNuYZC/eHYYIHrgmp7uG9hhmuN8caghckZUEPkYHq2MGlGLestRTnbRGZZaRfNrSyzFIyqYVSo3sBu4x+K+351qwapPZvHI8IMcjcnGTGvTGP+BH8elcfL4qvE1FoVnZlR0dZDF1T1xySDwuPpW7HdLIcX0UiXcaZIUY+YjoR0JGSfbNKMoq6iN36jtSudOvJi0avA8iMW52kEAdT+HSqC207gS3H2ZI0YfIDlh/wL/gI/Op5I0khjRWGJwDuYkZzjG7PfGB+NMtnktoJLYSB0YnACgMp7Y7HpkU0tdSG+xcsrB5498+4AEeZFEQCOSB+HI9+tUPFmqQ6KiySoJIlKmJAxzuJyQRx05555rT0aSeOUSO02wKdqOwyzYPAHfHrWN4psoNb3NPcgPAhBG0fICc/zHX3rWUXye7uQpa6mTB4km1K3e4s7YxTRDm4AGFOBnPqOKzNFtJZIrme6I84blVgc7SR9cdat2EVrpulvDImDCSxyfv5HBIx09q5ldVurrUXhKAxBikeF6/N1/WsLtWc3qTKzvYuNDPIrWslwzzmRtzP/AB56lj6c8e4rQ0uCaWaGzs4j5xG1SDjBOMnPYDmnC2SCOZp2DsV8xix78YHsOSPwrpfDli9rYyTzxlryVMnA/wBWnTH1NWo3ZMTpTA2haZDFE8bA5eV2PzT8d/YciuHu7i7uJWMKrtJLgAcAjPrXUFDcWolZgyY27ZOOOenbNYOoXFqIzCGYs2TyeAcnHStJwulYvn5VYx7O1F1MyTSqIkYNI8ZJPrtzirGo+LrDTXjiedEwSEQqc45AJHboPzqS2kisNLlQEgodwYn7z+pFc34dtrR9CudVuYrPUZ5XzcmZwDFH2Cg9+Ac+9N+6komLlrc6CwvlvWSaNhLGSWV88sMnt2HNZV74h0m41u3067adoH+WWa2ILocZAXPGe1O8PxBbArGogjcsRGrHhSSRk9uCKx/D2jWE/iq2stMvRe3052gbDtjbnJJPYYJz7UpNpK3UV73NLxL/AMIA08Frff8ACUsyE58pICWz6nHNXbV7TWtdtZ9KjuYrC3tbe2iFyFEpEYK5OMjnj/61WNY8KaXds1vF4umglHEzx6a7rn2bOcfSrqaJD4Tt4rWS4a6fyxJHIv3JQfusD1x7UlTvO5EbdzubJEimS14LyblVlGfYnJ5yeMfh2FSpYvKJPNkSBnZkkaTJyAPTtnH+d1LZySSqYcvH5pOWBGF44BPXGc+/XpmrM9vMsTtKZcoQfvA4AHUDpj3paM9F6ErqgMEfmubfyiVAwCxHBXjp3/L61SjlltL4pLHhX9B16YPGD2Jx6D2qwsbxiKSQrDFK+7E2MhApyeOmeB9akYQvefK3nzZdh5gADgjIP+ew96bHEeYI3t8YPklflwSTuz6Zyfmx9cAetZNzD9lvC7gyNkpKecA4y/fGBnA6/Ma1A52QyvFKWT94zvwUx6AdW5HHYt60y+Pl2cqPJGoOQRvygUcBc9eCR9WPtS3LVzMsJDevIPMVDkNiX+IAgE5HUDBwO/Nak7JDOwZ8k7gq7whHzHIxznOR1NV7OKG2cBQyzqFZowACCBgKmckKTyT7VJdyF5XCRHYCUbedwc7skg9xu/RT60LRDvqRXU6RsgB85XLK37wkKONwyDxjpkewFJNEGCvJJIrB/lj2gEFuME4wAF49TVW7u4olglypLnDH7pCJ0bgc5POPpWvFDFcW8efMJkcrlmOPmGcE92PT2zQhyZg2OmG3lld4mVE/eFflBYhgoznj8B2rXgPmI2wODlnZ1H3sYGSOwHNVfPfz5NsZwqEiMcjk4UkZ5C+tJYTwxxlZGyJAAMHqM9MehFMFF9R90u05UKZCuAo755z9anEji2jj8sBCCM7RnqDn19qsQEXUwSVmEe4tvzjYvKqB9aiW3CxA/OzkhQMYG7JH+FSVcI52mT5gCBlsEY68Vm3FmXnkWIsqRNsYFidoYnJJ+pH0rTCBEMbgLkbCZD90kAgeuODVW+SNzIBgjGOM5GCu449+tD2HcWSPzYvLSIMVRt5XIDHjdnPo386gnlVQzR7mRcbM/wAS/e/LqKsbWnkUqux2LbkyevBIz9BVOeSKSeTcFO75lz2UMRjjjgZoFHsMRVKxSOyPCXEWT0Ck5U/h0qGTaBtlDZjIEnc7RkBvrwDUtxIAQrMxTc6YGMMjLkn8Kh3rJGVm2m43RxnbjaXJ2gjHcHGfY0ENlXcXlPnBWRw3mIpIUno+PbBDVqssi3B3Sk7ASoUAZZVQgkn1wefQ1kPI5lMzRoYsguoYHZyY5VyecZAOKvW0ZW2AmaYFzE7sSQWCko4A9Pu80k7kvubFqQsX7weZEzkw54XG4fL9QxYYPFSYt5oSbidZIFdcgDbgleMA9tyjp71RSfdEhnDKqZ89kPKHYx4b2xn3rlvEF49nK6rNskRVKuRuCKPmV8dyRuP1OKcnyq7I1bsdDF9mjtEYKuMRfvIz2ZihPT15BqpavczNHBAA1uCY55C3CfwtyOvzAHHoaoabfzJJFG0qjKOg3vy7spfdz2HBx2NdNb20Qs5JMkxbS4ywywdAVOPdhx360LUG2nqQ2fmLfYMgillUJ868KxHJ+nABz6ird4FubIwrviO3azk4Ma+3uCMH2NUvtkclrMfKZo5JCm45UhQuDyOvHP6U6S7t4rYIu5SWCmRySclcsR6Dj9aba2bCzJVQWQLeQqxrF5axovCoeny/3sgir6alYu3lXOIk8s7y2CyEgLs49h+gqK31OO/ifahkaQYMmwDbxnOe4yAfzrmbvUTOJbWyhCSyKEdeMRuMYGcfd6c+9TOagrplRi5PVHRzyWzqt28ysjAeWW5O0/IRj17Y9RWFqt7ZtfXFnDcnEb7QNuFwwK4A7nn9aluBb/Z4Gj2fuySzuDjOCVx68g8CuX1DSfP1eSLzSkHmfNHIc/LnOc/w8cDuayqVGkVGKuai32pS6lG000bRIWEpx8m0KMLg84AIOe5NRXcD63p7xK0UMgKTO0gChT/CAQOeMDHoakv45VTdp7iSaf5fNl6LHgE5x0wAMZ71pTGJoYYljXynJ4cABnGOTx0HAH4U0rt3ZDlbYzbbT5bYvDC8VwnmYeIAbXKj7vPbJx9BVy/DSo6XjhYwxWQ5yxYjcCo9sfhVfTtRjt/M+1RSh5SztH5Z6Dd+AyR/Wrcf2e8WTKtG0uJBGFDAKoII3fWrhtaJDeupyWm6RLa3zyr93aFQysGZlGeAMcZroYpZLy4kS+VoJANuW4HTGF6HAA6+9MhtJpLu8ur6SVYjGsaxBQFXA9c+/wCpqxLdxSXsM+FEzRnaMHBPI57ADB/lRCnbUJS1HLcRXkoWLcxQfMeABxgAev8A9aqItoxInzxBsZ8tDngcn8eBUVzILszTRy7pIQm0ROBwCRz7AE/nWNJqN1FrLJAJEtyVjUTEMW9CMDjNXKVtzK99jY1q8FhG88rNErDYkjhmyCPQfQGuXj8UtP8AaZ1t1IVchmQAHJySQOvT+VP1vTTc4luGf7wOxXyOR83B9sdKkttIhdJrkeYlscIOBgnHYDpnBpS53K0diW0kVotbt72O4YxZinXCp5ecMTjPPWtjTtIht7JrqaArMXHyhcdevI/zxVDQNLjt1knnTe4GIYz/AAjoSMfhWnqOurp9rb2qSuZicLheQxxgdPeqSsrzI3ehoWmmxanfENFBCLbEkoJO088L7Z61vTeWY2Bm2NIOUxkDjqPXPFZlnGllp62byM9xKPMnkbBDP1APNRvJm5iCMFAVgPMG4JjPI9OD+ta6LoUjL8Q2D3LwpDdtGsfJI4759eD1zWNc61p+nsYfO3zEbl3Luzzg/wBa0tdildZEaFY7UEYcnBYcjOM/jXDXGli5unkhLEBtzKo59gD6VjOTi/dWoNnWT3dnOqfNFvkAYoxwR7n8c1RTQLAz7vs8R6f6vcSSMH6Vjf2e91qEZKqqRYB75x0B/WuytV2h2cIJANqoDwcev+NVBubtJbGbsRPaKIiiSrkkksw5zyKyfCuiNouqx31lK51Pfvh+T5foR3yM11MkMVvaxM5U72BP8/51jHW44L5JbS58ueH50kBGc9MAdz2rSUb6slySVjp1uYrm5aa88JPvUZdopJlVm9kxjFed+MPF0154iVZLaSGZQI44fKMYjQDCjaecV3t7e+O9blFxaWOsafFJGFcB9gyBy6qcMufTmuQk8PX76vJf6pcXE9/5e1numLOgH8J3en9alpte6ZwauenlkUyxwxytI7BEC4wAeCCfTg5Pt7VK2pzWbRW+5dm1SmQBv/3fTriprVIZ7mMALvDZ8vBGRggjA6jj+VZmsaS95qMF55rrEoctFn7ysTwT2H64/CskmerKzOhM5nt5ILjDytggq+VUDkZ9uvvT7U74lwnyxDYxHRVxuJ9h39egrPknmitjuKs5VfNCAAr0xgdjknjJ7Vowkw25kdWEgVcsz7sEjkDseAAPcmnqONki2pjdWiUDnDEPnBIG7J9AvBJ7monWCGOJy8aQxrkeb8qhvvcjrkDJ+pFEi+VmaQM67cFmO04Gd3TuWOKxprpprlYYpIfPVmkbIAMgzg9eMlgB9BQikr9TTFom7/UzNKiFg6phSnrycknJAHc81LcrPhVhlCEjAUt8sQPBPuFGFPuTSXFyFitGkiDMWEm2MkKzgYKHjnDZOB2FAUuJUmVI/wB6Qyg4B6uX9cbscVVrkpsoyr5movNF5YiDb2XP3FXgAZ9T2AqzbtOsSQNIxK4BXPQspI2nueSKJ4baQedFuZsoAYeV9hz6nJoCCVVXcioHZI5PTjGW/HNTsaLUgMIE4LxEGJQqlTjChcnGOfSqlxbhLZOkp2BgCcbSec5HXHSr0nkJD5Ic79m0OzcqQPmG3uO341WjhaWSNXGwtH94HPJ6gAfQUjRMZbXSpFEyuFUEkndzxxWpJc48qGNgsrLGMx4Y8+p9jWc9lHA07q6PIzSOMgMpVdoKkZ68Z+tRZcWzXIdoWSNU8o43ZBzkDvyaL6hZMm3OvmbkzsDEMQcbg/T34qO/QPu2jaiKF3YG9g7ckY7DinXWqA3oFtvdjcLGhQjDBiCcg+5NV2kxaiBovNYtEh2kjb85H4ii4jSlYpaz+Xud1bcyqcbCr7Tx2yprMWJ4JIJYowx3SqvAx8pxg/iw/KppLp5QC8gYIknzngH5xt6c+nWi6ihFkzuVDtJLtYA4L71AXPTk5qb32J2Rm6puNoxixtwpcEbkAbC4Pckc4xWJp8GoTXkipI5kR5YEkTgOzAhXB6EKFXp9a2S/lyYRsQo7xlwm0gGVcZzxjP8AKtCG3KMJbeNPLi2/PyCGCsHcD0Jb0pP3iWc/BGiXpcKGZpYJd3OQJUw4IPbKj3zWlHcRvFsnlaSZ4wgjPT94MAE9gWUmnXTCC3tHlAeaaO385cHH3iAQw9Gzkd81nRaTJDPbzTOojDyBVj+ZfMXjZnsBjqe/ShXWxLN23H2m2lhePY0h4dcKJXKuCCc8cAZNctqmmG5vJZ8BYZ/KYJCN+cR42JjspwR9a1P7UiAisxbqYf3K+eZM84I69iSW4FV9Mme4iuJIV22i24ZJlP8Aq/kACHGDg4J/CidmrMlb3M+3so7u7s7tr6IM8xEfJyDnJB9cEHJ98V1eqyC9hj8glIkjUAIAMkEFDnsBj681hfaYjDd3ccaWwi8yNACcvu5wP+BAfgazNI1cGUQpbyBJEKgZwxYqMEDuSR+gqVOMdO5Vr6m5Ekcnlxid3DPKyKnC7thbjPbnBPtTLx21KF4bcAyIpIdgTnKjDH2DE8HpUwnSKCWIma0umJCB8ZUfeJHXJJBHXpVK0+1veKd0ptIoMhiuA6Yx83vkk80nbYEzU0aJojaWwdBNCyBMMThPugkeuM1Laxxoz4SOKeTC525L+rDHboPqKTT50F2lwEb7Q8QDEEMNp5GMdAeefaotWu4rWNH89JHLvmVjjywq57DjkdPc1fLp6E8zuOeGW6UxrDsCB7hju+6hPb04Oe/XFU9R2m8W3uN8rS4bzkJ4wD1OP9rI9MU+Od/NVonH7tg33tocc8ED+EBvx4qa/mgSFVmJgUDJbkjqeMj6UmuZD5mgI8oSNECyytGigINqjuAO+SOTWdct9mjaa4VIolJmWInLMc5J+mNoxVvz4HdwsgEkYxuA2que2Op7nJqi1ut7BE90xiUjYoAySoIyMg4APy9Kpaqy3M72epYtHgku2likdxIckyISGJ5weecZ/WtNnWKchHWNQm5I9uQP9rr/AJxWJJPHZrDaxPAWycI0udhJOMe9Nws0kipNKSOrRjAPGCcn+VWnZbamcmN1C8kh5Vt9vu358sEyEnnI75zj2FY9rHqU1/NcasAiBdkcSHO3PcqDx0zj3rbS4trNkjlVnnPyDcCWQDnj07CsnUrmFI4p5NmRN5jAxktnPIGeM9aUop6tk8xqKtravsiRpVRCmzyiQ3qCfTis6FUWSVpUYhM5CgAL2A9uxqqdclmvH48uLqxzl2GPbvjPNWoreO7ka/m2iHdvjSU4DPj7ze3TFXo9jPUs6dZxasJbm/QRWzDCAnGePz7fpT9RPmEQyTpGgT/VxgqV2n+E/hn/AIFUWo6mhjS0kkEjgqQVcDII5BArMluku43d9uVw2Q/0+XB6CndbA11HG7RrUyi4b+ERqzYwRwAT+FVrOy87WJr+5Csig+WN2ApPQj6VDY2clzdqiTDyFcO2Vwfw9frVm8nvpZGdAEgTiNFUD2yf0qN/efQPQ1oACYkLkOBkCQ5HPJNWbq7kt40kkdPLA5IHGfb9Kx497zq01s75wSVJ5xzgAdOaZrEly8bQ20RaQ8uODt4yP6Va2uJysc54w1LVY4BbIfNDnIkRBn6A545rH0C21C4uyJAclcMxBzg9uK6GG11G7uR9pXIKkquAFUd810WiwGG4LIoVE6nqc+n+FZqm5yuxOWglhYrDaLjaCpyzkZyc/wBKSaaG2gVEwVGchT1A9aw/GcWpXskKWaBbeEbQFJBJ96x0sNQjjWK5kaVsbSNxxk/4CtXUs+VIjoHirWrhLoQWoZIJOHbG7aCOoqL4eRS6f4tttUk8yextJFdg2N2ORkA9xnI9xWjb2cn3JtpYjDOeieldP4QTT7LW7Fb50Nssg8wOOM9ifbOKTjfVi6E91Y6PZRPcf8JdiN283fcRzGbce5xyTXCeO/F9xrniRf7Le5NrFbxwCaVNj3G0cysO27+WK9V1q/TUJ7rRfFktuAxxBeIFP2diMryOqc8/X8ue+IFhHD4itC5gdIdPt4yyHIJAI49RUzv0ZMdHqeg3F9HBufJZ92Aoydr9MZHGOe/9Kv8A2mB0klhETyXMQKjk85yBtPGDx+FZQt33bI8iFiCEVsjgZ4x17D3rUtIVjmj8vAikYqd6klOONvpjk/QUI9TRoltbJ0SE+UoYZyFX73ynGOevU59CKkIjjjtVtxDEIgGQMd5RQOAB6jIb3JqtPcmygPngyx7l+4dvHDAsRyM8cfQVOJo3AVdoYkqjMOeCFyrdTk5yT2wBTEN1CfyMi5HGVOCMgYDYP1yCfqc1zj6fc+cfIR3beu3IHOF4z+LE/hXRyKZwjTEshTB55+bln98Z9e9SW/nrMZB82xdxcAdWztH4A0uVN6milZaGC85eECNvKMZJEiE5IXCjA6DOD+ea1klnVmto2hdiGZZGBLHkYGeh4z1q2PKclvJY7CqEMBuO3JI/PFNtuAIvlKKyKAVGck53Z/Pg03oCdyBNnmIyBmU7pMIuAoD9xnrwOahmbyoUYEvKXxvKjay5PJ4A71rmNZJFWUZhAKjZwDtBGSPqRx0rNnkCSMhDSxqdow2NwztA9Bjk470rDjLUz2l23K+Z50JG0HkMFDeh78CrFhbRTRRGEsA23avTZvc/NzwenSq1xCuoQwwPGTDBJvwPu4UkNux24FXYNNNrZRhwXC7Y9mCQpCtIGHPuBipcWXz6bk8lnIy3EEgjKTOyjaoBMe4A49t1Y+rNeWsLh1HlrvZflIxjCkcnjJz+Vb0bNGIzakjdIjmLOQPkyfpyATWPdfYxbvJKHlVrZriRskErvyoznBA5zTshRk76kdrbpLd26XHzlr0uZWHGAAAuR1ps8SCKKO2i2zBVLGPJclnbY2D2Xk1ovDBFMih98iXiuAiHaysAw6HHGOfpVee3ge5iunZ3uIFYyGNiw8oElRn+8QwIP1qbaDcrmXbGSaCNk8pTskBG3A3Fcde+WUsK0GaWaMxGNnmSSJWQcHPk5AB6A570WMqW9xaiQqjSQpEYR/G/ltgEjsARn61JdzuksbzSKC8RlURKSfKWEgnIH9496IqyJnIwJYNREebJRMhEsK3ErgBg0gxnsTnn8K2YVga0Qm4V55IX2uAAN7FVxk+pBIHvVaHUre3t7eCGEykCMntI4aMsyDP3BgDGKqq0IktrbyvIR1C7yASjDmLAB7ZPXuM1N0iW2zSvbiEWssP2g+Yg8ol0yNgk2hABzkZzmsW5hF7b29nbS74lcqzMwXesY3eYQenzEg05tSlFkIobeNUaH7SzSEFziXLZb8B0qISxNe/Z4X2yNO7RMBnPyZZc+hJJH0pOSegGfapJbabGDKFubgJMuBlfKXJHbgcEfjWlZRzpeWsL2oKxSBMCMKpxCSeB1BJxVOZCkNpFavJcwSGESO2CShPIxjJGeo7ZFbFpdtPFMruxuLdipOcZAJ4BHsMGiEehDetzNaWW7sfJvpBbQvGm1gmPLOSGIA9Tjr2p11d2NoLW+nD3FzCsYVQoiwQSy5A6kAc+9LbXNjqluk1ks0caqdsaJhtpY4GOwyOvao57WHVY3mlXyY5Mj5mJDgZO4enJwT+FTZobZGLYm8Fwk8kwaRCSq9MkOqj1JLDP0qxc3LebcSFncFAoj6qq7hxuHcH0HSmyPGttGolkjiQc4HzcApnHZs444PFZcd2scULTSOLZyixYOcHaMhsdyTkjpx3odkhczLlqG/tTybhW/fAt5hx/COQScemAOnNaGppM0aOoj81trPI2CNi5wAB3PJx6ViXFwvmSSg+aquxZOgBySDjP94Hj6VNc4mEYWIhmHl+YMg/e6gevAPtmnZJMTepYYyQO32dYnhlYYcLvAY8Ekds44pupahEYSZHPmhjGyFQwf6gc45/Sqcu9LuJLdpDbhRmMtgBgMnHr2GaqocPNEbhwXAC5IBHJ6+o/Gp16D5kW7FopfKjFxNGzMflkXazHb97PcdcCm31/PHfGJiIpG3KHOD5Y549Ofl7frWUmoyTXBjiiaJlG5XY7ixwRkHHb0qVVMlviKGItghnLEYPXJOOf8aqN+hm3djXt0NxJCX8oMd7lxz17Hrk8E1eubst5QXzFZgFjHYAc9+9UQ8cPmvJuSVcKduMAngnnr/TNNa9ZUhhkKQYXKsELDB6jPXvTirakSMy+u5iIoobhpMgrIUJwucZ/XNM2TCS2S4bzCp4jz06jnuc561NfMscn39+1WxsUZUcdvzxTrHdMiz/Ikigx5xzk98fj+FJK7IbLVuDFFEbklQjBZI1A3Yzn8R1rQ1O9kuHcQbAqhiyAc8ZH044NZV2GZdyorOoDZwOSVNUmYlGklklWUZyy8EN71fM1ohIY9yILpZpZHkmcE/NjCDAIAPr1p8U9vNPksMLg7c5YY7H8utUbq3bzRIykFuhLDA9MZ/GnWFr8skhBk9CDkEdST+tRFtOwNmt/bEcStFbhGuDwhB5VfUn8P1qa3eZnYcugwDuPXB55rKMUSxncyKxHzbTwPQZqaOd0kkTK7c49dvJ7/hWvM5bk6JFm71h/N2Q5iUMOcDcAf6c1Sl1iNpjGs21wRlRzn6+9VbyR7hRDbRks52DC8gdeabpOhCxZprs+bJjLKednuPenebJ0N+OYWsKvcM6uxJ8v+9mp0ukhaWTJZCMnbwR7VmKDiN5I2VCQAzdfzp1wzXEjIqlznjYePxNWm0IXUNWEkpNvIZJGXcTjhRVO086WQyKxZO/OCfpSRWwIKAoSTnHQAf1NJcSFW2I/ykgjHUkdqCXYrXf2p7mOEzJFaoQcIckfU+taFpO6Xpt4h580zBURTlmJOMCqrie9kAitwEI5Zhg1q+EYYtM16ynkZ0bLI023IQsrKGP0JB/ClazbQc2hp3OhpJdG3n1ywS/AKm3VHZEI6hpQNox0J6D1rPn0KS3naK/Elu8TbGiBBGf8O+fpXaaRpstv4gs7ueS4jmtraO3OnpbuxIVdpRGA2OjkFtxP8XPSqfigTvPHb2jR74LeOCRwdw3qOcHvjpn2qkriV7nY6cfNthvxxgdP9mp7WRmDqfuKFKp2XJKnH4UUUpHpQ2Dd5tnpjS/OZpFV8kjOWz2+gqo7uVUl2yJVQc9tpb88sTRRTQzUsAbm2AlZirHkZ4JBUA/kKhuJGg+0eSdnKA47/KKKKllU9x63k8FpHIshMpRQXbknk9a0rglYI5s5lcj5j1HydvyooqoBJahkRtMqqvA8zJGTkvg/mOtZs773uEdVYLHIQccgqwA/maKKnqJFa2gDTxKWfaz4IzwcvXSWtjBIf3gLKTJlSeCd2M/XHFFFNE1NjKW4kbSpSuEBtZpMIMAMHIBHvUBmBuUUxRbNvlFNvylS/INFFJjjszJaaQahYtvYGS9l3YJA+WPjgcUkEpim0dcBybJZCzckl2YN+lFFZdfmavoS2Xz3OnkkgizhlBBxglyP6CsW91C5/sK5dpCzhkKseq8HIHsaKKa+Fj6/cUoL2aaGCZ9vntpU0rShfmLbtmc/SoYpXik89Dh0u5CBjIOxAFB/M0UVixCFQLyO0PzW7RSHYew+9gY7ZqfwyxbUbgYAWIGUKOhLRnOaKKIfEvmTPYbeL9lvbTy2bDLGNpPABBJAHYcCs/V7qayntjat5bXjgSkDJIPJAz0zuNFFOXwsnsa8kv2aGZbaOOHypNylBznKjv7ZrJsp5Z5IpmkZZFk2ZU4yPtGMH1ooraZgZ39p3EUt1DEQkaTmNQuRtALnjmpLtxe2h82NAIzIFC5Hcn19RmiisTVDL9EgilkVFJORhug+bHH13GrzTNLJbbgAMZwOO2cfSiikt2T1HwPI0MM/muJAqtkYGfkzj6e1c1A7M8zk5YKSP50UU5bIHuMaaR7qEs33n2kYGCM9Kv6g5gMXl4BkAZj70UVX2TLqOQmaR1k+bcGDHuazXY/YbduMyKNx+rEH9AKKKJfCBHbxrOjM46vjg44Gau3Ci3s5nT+EqADyKKKlbEy3KUU8iWwMbmPcATt49azJbmVJZmDZbIJJ5ycUUVMugiFZ5IyXDcsec96u58q1bZkD5eM+q0UURExpy1tuJI3SFSB6ADFPLNFD8jH5jzk9aKK3WxEi3qkrWFvZJbYUTqXc4ySfrTNxitTIDuckDLc+tFFavckrJdzXTFZmyoc4A4Aqe1z5oQMQr/ewcZoopwJe5ZnhUO8KZVFGPlODVO2JZIVJIBfBx1NFFEtxo6CNERVRVGN/p7VbxtMeKKKv7JaNSbU722tFt4bmZYNuPLDnbj6ZqmHP2dT70UU3uO2h/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple vesicles and pustules are present on the plantar foot of this patient with reactive arthritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_62_25573=[""].join("\n");
var outline_f24_62_25573=null;
var title_f24_62_25574="Urocortins";
var content_f24_62_25574=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F83570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F83570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 579px\">",
"   <div class=\"ttl\">",
"    Urocortins and their interactions in pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 559px; height: 367px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CRH: Corticotropin-releasing hormone; ACTH: Adrenocorticotropic hormone; Ucn: Urocortin; Ucn2: Urocortin 2; Ucn3: Urocortin 3; DHEA-S: Dehydroepiandrosterone sulfate.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Felice Petraglia, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_62_25574=[""].join("\n");
var outline_f24_62_25574=null;
var title_f24_62_25575="Hemangiopericytoma Light";
var content_f24_62_25575=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sinonasal hemangiopericytoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph of an hemangiopericytoma with a bland cellular stroma and rich vascular pattern.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of G Kenneth Haines, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_62_25575=[""].join("\n");
var outline_f24_62_25575=null;
var title_f24_62_25576="Paragonimiasis life cycle";
var content_f24_62_25576=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 573px\">",
"   <div class=\"ttl\">",
"    Paragonimiasis life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 553px; height: 476px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The eggs are excreted unembryonated in the sputum, or, alternately, they are swallowed and passed with stool",
"    <strong>",
"     (1)",
"    </strong>",
"    . In the external environment, the eggs become embryonated",
"    <strong>",
"     (2)",
"    </strong>",
"    , and miracidia hatch and seek the first intermediate host, a snail, and penetrate its soft tissues",
"    <strong>",
"     (3)",
"    </strong>",
"    . Miracidia go through several developmental stages inside the snail",
"    <strong>",
"     (4)",
"    </strong>",
"    : sporocysts",
"    <strong>",
"     (4a)",
"    </strong>",
"    , rediae",
"    <strong>",
"     (4b)",
"    </strong>",
"    , with the latter giving rise to many cercariae",
"    <strong>",
"     (4c)",
"    </strong>",
"    , which emerge from the snail. The cercariae invade the second intermediate host, a crustacean, such as a crab or crayfish, where they encyst and become metacercariae. This is the infective stage for the mammalian host",
"    <strong>",
"     (5)",
"    </strong>",
"    . Human infection with",
"    <em>",
"     P. westermani",
"    </em>",
"    occurs by eating inadequately cooked or pickled crab or crayfish that harbor metacercariae of the parasite",
"    <strong>",
"     (6)",
"    </strong>",
"    . The metacercariae excyst in the duodenum",
"    <strong>",
"     (7)",
"    </strong>",
"    , penetrate through the intestinal wall into the peritoneal cavity, then through the abdominal wall and diaphragm into the lungs, where they become encapsulated and develop into adults",
"    <strong>",
"     (8)",
"    </strong>",
"    (7.5 to 12 mm by 4 to 6 mm). The worms can also reach other organs and tissues, such as the brain and striated muscles, respectively. However, when this takes place completion of the life cycles is not achieved, because the eggs laid cannot exit these sites. Time from infection to oviposition is 65 to 90 days. Infections may persist for 20 years in humans. Animals such as pigs, dogs, and a variety of feline species can also harbor",
"    <em>",
"     P. westermani",
"    </em>",
"    .",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Paragonimiasis. Available at:",
"     <a href=\"file://dpd.cdc.gov/dpdx/html/Paragonimiasis.htm\" target=\"_blank\">",
"      file://dpd.cdc.gov/dpdx/html/Paragonimiasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_62_25576=[""].join("\n");
var outline_f24_62_25576=null;
var title_f24_62_25577="Cystine stones";
var content_f24_62_25577=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"28\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cystine stones",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/62/25577/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/62/25577/contributors\">",
"     Elaine Worcester, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/62/25577/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/62/25577/contributors\">",
"     Stanley Goldfarb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/62/25577/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/62/25577/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/62/25577/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystinuria is a genetic cause of kidney stones with an average prevalence of 1 in 7000 births [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/1\">",
"     1",
"    </a>",
"    ]. Cystine stones are found in 1 to 2 percent of stone formers, although they represent a higher percentage of stones in children (about 5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cystinuria is a different disorder from cystinosis, which is characterized by intracellular cystine accumulation leading to the Fanconi syndrome and progressive renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12584?source=see_link\">",
"     \"Cystinosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178545215\">",
"    <span class=\"h1\">",
"     PATHOGENESIS, GENETICS, AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystine is a homodimer of the amino acid cysteine. Patients with cystinuria have impairment of renal cystine transport, with decreased proximal tubular reabsorption of filtered cystine resulting in increased urinary cystine excretion and cystine nephrolithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. The cystine transporter also promotes the reabsorption of the other dibasic amino acids, including ornithine, arginine, and lysine, but these compounds are relatively soluble and an increase in their excretion does not lead to stones. Intestinal cystine transport is also diminished, but the result is of uncertain clinical significance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346007738\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previously, cystinuria was classified according to the amount of cystine excreted by the parents of the affected child (phenotypic classification). Patients were classified as type I if their parents excreted normal amounts of cystine, and types II or III if parental cysteine excretion was either greatly (II) or moderately (III) increased. However, with the identification of the genes responsible for this disorder (specifically, SLC3A1 and SLC7A9), a genotypic classification of cystinuria has been introduced [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Neither the genotypic nor the phenotypic classification appears to be relevant with respect to the clinical course in patients with cystinuria, as is discussed below. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Genotype-phenotype correlation with stone risk'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The genotypic classification scheme is summarized here:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Defects in SLC3A1 &minus; this gene encodes rBAT, a protein required for normal cystine and dibasic acid transport. Patients who are homozygous for this mutation are referred to as having type A cystinuria. In most cases, patients with type A cystinuria also have a type I phenotype, meaning that their parents have normal cystine excretion.",
"     </li>",
"     <li>",
"      Defects in SLC7A9 &minus; this gene encodes an amino acid transporter, b",
"      <sup>",
"       0,+",
"      </sup>",
"      AT. Homozygotes are classified as having type B cystinuria [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/9\">",
"       9",
"      </a>",
"      ]. In most cases, patients with type B cystinuria have parents with elevated levels of urinary cystine (but who do not have stones), and thus have the non-type I phenotype (called either type II or type III cystinuria in the older scheme, depending on the level of urine cystine in the parents). Since the parents of patients with non-type I cystinuria have increased levels of cystine excretion, but rarely have cystine stones, non-type I cystinuria should be considered an autosomal dominant disorder with incomplete penetrance for nephrolithiasis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178545747\">",
"    <span class=\"h2\">",
"     SLC3A1 defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;SLC3A1 is located on chromosome 2p16.3-p21 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/10-12\">",
"     10-12",
"    </a>",
"    ], and encodes a glycoprotein, rBAT, which forms a heterodimer with the gene product of SLC7A9. The heterodimer mediates sodium-independent transport of cystine and dibasic acids in the apical membrane of the proximal tubule and small intestine [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/1\">",
"     1",
"    </a>",
"    ]. rBAT is the heavy chain subunit of the dimer, and appears to target the transporter to the brush border membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/13\">",
"     13",
"    </a>",
"    ]. The severity of the defect in protein function and therefore in cystine handling varies in part with the type of mutation that is present (point mutation, gene deletion, etc) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/10\">",
"     10",
"    </a>",
"    ]. Most known mutations result in abnormalities of heterodimer folding or trafficking [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178545963\">",
"    <span class=\"h3\">",
"     SLC3A1 genotype - phenotype correlation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with type I disease have inherited mutations in both alleles of the SLC3A1 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/15\">",
"     15",
"    </a>",
"    ], and a large number of different mutations in this gene have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/16\">",
"     16",
"    </a>",
"    ]. The correlation between SLC3A1 and the type I cystinuria phenotype was illustrated in a study of 164 probands from the International Cystinuria Consortium, of whom 97 were typed by urine excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 37 patients who had the type I phenotype, 34 carried at least one SLC3A1 mutation, and 29 had two mutated SLC3A1 alleles (genotype AA).",
"     </li>",
"     <li>",
"      A rare in-frame duplication of SLC3A1 was associated with non-type I cystinuria. However, with this solitary exception, all patients with cystinuria who had SLC3A1 mutations displayed the type I phenotype.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178545754\">",
"    <span class=\"h2\">",
"     SLC7A9 defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SLC7A9 gene is located on chromosome 19q12-13.1, and encodes b",
"    <sup>",
"     0,+",
"    </sup>",
"    AT, the amino acid transporting subunit of the heteromeric complex [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/9,12,17-19\">",
"     9,12,17-19",
"    </a>",
"    ]. Many disease-causing mutations have been reported in this gene [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178546021\">",
"    <span class=\"h3\">",
"     SLC7A9 genotype - phenotype correlation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with non-type I cystinuria have inherited defects in both alleles of this gene. However, patients with mutations in SLC7A9 can also have the type I phenotype or a mixed-type phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The following studies illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 43 non-type I probands, 41 had mutations in SLC7A9, and 34 had two mutated SLC7A9 alleles (genotype BB) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/16\">",
"       16",
"      </a>",
"      ]. Mixed type probands (n = 14), who had only one parent with elevated cystine excretion, carried mutations in either SLC7A9 or SLC3A1, with two SLC7A9 abnormalities being the most representative genotype.",
"     </li>",
"     <li>",
"      Another study examining genotype-phenotype correlations found that the same mutation in the SLC7A9 gene was responsible for both type II and type III phenotype in four different patients, and two different missense mutations in the SLC7A9 gene were linked to type I phenotype [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178546152\">",
"    <span class=\"h2\">",
"     Other genetic defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Known defects in SLC3A1 and SLC7A9 do",
"    <strong>",
"     not",
"    </strong>",
"    explain all cases of cystinuria (9 percent of patients in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/16\">",
"     16",
"    </a>",
"    ], suggesting other as yet unidentified genetic defects may contribute. However, investigations using a candidate gene approach have not yet been successful [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Very rarely, cystine stone formation can occur in patients who have only one mutant SLC3A1 allele when another gene, called prolyl endopeptidase-like (PREPL), is also defective:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with the hypotonia-cystinuria syndrome have one mutant SLC3A1 allele and mutation in a second gene called PREPL. In addition to cystine stones, patients have infantile hypotonia and poor feeding during infancy.",
"     </li>",
"     <li>",
"      Patients with the 2p21 deletion syndrome have deletion of PREPL and two other genes, and have severe developmental retardation, an elevated serum lactate, hypotonia, poor feeding, and cystinuria [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of cystinuria are those related to stone formation, such as flank pain, stone passage, and hematuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cystinuria should be suspected in someone presenting with their first stone during childhood or adolescence. However, patients with cystinuria may present with their first stone at older ages. The median age of onset of stones was 12 years in a cohort of over 200 patients, but onset of stone formation may also occur in infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/6\">",
"     6",
"    </a>",
"    ] and even late adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/22\">",
"     22",
"    </a>",
"    ]. For unclear reasons, males appear to be more severely affected than females. Cystinuria should also be suspected in patients with large branched (staghorn) calculi, filling the collecting system and requiring surgical management [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30695?source=see_link\">",
"     \"Options in the management of renal and ureteral stones in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40231?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of struvite or staghorn calculi\", section on 'Treatment options'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cystine stone formers have slightly lower creatinine clearance estimates than other stone formers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/24\">",
"     24",
"    </a>",
"    ]. This is possibly related to the need for multiple urological procedures to remove stones beginning at a young age. Such procedures, including shock-wave lithotripsy, have been associated with decreased kidney function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/10/27812?source=see_link\">",
"     \"Renal complications of extracorporeal shock wave lithotripsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Genotype-phenotype correlation with stone risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are conflicting, the clinical manifestations of type I and non-type I cystinuria appear to be similar [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/6,15\">",
"     6,15",
"    </a>",
"    ]. Of note, not all individuals with genotypically proven cystinuria develop stones, indicating that other factors, perhaps environmental or related to risk-modifying genes, may contribute to the risk for stone formation in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193492902\">",
"    <span class=\"h2\">",
"     Radiologic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other types of stones, cystine stones are well visualized with non-contrast computed tomography (CT). Plain films of the abdomen are less sensitive for cystine stones because they are less radio-opaque than calcium stones [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/3\">",
"     3",
"    </a>",
"    ]. Although cystine stones are usually discrete, cystinuria should also be suspected in patients with large branched (staghorn) calculi.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RENAL PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a kidney biopsy is not usually performed, examination of renal tissue obtained during stone removal procedures reveals associated parenchymal abnormalities that may partly explain the loss of kidney function associated with cystinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/25\">",
"     25",
"    </a>",
"    ]. These findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ducts of Bellini are plugged with cystine crystals.",
"     </li>",
"     <li>",
"      Apatite (calcium phosphate) crystals can be seen in the inner medullary collecting ducts and in the thin loops of Henle (possibly related to the long-standing alkaline urine).",
"     </li>",
"     <li>",
"      Focal areas of tubule dilatation with varying degrees of surrounding interstitial fibrosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings contrast to the histopathology of routine calcium oxalate stone formers, in whom interstitial deposits of apatite are noted in the absence of intratubular crystals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193492926\">",
"    <span class=\"h2\">",
"     Diagnostic confirmation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystinuria is diagnosed among patients with nephrolithiasis and one or more of the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stone analysis showing cystine",
"     </li>",
"     <li>",
"      Positive family history of cystinuria",
"     </li>",
"     <li>",
"      Identification of pathognomonic hexagonal cystine crystals on urinalysis (seen on initial urinalysis in about 25 percent of patients) (",
"      <a class=\"graphic graphic_picture graphicRef56834 \" href=\"UTD.htm?2/10/2208\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All patients presenting with new onset of nephrolithiasis should have stone composition determined when possible. Patients with suspected cystinuria who do not have a stone available for analysis and in whom cystine crystals are not visualized in the urine should be screened for urine cystine using the cyanide-nitroprusside test. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193492994\">",
"    <span class=\"h3\">",
"     Cyanide-nitroprusside screen",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive cyanide-nitroprusside screen indicates a urinary cystine concentration &gt;75",
"    <span class=\"nowrap\">",
"     mg/L.",
"    </span>",
"    A negative test generally excludes the diagnosis of cystinuria; however, rare heterozygous patients may have a negative test [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H252939269\">",
"    <span class=\"h3\">",
"     Urinary cystine excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with confirmed cystine stones, urinary cystine crystals,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a positive cyanide-nitroprusside screen should have quantitative testing of urinary cystine excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/29\">",
"     29",
"    </a>",
"    ]. The normal rate of cystine excretion is 30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (0.13",
"    <span class=\"nowrap\">",
"     mmol/day);",
"    </span>",
"    by comparison, patients with cystinuria generally excrete more than 400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (1.7",
"    <span class=\"nowrap\">",
"     mmol/day)",
"    </span>",
"    and some excrete as much as 3600",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (15",
"    <span class=\"nowrap\">",
"     mmol/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/3,30,31\">",
"     3,30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Heterozygotes for cystinuria and patients with the Fanconi syndrome, in which there is a generalized defect in proximal tubular function, generally excrete less than 250 mg (approximately 1 mmol) per day. Such patients usually do not form stones because the cystine concentration remains within the range of solubility [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/32\">",
"     32",
"    </a>",
"    ]. Diurnal variations in cystine excretion and urine pH, with periodically high urine cystine concentrations coinciding with a low urine pH, may explain the occasional nephrolithiasis in such patients, and a fractionated urine collection may be necessary. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H163732240\">",
"    <span class=\"h3\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic analysis of patients and their families for mutations in SLC3A1 and SLC7A9 is still largely a research tool. However, it may play a role in the diagnosis and characterization of this disorder in the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90357407\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis is similar to that in young patients with other types of kidney stones. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193493001\">",
"    <span class=\"h2\">",
"     Theoretical basis for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aim of medical therapy is to maintain the cystine concentration in the urine below its solubility level. The solubility of cystine in urine is pH dependent, being higher at alkaline pH, and it is also affected by other urinary ions and macromolecules. However, it is hard to predict the solubility of cystine in a given urine, as the empirically determined solubility of cystine in urine can vary from 175 to 360",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    (0.7 to 1.47",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    at urine pH values in the range of 7.0 to 7.5 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/29,33,34\">",
"     29,33,34",
"    </a>",
"    ]. The limit of solubility is best derived experimentally, but can be conservatively estimated as about 243",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    (1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    at a urine pH of 7 or higher, since this concentration of cystine will be soluble at this pH in most patients.",
"   </p>",
"   <p>",
"    The concept of urinary supersaturation is important to understand, as it is the basis for treating patients with cystine stones. When cystine is present in concentrations above its solubility, the urine is said to be supersaturated. The degree of supersaturation may be expressed as the ratio between the actual concentration and the solubility limit, as shown here:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Measured cystine concentration",
"    <br/>",
"    &nbsp; &nbsp;Supersaturation of cystine &nbsp;= &nbsp;-------------------------------------------",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Estimated cystine solubility",
"   </p>",
"   <p>",
"    Cystine crystals will dissolve when the supersaturation is below 1.0, while values above 1.0 are associated with an increased likelihood of stone formation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/29\">",
"     29",
"    </a>",
"    ]. Although the ideal saturation level has not been defined, we aim for a supersaturation level of 0.6 in a 24-hour urine specimen. This allows for variation in saturation over the course of the day, including the inevitable increase in supersaturation overnight when urine volume drops [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/29\">",
"     29",
"    </a>",
"    ]. Achieving this degree of reduction in cystine supersaturation can prevent new stone formation and cause dissolution of preexisting stones [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/3,31,35,36\">",
"     3,31,35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6937161\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two main approaches for reducing the urinary supersaturation of cystine include conservative measures, which should be prescribed to all affected patients, and thiol-containing drugs. A trial of conservative measures is usually pursued before thiol-containing drugs are prescribed, unless the urine cystine concentration is sufficiently high that conservative measures are not likely to lower the supersaturation of cystine to below 1.0. These issues are discussed in detail in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Initial therapy with conservative measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is possible to reduce the supersaturation of cystine by increasing fluid intake (which decreases the cystine concentration), restricting sodium and protein intake (which reduces cystine excretion and, therefore, cystine concentration), and by urinary alkalinization (which increases the solubility of cystine). These three conservative measures are complementary and should be attempted in all patients with cystinuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     High fluid intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowledge of the rate of cystine excretion can be used to estimate the optimal urine output to achieve a urine cystine concentration of less than 243",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    (1",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    If, for example, cystine excretion is 750",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (3.1",
"    <span class=\"nowrap\">",
"     mmol/day),",
"    </span>",
"    then a urine output of at least 3",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    will be needed to keep the urine cystine supersaturation less than 1.0 at a urine pH above 7.0. A higher volume is advisable to keep supersaturation low throughout the day.",
"   </p>",
"   <p>",
"    The patient should be provided with specific instructions regarding fluid intake and daily urine output goals, and instructed to drink at night as well as during the day to achieve this goal, since high urine outputs during the day may not prevent stone formation if volume drops and supersaturation increases markedly overnight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H252939369\">",
"    <span class=\"h3\">",
"     Sodium and protein restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-term studies have demonstrated reductions in cystine excretion with sodium restriction, although the mechanism by which this occurs is incompletely understood [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Protein restriction also decreases cystine excretion probably by decreasing the intake of methionine, the precursor of cystine [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lowering sodium intake to 50",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    can markedly reduce cystine excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/37\">",
"     37",
"    </a>",
"    ], but adherence to such a diet is difficult. Since there is a linear relationship between sodium and cystine excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/38\">",
"     38",
"    </a>",
"    ], a dietary sodium intake of 100",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    is better than 200",
"    <span class=\"nowrap\">",
"     meq/day.",
"    </span>",
"    Thus, patients are advised to moderately restrict sodium to 100",
"    <span class=\"nowrap\">",
"     meq/day.",
"    </span>",
"    We also suggest a moderate protein intake (0.8 to 1.0",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day), as this provides adequate nutrition and should be tolerated by most patients.",
"   </p>",
"   <p>",
"    There are no long-term studies demonstrating a benefit from moderate sodium and protein restriction on prevention of cystine stones. However, the risks of moderate sodium and protein restriction are few, and the efficacy of these interventions on cystine excretion in a given patient can be easily assessed with 24-hour urine studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Urinary alkalinization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystine solubility increases by up to threefold in an alkaline urine, but only if the urine pH is greater than 7.0 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/3\">",
"     3",
"    </a>",
"    ]. This degree of urinary alkalinization may require up to 3 to 4",
"    <span class=\"nowrap\">",
"     meq/kg",
"    </span>",
"    per day of potassium citrate or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/35/7731?source=see_link\">",
"     potassium bicarbonate",
"    </a>",
"    , taken in three to four divided doses. We begin with doses of 20 meq three times daily, and adjust based upon the urine pH. To maintain an alkaline urine pH overnight, the last dose of potassium citrate or potassium bicarbonate should be taken at bedtime. In selected cases,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    may also be used [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    is used, the patient must be monitored for the development of metabolic acidosis, which can result in hypocitraturia and increase the risk of developing calcium stones [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sodium citrate or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    should be avoided, since the associated volume expansion can enhance calcium, cystine, and uric acid excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/37\">",
"     37",
"    </a>",
"    ]. However, sodium salts may be appropriate if hyperkalemia prevents use of potassium. Raising the urine pH lowers the solubility of calcium phosphate, increasing the risk of forming calcium phosphate stones. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link\">",
"     \"Prevention of recurrent calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adherence with alkali therapy may be difficult since both alkali and water loading can lead to abdominal bloating [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Patients who fail or are likely to be resistant to conservative therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystine is formed from the linkage of two cysteine molecules by a disulfide bond to form a homodimer. Thiol-containing drugs have sulfhydryl groups that can reduce this disulfide bond, producing mixed disulfides with cysteine that are more soluble than the homodimer cystine.",
"   </p>",
"   <p>",
"    A thiol-containing drug may be used in conjunction with conservative measures if, after a three-month trial, these measures are ineffective, or are limited by inadequate compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/42\">",
"     42",
"    </a>",
"    ]. Failure of conservative measures is defined by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Failure to lower the urine cystine concentration to below 243",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      and to raise the urine pH to above 7.0 in a 24 urine (or, if available, failure to lower the urinary supersaturation of cystine to below 1.0).",
"     </li>",
"     <li>",
"      Persistence of cystine crystals visualized by urinalysis (",
"      <a class=\"graphic graphic_picture graphicRef56834 \" href=\"UTD.htm?2/10/2208\">",
"       picture 1",
"      </a>",
"      ), indicating that the urine is supersaturated with cystine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A thiol-containing drug may also be used with conservative measures as first line therapy in patients who have a urinary cystine excretion that is so high that conservative measures are unlikely to be sufficient. As an example, a patient who excretes 1000 mg of cystine per day would require more than 4 liters of urine output per day to achieve a urine cystine concentration below 243",
"    <span class=\"nowrap\">",
"     mg/L.",
"    </span>",
"    This degree of urine output is unrealistic in most patients, and thus a thiol-containing drug could be used as first line therapy. These agents are always used in",
"    <strong>",
"     conjunction",
"    </strong>",
"    with fluid and alkali therapy (not as sole therapy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Penicillamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;D-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    forms a penicillamine-cysteine disulfide that is 50 times more soluble than cystine. In uncontrolled trials and observational studies, penicillamine decreases stone size or dissolves stones in up to 75 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/3,31,35\">",
"     3,31,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Each 250 mg tablet will decrease urine cystine by approximately 75 to 100",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    The daily dose should be adjusted based upon usual fluid intake and 24-hour cystine excretion, with the goal of reducing the unbound urinary cystine concentration to below 243",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    (1",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     Penicillamine",
"    </a>",
"    comes in 125 and 250 mg tablets, and the typical dose range is 0.5 to 2",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    given in three to four divided doses.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    is often limited by a relatively high incidence of side effects, such as fever, rash, abnormal taste, arthritis, leukopenia, aplastic anemia, hepatotoxicity, and pyridoxine (vitamin B6) deficiency. In addition, patients treated with penicillamine may develop proteinuria (usually due to membranous nephropathy) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/43,44\">",
"     43,44",
"    </a>",
"    ], typically within the first 6 to 12 months of therapy, or, less commonly, crescentic glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of side effects may be minimized by starting with low doses and gradually increasing the dose, a strategy that has been successfully implemented in children with cystinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/46\">",
"     46",
"    </a>",
"    ]. Complete blood counts and urine protein should be monitored twice a week for the first month of treatment, every two weeks for the next five months, and monthly thereafter, and liver enzymes should be measured every six months.",
"   </p>",
"   <p>",
"    Given the high incidence of side effects, drug therapy may be discontinued once preexisting stones have dissolved. Additional courses can be given if stones recur. If",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    is to be used long term, pyridoxine supplementation (50",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is required [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28650?source=see_link&amp;anchor=H39#H39\">",
"     \"Overview of water-soluble vitamins\", section on 'Vitamin B6 (pyridoxine)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Tiopronin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In uncontrolled trials,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/12/21699?source=see_link\">",
"     tiopronin",
"    </a>",
"    (2-mercaptopropionylglycine) was similar in efficacy to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    . Tiopronin reduces cystine excretion and stone recurrences in up to 70 percent of patients at doses of 400 to 1200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in three divided doses [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/38,48,49\">",
"     38,48,49",
"    </a>",
"    ]. Tiopronin comes in 100 mg tablets.",
"   </p>",
"   <p>",
"    The same side effects seen with D-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    may occur with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/12/21699?source=see_link\">",
"     tiopronin",
"    </a>",
"    , including proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/50\">",
"     50",
"    </a>",
"    ]. However, we prefer tiopronin because the incidence of these side effects is lower than with penicillamine [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/3,51-53\">",
"     3,51-53",
"    </a>",
"    ]. In our experience, patients who have been unable to tolerate penicillamine may be able to take tiopronin, and it can be used as a long-term preventive therapy if well-tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Captopril",
"    </span>",
"    &nbsp;&mdash;&nbsp;The angiotensin converting enzyme inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    contains sulfhydryl groups, and captopril-cysteine disulfides are more soluble than cystine alone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proportion of orally administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    that appears in the urine is low. Thus, the doses of captopril required to reduce cystine excretion (more than 150",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    may not be tolerated because of hypotension. In addition, the efficacy of captopril as a treatment for cystinuria remains unproven. Thus, its use is typically limited to patients who cannot tolerate other cystine binding agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the relative difficulty in treating cystine stones, and the side effects of accepted therapies, the possible efficacy of alternative agents has been evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/52,56\">",
"     52,56",
"    </a>",
"    ]. One such therapy, N-acetylcysteine, led to the undesirable outcome of an increase in cystine excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Effectiveness of medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although medical therapy is clearly beneficial with adequate patient adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/57\">",
"     57",
"    </a>",
"    ], there is a high rate of continued stone formation. The following reports illustrate these observations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 16 patients followed for an average of 6.5 years, there were 1.6 stone events per patient year (defined as the appearance of a new stone radiographically or clinically or enlargement of a prior stone) during therapy with alkalinization and hydration alone, and 0.5 to 0.7 events per patient year during therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/12/21699?source=see_link\">",
"       tiopronin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 52 cystine stone formers treated for a mean of 4.3 years, fluids, alkali, and, in 24 patients, a thiol-containing drug, decreased the need for stone removal procedures from four to one per patient per year [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/58\">",
"       58",
"      </a>",
"      ]. This rate of stone removal procedures while on therapy was still much higher than the rate observed among treated patients with other types of stones (0.2 per patient per year).",
"     </li>",
"     <li>",
"      In 27 cystine stone formers followed for a mean of 12 years, 18 were treated with fluids and alkali alone, and nine also received a thiol-containing drug for at least three months because of failure of conservative therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/42\">",
"       42",
"      </a>",
"      ]. The number of stone episodes fell from 0.93 to 0.20 per patient per year during treatment, and fewer urological procedures were required. The most important factor associated with stone formation rate in this study was urine volume, which was significantly higher in those patients without further stone formation (3.2 versus 2.4",
"      <span class=\"nowrap\">",
"       L/day).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the efficacy of medical therapy shown in these studies, a large proportion of patients with cystinuria may fail to achieve therapeutic success. In a study of 26 patients followed for approximately three years, only four maintained their urine cystine at concentrations below 300",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/60\">",
"     60",
"    </a>",
"    ]. Of the remaining 22 patients, six were lost to follow-up, five were never able to adequately reduce their urine cystine concentrations, and the rest were only transiently successful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Monitoring response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to therapy is monitored both biochemically and radiologically. The effectiveness of medical therapy is typically determined on the basis of new stone formation or existing stone growth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H252939623\">",
"    <span class=\"h3\">",
"     Biochemical monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to and adherence with therapy should be monitored by obtaining a 24 hour urine collection to assess the urine volume, and to measure cystine, urine pH, creatinine, sodium, and calcium. Optimally, the supersaturation of cystine, as well as calcium phosphate and calcium oxalate, should be measured in order to determine the risk of stone formation. Patients treated for cystinuria may occasionally continue to form stones despite a supersaturation of cystine that is below 1.0 in a 24 hour urine specimen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/32\">",
"     32",
"    </a>",
"    ]. Diurnal variation in cystine excretion and urine flow may explain the nephrolithiasis in such cases. Measuring daytime and nighttime cystine excretion separately may be helpful to evaluate for transient nighttime supersaturation, which may occur despite apparently effective solubilizing therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We initially monitor every three to six months until the patient is stable on therapy, then approximately every six months. Monitoring can probably be decreased to yearly if there has been no evidence of stone formation for several years on a constant regimen.",
"   </p>",
"   <p>",
"    If thiol-containing drugs are used, it is useful to estimate the amount of cystine that is probably present as a soluble mixed disulfide and how much is present as unbound cysteine or cystine. However, measurement of urinary cystine is usually imprecise in the presence of thiol drugs. Colorimetric assays are unable to distinguish cystine from the thiol drug-bound cysteine complexes; thus, the amount of cystine reported is greater than the unbound cystine that is available for stone formation. In contrast to colorimetric assays, chromatographic methods can distinguish cystine and cysteine from thiol drug, but sample preparation may disrupt the drug-cysteine bond and give misleading results. On the other hand, urinary cystine may crystallize during the collection period, especially if urine pH is low, leading to artifactually low measured cystine levels (since the precipitated cystine might not be measured).",
"   </p>",
"   <p>",
"    To address this problem and improve monitoring of therapy, an assay to quantify urinary cystine levels in the presence or absence of thiol-containing drugs has been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/38,58,62\">",
"     38,58,62",
"    </a>",
"    ]. This assay can be used to assess changes in urinary cystine and cystine supersaturation in response to dietary modifications and medical therapy with thiol-containing drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/29,63\">",
"     29,63",
"    </a>",
"    ]. This assay is commercially available (www.litholink.com). An alternative cystine assay that can differentiate between cystine and drug-cysteine complexes is high-performance liquid chromatography.",
"   </p>",
"   <p>",
"    In addition to collecting 24 hour urine specimens, urine microscopy should be regularly examined for cystine crystals, which would indicate that supersaturation is present (",
"    <a class=\"graphic graphic_picture graphicRef56834 \" href=\"UTD.htm?2/10/2208\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H252939768\">",
"    <span class=\"h3\">",
"     Radiologic monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred imaging test is noncontrast CT for diagnosis in symptomatic patients, because stone visualization is excellent. Follow-up in asymptomatic patients is more problematic. Renal ultrasound or KUB deliver less radiation, but are insensitive for detection of stones. No studies have assessed the ideal monitoring strategy. We monitor annually and use CT if symptoms develop. Low dose protocols for CT may allow more frequent use of this technique with less radiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Surgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continued stone formation can lead to large stones (including staghorn calculi) and urinary obstruction, which may require urologic intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. The indications for surgery in those with cystine stones are the same as those with non-cystine stones and are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30695?source=see_link\">",
"     \"Options in the management of renal and ureteral stones in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40231?source=see_link\">",
"     \"Management of struvite or staghorn calculi\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Their uniform crystal structure makes cystine stones relatively resistant to fragmentation by extracorporeal shock-wave lithotripsy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/1,63,64\">",
"     1,63,64",
"    </a>",
"    ]. As a result, this modality is usually reserved for stones smaller than 1.5 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/65\">",
"     65",
"    </a>",
"    ]. Ureteroscopic stone removal may also be used, with intracorporeal fragmentation by holmium laser lithotripsy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Percutaneous nephrolithotomy with ultrasonic or laser lithotripsy is the preferred procedure for larger stones [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. This procedure involves percutaneous insertion of a nephroscope into the renal pelvis. An ultrasonic or laser probe is then used to break up the stone, and fragments are removed as they are formed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Management of other stones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystinuric patients can form calcium oxalate or calcium phosphate stones, since many of these patients have predisposing metabolic abnormalities such as hypercalciuria, hyperuricosuria, or hypocitraturia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/68\">",
"     68",
"    </a>",
"    ]. Thus, the excretion of these solutes should also be measured at the initial evaluation and appropriate therapy instituted if indicated. Recurrent stones of cystinuric patients should be analyzed to determine whether new stone types are being formed, which may contribute to treatment failures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link\">",
"     \"Prevention of recurrent calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9142623\">",
"    <span class=\"h2\">",
"     Future directions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chaperone therapy is a technique that may be useful for diseases caused by mutations that lead to misfolded proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/69\">",
"     69",
"    </a>",
"    ], and it is already being investigated for several monogenic diseases. Because some of the mutations in patients with cystinuria may lead to protein misfolding, this approach may be useful in selected patients with cystinuria.",
"   </p>",
"   <p>",
"    Inhibitors of crystal growth are known to modulate crystallization in urine, and specially designed synthetic inhibitors of cystine crystals might be able to slow or prevent cystine stone growth [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/70\">",
"     70",
"    </a>",
"    ]. Much work remains to be done before these strategies become clinically useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     RENAL TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, patients with multiple renal stones progress to end-stage renal disease. Renal transplantation has been performed in a limited number of patients; recurrent stone formation does not occur, since the new kidney transports cystine normally [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25577/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cystinuria is a genetic cause of kidney stones with an average prevalence of 1 in 7000 births. Cystine stones are found in 1 to 2 percent of all stone formers, and about 5 percent of children who form stones. Affected patients have defects in an amino acid transporter, leading to decreased reabsorption and thus high urinary excretion of the relatively insoluble cystine. Cystinuria is",
"      <strong>",
"       not",
"      </strong>",
"      the same as cystinosis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with cystinuria are typically homozygous for inactivating mutations in either SLC3A1 or SLC7A9. The protein products of these two genes heterodimerize to form the amino acid transporter. Heterozygous carriers of SLC3A1 mutations usually have normal urinary cystine concentrations; heterozygotes for SLC7A9 have elevated urinary cystine, but seldom high enough to produce nephrolithiasis. (See",
"      <a class=\"local\" href=\"#H178545215\">",
"       'Pathogenesis, genetics, and classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with cystinuria present with nephrolithiasis, and should also be suspected in someone presenting with their first stone during childhood or adolescence. Although the median age at presentation is 12 years, stones disease may occasionally present in infancy or late adulthood. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As with other types of stones, cystine stones can be visualized with non-contrast computed tomography (CT). Although cystine stones are usually discrete, cystinuria should also be suspected in patients with large branched (staghorn) calculi. (See",
"      <a class=\"local\" href=\"#H193492902\">",
"       'Radiologic imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a patient with nephrolithiasis and suspected cystinuria, the diagnosis can be made from stone analysis, a positive family history, or identification of pathognomonic hexagonal cystine crystals on urinalysis (seen on initial urinalysis in about 25 percent of patients) (",
"      <a class=\"graphic graphic_picture graphicRef56834 \" href=\"UTD.htm?2/10/2208\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H193492926\">",
"       'Diagnostic confirmation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with suspected cystinuria who do not have a stone available for analysis and in whom cystine crystals are not visualized in the urine should be screened for urine cystine using the cyanide-nitroprusside test. A positive cyanide-nitroprusside screen indicates a urinary cystine concentration &gt;75",
"      <span class=\"nowrap\">",
"       mg/L.",
"      </span>",
"      A negative test generally excludes the diagnosis of cystinuria. (See",
"      <a class=\"local\" href=\"#H193492994\">",
"       'Cyanide-nitroprusside screen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with confirmed cystine stones, urinary cystine crystals,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a positive cyanide-nitroprusside screen should have quantitative testing of urinary cystine excretion. The normal rate of cystine excretion is 30",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (0.13",
"      <span class=\"nowrap\">",
"       mmol/day);",
"      </span>",
"      by comparison, patients with cystinuria generally excrete more than 400",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (1.7",
"      <span class=\"nowrap\">",
"       mmol/day).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H252939269\">",
"       'Urinary cystine excretion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The aim of medical therapy is to maintain the cystine concentration in the urine below its solubility level. The limit of solubility can be conservatively estimated as about 243",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      (1",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      provided the urine pH is 7.0 or higher. A urine cystine concentration below this level will usually prevent cystine crystallization and may lead to dissolution of existing crystals. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In all patients with cystinuria, we recommend increased fluid intake, modest reductions in sodium and protein intake, and urinary alkalinization (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). It is possible to reduce the likelihood of cystine crystallization by increasing fluid intake (which decreases the cystine concentration), restricting sodium and protein intake (which modestly reduces cystine excretion and, therefore, cystine concentration), and by urinary alkalinization (which increases the solubility of cystine). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Initial therapy with conservative measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If conservative measures are unable to adequately reduce the urinary cystine concentration, or stones recur, we recommend adding a thiol-containing drug, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/12/21699?source=see_link\">",
"       tiopronin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Patients with extremely high cystine excretion rates may require such agents as part of initial therapy. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Patients who fail or are likely to be resistant to conservative therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who require a thiol-containing drug, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/12/21699?source=see_link\">",
"       tiopronin",
"      </a>",
"      given the apparent lower incidence of side effects compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Typically, tiopronin is given in doses of 400 to 1200",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      administered in three divided doses. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Tiopronin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The response to and adherence with therapy should be monitored by obtaining a 24 hour urine collection to assess the urine volume, and to measure cystine, urine pH, creatinine, sodium, and calcium. In patients on thiol-binding drugs, an assay that does not disrupt the cysteine-thiol bond and reports free (unbound) cystine is required. Optimally, the supersaturation of cystine, as well as calcium phosphate and calcium oxalate, should be calculated in order to determine the risk of stone formation. We initially monitor every three to six months until the patient is stable on therapy, then approximately every 6 to 12 months. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Monitoring response to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We monitor patients with cystinuria radiographically with a spiral CT annually or more frequently if symptoms develop. (See",
"      <a class=\"local\" href=\"#H252939768\">",
"       'Radiologic monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/1\">",
"      Chillar&oacute;n J, Font-Llitj&oacute;s M, Fort J, et al. Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 2010; 6:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/2\">",
"      Stapleton FB. Childhood stones. Endocrinol Metab Clin North Am 2002; 31:1001.",
"     </a>",
"    </li>",
"    <li>",
"     Palacin, M, Goodyer, P et al. Cystinuria. In: The Metabolic and Molecular Basis of Inherited Disease, 8th Ed, Scriver, CR, Beaudet, AL, Sly, WS, Valle, D (Eds), McGraw-Hill, New York 2001. p.4909.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/4\">",
"      Goodyer P. The molecular basis of cystinuria. Nephron Exp Nephrol 2004; 98:e45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/5\">",
"      Mattoo A, Goldfarb DS. Cystinuria. Semin Nephrol 2008; 28:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/6\">",
"      Dello Strologo L, Pras E, Pontesilli C, et al. Comparison between SLC3A1 and SLC7A9 cystinuria patients and carriers: a need for a new classification. J Am Soc Nephrol 2002; 13:2547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/7\">",
"      Leclerc D, Boutros M, Suh D, et al. SLC7A9 mutations in all three cystinuria subtypes. Kidney Int 2002; 62:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/8\">",
"      Chesney RW. Mutational analysis of patients with cystinuria detected by a genetic screening network: powerful tools in understanding the several forms of the disorder. Kidney Int 1998; 54:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/9\">",
"      Feliubadal&oacute; L, Font M, Purroy J, et al. Non-type I cystinuria caused by mutations in SLC7A9, encoding a subunit (bo,+AT) of rBAT. Nat Genet 1999; 23:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/10\">",
"      Calonge MJ, Gasparini P, Chillar&oacute;n J, et al. Cystinuria caused by mutations in rBAT, a gene involved in the transport of cystine. Nat Genet 1994; 6:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/11\">",
"      Bisceglia L, Purroy J, Jim&eacute;nez-Vidal M, et al. Cystinuria type I: identification of eight new mutations in SLC3A1. Kidney Int 2001; 59:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/12\">",
"      Schmidt C, Vester U, Wagner CA, et al. Significant contribution of genomic rearrangements in SLC3A1 and SLC7A9 to the etiology of cystinuria. Kidney Int 2003; 64:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/13\">",
"      Palac&iacute;n M, Nunes V, Font-Llitj&oacute;s M, et al. The genetics of heteromeric amino acid transporters. Physiology (Bethesda) 2005; 20:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/14\">",
"      Bartoccioni P, Rius M, Zorzano A, et al. Distinct classes of trafficking rBAT mutants cause the type I cystinuria phenotype. Hum Mol Genet 2008; 17:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/15\">",
"      Goodyer P, Saadi I, Ong P, et al. Cystinuria subtype and the risk of nephrolithiasis. Kidney Int 1998; 54:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/16\">",
"      Font-Llitj&oacute;s M, Jim&eacute;nez-Vidal M, Bisceglia L, et al. New insights into cystinuria: 40 new mutations, genotype-phenotype correlation, and digenic inheritance causing partial phenotype. J Med Genet 2005; 42:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/17\">",
"      Horsford J, Saadi I, Raelson J, et al. Molecular genetics of cystinuria in French Canadians: identification of four novel mutations in type I patients. Kidney Int 1996; 49:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/18\">",
"      Wartenfeld R, Golomb E, Katz G, et al. Molecular analysis of cystinuria in Libyan Jews: exclusion of the SLC3A1 gene and mapping of a new locus on 19q. Am J Hum Genet 1997; 60:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/19\">",
"      Chillar&oacute;n J, Roca R, Valencia A, et al. Heteromeric amino acid transporters: biochemistry, genetics, and physiology. Am J Physiol Renal Physiol 2001; 281:F995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/20\">",
"      Pineda M, Font M, Bassi MT, et al. The amino acid transporter asc-1 is not involved in cystinuria. Kidney Int 2004; 66:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/21\">",
"      Parvari R, Hershkovitz E. Chromosomal microdeletions and genes' functions: a cluster of chromosomal microdeletions and the deleted genes' functions. Eur J Hum Genet 2007; 15:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/22\">",
"      Lambert EH, Asplin JR, Herrell SD, Miller NL. Analysis of 24-hour urine parameters as it relates to age of onset of cystine stone formation. J Endourol 2010; 24:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/23\">",
"      Cranidis AI, Karayannis AA, Delakas DS, et al. Cystine stones: the efficacy of percutaneous and shock wave lithotripsy. Urol Int 1996; 56:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/24\">",
"      Worcester EM, Parks JH, Evan AP, Coe FL. Renal function in patients with nephrolithiasis. J Urol 2006; 176:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/25\">",
"      Evan AP, Coe FL, Lingeman JE, et al. Renal crystal deposits and histopathology in patients with cystine stones. Kidney Int 2006; 69:2227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/26\">",
"      Finocchiaro R, D'Eufemia P, Celli M, et al. Usefulness of cyanide-nitroprusside test in detecting incomplete recessive heterozygotes for cystinuria: a standardized dilution procedure. Urol Res 1998; 26:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/27\">",
"      Nakagawa Y, Coe FL. A modified cyanide-nitroprusside method for quantifying urinary cystine concentration that corrects for creatinine interference. Clin Chim Acta 1999; 289:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/28\">",
"      Giugliani R, Ferrari I, Greene LJ. An evaluation of four methods for the detection of heterozygous cystinuria. Clin Chim Acta 1987; 164:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/29\">",
"      Nakagawa Y, Asplin JR, Goldfarb DS, et al. Clinical use of cystine supersaturation measurements. J Urol 2000; 164:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/30\">",
"      Botzenhart E, Vester U, Schmidt C, et al. Cystinuria in children: distribution and frequencies of mutations in the SLC3A1 and SLC7A9 genes. Kidney Int 2002; 62:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/31\">",
"      Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med 1992; 327:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/32\">",
"      van Hoeve K, Vermeersch P, Regal L, Levtchenko E. Necessity of fractionated urine collection for monitoring patients with cystinuria. Clin Chem 2011; 57:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/33\">",
"      Pak CY, Fuller CJ. Assessment of cystine solubility in urine and of heterogeneous nucleation. J Urol 1983; 129:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/34\">",
"      Tiselius HG. New horizons in the management of patients with cystinuria. Curr Opin Urol 2010; 20:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/35\">",
"      Singer A, Das S. Cystinuria: a review of the pathophysiology and management. J Urol 1989; 142:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/36\">",
"      Rogers A, Kalakish S, Desai RA, Assimos DG. Management of cystinuria. Urol Clin North Am 2007; 34:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/37\">",
"      Jaeger P, Portmann L, Saunders A, et al. Anticystinuric effects of glutamine and of dietary sodium restriction. N Engl J Med 1986; 315:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/38\">",
"      Goldfarb DS, Coe FL, Asplin JR. Urinary cystine excretion and capacity in patients with cystinuria. Kidney Int 2006; 69:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/39\">",
"      Sterrett SP, Penniston KL, Wolf JS Jr, Nakada SY. Acetazolamide is an effective adjunct for urinary alkalization in patients with uric acid and cystine stone formation recalcitrant to potassium citrate. Urology 2008; 72:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/40\">",
"      Ahlstrand C, Tiselius HG. Urine composition and stone formation during treatment with acetazolamide. Scand J Urol Nephrol 1987; 21:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/41\">",
"      Barbey F, Nseir G, Ferrier C, et al. [Carbonic anhydrase inhibitors and calcium phosphate stones]. Nephrologie 2004; 25:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/42\">",
"      Barbey F, Joly D, Rieu P, et al. Medical treatment of cystinuria: critical reappraisal of long-term results. J Urol 2000; 163:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/43\">",
"      Hall CL, Jawad S, Harrison PR, et al. Natural course of penicillamine nephropathy: a long term study of 33 patients. Br Med J (Clin Res Ed) 1988; 296:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/44\">",
"      Habib GS, Saliba W, Nashashibi M, Armali Z. Penicillamine and nephrotic syndrome. Eur J Intern Med 2006; 17:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/45\">",
"      Ntoso KA, Tomaszewski JE, Jimenez SA, Neilson EG. Penicillamine-induced rapidly progressive glomerulonephritis in patients with progressive systemic sclerosis: successful treatment of two patients and a review of the literature. Am J Kidney Dis 1986; 8:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/46\">",
"      DeBerardinis RJ, Coughlin CR 2nd, Kaplan P. Penicillamine therapy for pediatric cystinuria: experience from a cohort of American children. J Urol 2008; 180:2620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/47\">",
"      Knoll T, Z&ouml;llner A, Wendt-Nordahl G, et al. Cystinuria in childhood and adolescence: recommendations for diagnosis, treatment, and follow-up. Pediatr Nephrol 2005; 20:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/48\">",
"      Pak CY, Fuller C, Sakhaee K, et al. Management of cystine nephrolithiasis with alpha-mercaptopropionylglycine. J Urol 1986; 136:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/49\">",
"      Lindell A, Denneberg T, Hellgren E, et al. Clinical course and cystine stone formation during tiopronin treatment. Urol Res 1995; 23:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/50\">",
"      Tasic V, Lozanovski VJ, Ristoska-Bojkovska N, et al. Nephrotic syndrome occurring during tiopronin treatment for cystinuria. Eur J Pediatr 2011; 170:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/51\">",
"      Purohit RS, Stoller ML. Stone clustering of patients with cystine urinary stone formation. Urology 2004; 63:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/52\">",
"      M&aring;rtensson J, Denneberg T, Lindell A, Textorius O. Sulfur amino acid metabolism in cystinuria: a biochemical and clinical study of patients. Kidney Int 1990; 37:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/53\">",
"      Lindell A, Denneberg T, Enestr&ouml;m S, et al. Membranous glomerulonephritis induced by 2-mercaptopropionylglycine (2-MPG). Clin Nephrol 1990; 34:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/54\">",
"      Sloand JA, Izzo JL Jr. Captopril reduces urinary cystine excretion in cystinuria. Arch Intern Med 1987; 147:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/55\">",
"      Perazella MA, Buller GK. Successful treatment of cystinuria with captopril. Am J Kidney Dis 1993; 21:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/56\">",
"      Parvex P, Rozen R, Dziarmaga A, Goodyer P. Studies of urinary cystine precipitation in vitro: ontogeny of cystine nephrolithiasis and identification of meso-2,3-dimercaptosuccinic acid as a potential therapy for cystinuria. Mol Genet Metab 2003; 80:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/57\">",
"      Pareek G, Steele TH, Nakada SY. Urological intervention in patients with cystinuria is decreased with medical compliance. J Urol 2005; 174:2250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/58\">",
"      Worcester EM, Coe FL, Evan AP, Parks JH. Reduced renal function and benefits of treatment in cystinuria vs other forms of nephrolithiasis. BJU Int 2006; 97:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/59\">",
"      Chow GK, Streem SB. Medical treatment of cystinuria: results of contemporary clinical practice. J Urol 1996; 156:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/60\">",
"      Pietrow P, Auge BK, Weizer AZ, et al. Durability of the medical management of cystinuria. J Urol 2003; 169:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/61\">",
"      Fjellstedt E, Denneberg T, Jeppsson JO, et al. Cystine analyses of separate day and night urine as a basis for the management of patients with homozygous cystinuria. Urol Res 2001; 29:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/62\">",
"      Coe FL, Clark C, Parks JH, Asplin JR. Solid phase assay of urine cystine supersaturation in the presence of cystine binding drugs. J Urol 2001; 166:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/63\">",
"      Knoll LD, Segura JW, Patterson DE, et al. Long-term followup in patients with cystine urinary calculi treated by percutaneous ultrasonic lithotripsy. J Urol 1988; 140:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/64\">",
"      Segura JW. Surgical management of urinary calculi. Semin Nephrol 1990; 10:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/65\">",
"      Kachel TA, Vijan SR, Dretler SP. Endourological experience with cystine calculi and a treatment algorithm. J Urol 1991; 145:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/66\">",
"      Chow GK, Streem SB. Contemporary urological intervention for cystinuric patients: immediate and long-term impact and implications. J Urol 1998; 160:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/67\">",
"      Shekarriz B, Stoller ML. Cystinuria and other noncalcareous calculi. Endocrinol Metab Clin North Am 2002; 31:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/68\">",
"      Sakhaee K, Poindexter JR, Pak CY. The spectrum of metabolic abnormalities in patients with cystine nephrolithiasis. J Urol 1989; 141:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/69\">",
"      Chaudhuri TK, Paul S. Protein-misfolding diseases and chaperone-based therapeutic approaches. FEBS J 2006; 273:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/70\">",
"      Rimer JD, An Z, Zhu Z, et al. Crystal growth inhibitors for the prevention of L-cystine kidney stones through molecular design. Science 2010; 330:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25577/abstract/71\">",
"      Tuso P, Barnett M, Yasunaga C, Nortman D. Cystinuria and renal transplantation. Nephron 1993; 63:478.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7362 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-61.234.146.186-FE4A772EBF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_62_25577=[""].join("\n");
var outline_f24_62_25577=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H178545215\">",
"      PATHOGENESIS, GENETICS, AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H346007738\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H178545747\">",
"      SLC3A1 defects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H178545963\">",
"      - SLC3A1 genotype - phenotype correlation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H178545754\">",
"      SLC7A9 defects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H178546021\">",
"      - SLC7A9 genotype - phenotype correlation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H178546152\">",
"      Other genetic defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Genotype-phenotype correlation with stone risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H193492902\">",
"      Radiologic imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RENAL PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H193492926\">",
"      Diagnostic confirmation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H193492994\">",
"      - Cyanide-nitroprusside screen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H252939269\">",
"      - Urinary cystine excretion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H163732240\">",
"      - Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90357407\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H193493001\">",
"      Theoretical basis for treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6937161\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Initial therapy with conservative measures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - High fluid intake",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H252939369\">",
"      - Sodium and protein restriction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Urinary alkalinization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Patients who fail or are likely to be resistant to conservative therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Penicillamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Tiopronin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Captopril",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Effectiveness of medical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Monitoring response to therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H252939623\">",
"      - Biochemical monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H252939768\">",
"      - Radiologic monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Management of other stones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9142623\">",
"      Future directions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      RENAL TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7362\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7362|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/10/2208\" title=\"picture 1\">",
"      Cystine crystals",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12584?source=related_link\">",
"      Cystinosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20266?source=related_link\">",
"      Diagnosis and acute management of suspected nephrolithiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40231?source=related_link\">",
"      Management of struvite or staghorn calculi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30695?source=related_link\">",
"      Options in the management of renal and ureteral stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28650?source=related_link\">",
"      Overview of water-soluble vitamins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=related_link\">",
"      Prevention of recurrent calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/10/27812?source=related_link\">",
"      Renal complications of extracorporeal shock wave lithotripsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_62_25578="Treatment of anemia due to iron deficiency";
var content_f24_62_25578=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of anemia due to iron deficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/62/25578/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/62/25578/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/62/25578/contributors\">",
"     Michael Auerbach, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/62/25578/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/62/25578/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/62/25578/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/62/25578/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/62/25578/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of adults with anemia due to iron deficiency, including the relevant diagnostic and therapeutic issues as well as the choice of iron preparation, will be discussed here.",
"   </p>",
"   <p>",
"    The causes and diagnosis of iron deficiency are discussed separately, as is the treatment of iron deficiency in infants and young children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38949?source=see_link\">",
"     \"Iron deficiency in infants and young children: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The uses of iron preparations for the treatment of functional iron deficiency in patients with chronic kidney disease as well as malignancy being treated with erythropoietin are specialized subjects and are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=see_link\">",
"     \"Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=see_link\">",
"     \"Use of iron preparations in hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28005?source=see_link\">",
"     \"Diagnosis of iron deficiency in chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link&amp;anchor=H34#H34\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\", section on 'Iron monitoring and supplementation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MANAGEMENT OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual presenting symptoms in adults, as seen in current practice, are primarily due to anemia, and include weakness, headache, irritability, and varying degrees of fatigue and exercise intolerance. However, many patients are asymptomatic and may recognize that they had fatigue, weakness, exercise intolerance, pagophagia (ice craving, a form of pica), or restless legs syndrome only after successful treatment with iron. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link&amp;anchor=H17#H17\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Diagnostic issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful overall management of the patient with iron deficiency anemia",
"    <strong>",
"     requires an attempt to identify and treat the underlying cause(s) of the iron deficiency",
"    </strong>",
"    (eg, blood loss from a tumor, varicosity, or other bleeding lesion; iron malabsorption). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Treatment issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of iron preparation depends upon the acuity of illness, as well as the ability of the patient to tolerate oral iron preparations. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'General principles'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Oral iron therapy",
"      </strong>",
"      &mdash; Because oral iron is inexpensive and effective when taken as prescribed, it is considered front line therapy. There are numerous conditions, however, for which oral iron is either poorly tolerated or ineffective. As examples:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Gastrointestinal side effects are extremely common and may result in poor adherence to therapy. It is estimated that more than 70 percent of some populations to whom oral iron is prescribed do not take it [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Various malabsorptive states (eg, celiac disease, Whipple&rsquo;s disease, bacterial overgrowth syndromes) may be associated with an inability to absorb iron optimally. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Failure to respond to oral iron therapy'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link&amp;anchor=H21#H21\">",
"       \"Regulation of iron balance\", section on 'Intestinal iron absorption'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment with oral iron may take as long as six to eight weeks in order to fully ameliorate the anemia, and as long as six months in order to replete iron stores.",
"     </li>",
"     <li>",
"      In patients with inflammatory bowel disease, the use of oral iron has been associated with worsening of the underlying disease, and may be poorly tolerated and ineffective [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43113?source=see_link&amp;anchor=H14#H14\">",
"       \"Nutrient deficiencies in inflammatory bowel disease\", section on 'Iron'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In conditions such as heavy uterine bleeding, hereditary hemorrhagic telangiectasia, gastric bypass, or other causes of heavy blood loss, absorption of oral iron, even in maximal doses, may be unable to keep up with blood loss.",
"     </li>",
"     <li>",
"      Dialysis patients, especially those being treated with erythropoiesis-stimulating agents (ESAs), are unable to fully utilize iron administered orally [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=see_link&amp;anchor=H8#H8\">",
"       \"Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients\", section on 'Indications for oral versus intravenous iron therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Non-dialysis chronic kidney disease patients have a number of reasons for their inability to absorb oral iron (eg, impaired iron transport, concomitant use of calcium-containing salts, H",
"      <sub>",
"       2",
"      </sub>",
"      blockers, phosphate binders, generalized malabsorption) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oral iron, unlike the intravenous preparations, does not synergize well with ESAs (eg, erythropoietin, darbepoetin) in anemic cancer patients both on and off chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link&amp;anchor=H34#H34\">",
"       \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\", section on 'Iron monitoring and supplementation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inflammation-mediated induction of hepcidin, which regulates iron homeostasis, may result in suboptimal gastrointestinal absorption of orally administered iron in iron deficient subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/8\">",
"       8",
"      </a>",
"      ]. Non-response to oral iron therapy did not rule out iron deficiency in such subjects, since two-thirds of the non-responders in this study responded to treatment with intravenous iron. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link&amp;anchor=H22#H22\">",
"       \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'Supplemental iron'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Over a quarter of the world's population remains anemic; about half of this burden is due to iron deficiency anemia (IDA). Strategies to control IDA include daily and intermittent iron supplementation, home fortification with micronutrient powders, fortification of staple foods and condiments, and activities to improve food security and dietary diversity [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/9\">",
"       9",
"      </a>",
"      ]. The safety of routine iron supplementation in settings where infectious diseases such as malaria are endemic remains uncertain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Parenteral iron",
"      </strong>",
"      &mdash; Clinicians&rsquo; historical reluctance to use parenteral iron preparations more widely can be traced, at least in part, to severe side effects (eg, anaphylaxis, shock, death) associated with earlier parenteral iron preparations, such as high molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/46/21222?source=see_link\">",
"       iron dextran",
"      </a>",
"      . However there are numerous settings in which the use of intravenous iron preparations may be preferable. As examples:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      With the advent of parenteral iron formulations with improved toxicity profiles, the early switch to intravenous iron should be considered in those intolerant to the use of oral iron preparations. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Parenteral iron therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      It has been estimated that the maximum amount of elemental iron that can be absorbed with an oral iron preparation is 25",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/10\">",
"       10",
"      </a>",
"      ], whereas, depending upon the preparation used, up to 1000 mg of elemental iron can be administered following a single infusion of intravenous iron. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Available preparations'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Intravenous iron is effective for those unresponsive to or intolerant of oral iron. Published evidence supports the consideration of intravenous iron as an early option for those with inflammatory bowel disease (IBD) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/2\">",
"       2",
"      </a>",
"      ]. As a result, intravenous iron is considered frontline therapy in Europe for iron deficiency anemia associated with IBD with or without oral iron intolerance or ineffectiveness [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/2\">",
"       2",
"      </a>",
"      ]. For patients with chemotherapy induced anemia, NCCN Guidelines state that intravenous iron is the preferred route when iron supplementation is indicated, and",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      guidelines indicate its use for iron replacement in dialysis patients. These issues are discussed in greater detail elsewhere in UpToDate.",
"     </li>",
"     <li>",
"      Intravenous iron is required when the amount of iron lost through daily blood loss exceeds the capacity of the gastrointestinal tract to absorb oral iron preparations. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Indications'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For those who have undergone gastric bypass surgery",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      subtotal gastric resection, the limited ability of the remaining stomach to oxidize ferrous to ferric iron, facilitating absorption in the distal duodenum and proximal jejunum, makes intravenous iron an especially good choice. Some patients, especially those having undergone minimally invasive procedures, such as gastric banding, may tolerate oral iron. This is less likely in Roux-en-Y or biliopancreatic diversion procedures. However, it is important to remember that all gastric bypass patients have a host of other nutritional perturbations post-operatively, and intravenous iron may simplify care.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Blood transfusion",
"      </strong>",
"      &mdash; Blood transfusion should be reserved for the patient who is hemodynamically unstable because of active bleeding",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      shows evidence for end-organ ischemia. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Blood transfusion'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ORAL IRON THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral iron provides an inexpensive and effective means of restoring iron balance in a patient with iron deficiency without complicating co-morbid conditions. Frequent gastrointestinal side effects range from mild to severe constipation (especially in pregnant women), diarrhea, metallic taste, and thick, green stool. There are a few simple principles governing the use of oral iron [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Iron is not absorbed in the stomach and is absorbed best from the duodenum and proximal jejunum, where the iron transport proteins (eg, duodenal iron transporter, divalent metal transport protein and the iron export protein to blood, ferroportin) are most strongly expressed. Accordingly, enteric coated or sustained release capsules, which release iron further down in the intestinal tract, or which may be excreted intact in the stool, are inefficient sources of iron. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link&amp;anchor=H10#H10\">",
"       \"Regulation of iron balance\", section on 'Duodenal iron transporter'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link&amp;anchor=H13#H13\">",
"       \"Regulation of iron balance\", section on 'Ferroportin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Iron salts should not be given with food because phosphates, phytates, and tannates in food bind the iron and impair its absorption (",
"      <a class=\"graphic graphic_table graphicRef64874 \" href=\"UTD.htm?26/5/26715\">",
"       table 1",
"      </a>",
"      ). A number of other factors can inhibit the absorption of iron salts, including antacids, H",
"      <sub>",
"       2",
"      </sub>",
"      receptor blockers, proton pump inhibitors, calcium-containing foods and beverages, calcium supplements, certain antibiotics (eg, quinolones,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      ), and the ingestion of iron along with cereals, dietary fiber, tea, coffee, eggs, or milk.",
"     </li>",
"     <li>",
"      Iron should be given two hours before, or four hours after, ingestion of antacids.",
"     </li>",
"     <li>",
"      Iron is best absorbed as the ferrous (Fe",
"      <sup>",
"       ++",
"      </sup>",
"      ) salt in a mildly acidic medium. As a result, we usually add a 250 mg ascorbic acid tablet or a half-glass of orange juice at the time of iron administration to enhance the degree of iron absorption.",
"     </li>",
"     <li>",
"      The iron preparation used should be based upon cost and effectiveness with minimal side effects. The least expensive preparation is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37046?source=see_link\">",
"       ferrous sulfate",
"      </a>",
"      ; each tablet contains 325 mg of iron salts, of which 65 mg is elemental iron [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gastrointestinal tract symptoms (eg, abdominal discomfort,",
"      <span class=\"nowrap\">",
"       nausea/vomiting,",
"      </span>",
"      <span class=\"nowrap\">",
"       diarrhea/constipation)",
"      </span>",
"      suffered by some patients seem to be directly related to the amount of elemental iron ingested [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/14\">",
"       14",
"      </a>",
"      ]. Thus, the reported low incidence of side effects for some preparations can be explained by their low elemental iron content. As examples, one tablet of iron bis-glycinate (Ferrochel, Gentle Iron) contains 27 mg of elemental iron, while a 325 mg tablet of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/37/38485?source=see_link\">",
"       ferrous gluconate",
"      </a>",
"      contains 36 mg of elemental iron. Both of these preparations contain significantly less elemental iron than a 325 mg tablet of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37046?source=see_link\">",
"       ferrous sulfate",
"      </a>",
"      (65 mg).",
"     </li>",
"     <li>",
"      Patients with persistent gastric intolerance to oral iron tablets may tolerate",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37046?source=see_link\">",
"       ferrous sulfate",
"      </a>",
"      elixir, which provides 44 mg of elemental iron per 5 mL. Patients can titrate the dose up or down to the level at which the gastrointestinal symptoms become acceptable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Choice of preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most appropriate oral iron therapy is use of a tablet containing ferrous salts, such as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7798?source=see_link\">",
"       Ferrous fumarate",
"      </a>",
"      &mdash; 106 mg elemental",
"      <span class=\"nowrap\">",
"       iron/tablet",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37046?source=see_link\">",
"       Ferrous sulfate",
"      </a>",
"      &mdash; 65 mg elemental",
"      <span class=\"nowrap\">",
"       iron/tablet",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/37/38485?source=see_link\">",
"       Ferrous gluconate",
"      </a>",
"      &mdash; 28 to 36 mg",
"      <span class=\"nowrap\">",
"       iron/tablet",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The recommended oral daily dose for the treatment of iron deficiency in adults is in the range of 150 to 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of elemental iron. As an example, a single 325 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37046?source=see_link\">",
"     ferrous sulfate",
"    </a>",
"    tablet taken orally three times daily between meals provides an oral dose of 195 mg of elemental iron per day. There is no evidence that one of the above iron preparations is more effective than another for this purpose.",
"   </p>",
"   <p>",
"    A large number of other oral iron preparations are available. They are generally more expensive than those described above and some may be poorly absorbed (eg, enteric coated, sustained release preparations).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Dosing in older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate dosing of iron for older adults with iron deficiency anemia is unclear. In a randomized study in 90 iron deficient hospitalized patients &gt;80 years of age, daily doses of 15, 50, or 150 mg of elemental iron for two months were equally effective in raising hemoglobin and ferritin concentrations, while adverse side effects were significantly more common at the higher iron doses [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our practice we treat iron deficiency in older adults by using 10 mL of iron sulfate elixir once daily (elemental iron content 88 mg) mixed in one-fifth of a glass of orange juice and taken 30 minutes before breakfast. The dose of elixir can be reduced to 5 mL if the 10 mL dose causes irritation. Similarly, a 50 or 100 mg tablet of ascorbic acid can be substituted for the orange juice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Expected response",
"    </span>",
"    &nbsp;&mdash;&nbsp;An effective regimen for the treatment of uncomplicated iron deficiency with oral iron preparations should lead to the following responses:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If pagophagia (pica for ice) or restless leg syndrome is present, it often disappears almost as soon as oral or intravenous iron therapy is begun, well before there are any observable hematologic changes such as reticulocyte response. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link&amp;anchor=H20#H20\">",
"       \"Causes and diagnosis of anemia due to iron deficiency\", section on 'Pica and pagophagia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The patient will note an improved feeling of well-being within the first few days of treatment.",
"     </li>",
"     <li>",
"      In patients with moderate to severe anemia, a modest reticulocytosis will be seen, maximal in approximately 7 to 10 days. Patients with mild anemia may have little or no reticulocytosis.",
"     </li>",
"     <li>",
"      The hemoglobin concentration will rise slowly, usually beginning after approximately one to two weeks of treatment, and will rise approximately 2",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      over the ensuing three weeks. The hemoglobin deficit should be halved by approximately one month, and the hemoglobin level should return to normal by six to eight weeks.",
"     </li>",
"     <li>",
"      Typically, papillation of the tongue is decreased in patients with iron deficiency and can be used as a gauge of duration of symptoms. Classically, loss of papillae begins at the tip and lateral borders, and moves posteriorly and centrally. Following iron repletion, a rapid correction (weeks to months) is observed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates are that up to 50 percent of patients complain of nausea, constipation, diarrhea, epigastric distress",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vomiting after taking various oral iron preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/15\">",
"     15",
"    </a>",
"    ]. There are a number of treatment options for such patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient may take an iron preparation containing a smaller dose of elemental iron (eg, switching from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37046?source=see_link\">",
"       ferrous sulfate",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/37/38485?source=see_link\">",
"       ferrous gluconate",
"      </a>",
"      ), or may switch from a tablet to a liquid preparation, the dose of which (44 mg elemental iron per 5 mL) can be easily titrated by the patient (see",
"      <a class=\"local\" href=\"#H6\">",
"       'General principles'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The patient may slowly increase the dose from one tablet per day to the recommended three times per day, as tolerated.",
"     </li>",
"     <li>",
"      The iron may be taken with meals, although this will decrease absorption somewhat.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, with the advent of parenteral iron formulations with more favorable toxicity profiles, the early use of intravenous iron should be considered in those intolerant to the use of oral iron preparations (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Parenteral iron therapy'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Duration of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is disagreement as to how long to continue oral iron therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some physicians stop treatment with iron when the hemoglobin level becomes normal, so that further blood loss will cause anemia and alert the patient and physician to the return of the problem which caused the iron deficiency in the first place.",
"     </li>",
"     <li>",
"      Others believe that it is wise to treat for at least six months after the hemoglobin has normalized, in order to replenish iron stores.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our practice is to individualize the duration of iron replacement. As an example, it makes sense to fully replenish iron stores in a patient who became iron deficient as a consequence of multiple pregnancies. On the other hand, we stop therapy once the hemoglobin concentration is normalized in a patient who has occult gastrointestinal bleeding. In this latter setting, the return of iron deficiency is an important clue that bleeding has recurred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Failure to respond to oral iron therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;On occasion, a patient may not respond to oral iron therapy. The potential causes for this situation include the following (",
"    <a class=\"graphic graphic_table graphicRef56310 \" href=\"UTD.htm?21/33/22044\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Incorrect diagnosis (eg, thalassemia, myelodysplastic syndrome)",
"     </li>",
"     <li>",
"      Patient is non-adherent",
"     </li>",
"     <li>",
"      Presence of a coexisting disease or treatment interfering with response (eg, elevated hepcidin levels [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/8\">",
"       8",
"      </a>",
"      ], renal failure, treatment with erythropoietin",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cancer chemotherapy). Failure of response to oral iron therapy in these settings does not rule out the presence of iron deficiency, as some will respond to treatment with parenteral iron. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Indications'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Medication is not being absorbed for physical reasons (eg, enteric coated tablets, concomitant use of antacids)",
"     </li>",
"     <li>",
"      Iron (blood) loss or need is in excess of the amount ingested (eg, severe continuous GI bleeding, dialysis patient, idiopathic pulmonary hemosiderosis). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12089?source=see_link\">",
"       \"Idiopathic pulmonary hemosiderosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=see_link\">",
"       \"Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The patient has acquired malabsorption for iron. In one study, for example, refractoriness to oral iron treatment was noted in all patients with celiac disease and approximately 70 percent of those with autoimmune atrophic gastritis or Helicobacter pylori infection [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link&amp;anchor=H20#H20\">",
"       \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Iron deficiency'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24185?source=see_link&amp;anchor=H12#H12\">",
"       \"Metaplastic (chronic) atrophic gastritis\", section on 'Helicobacter pylori'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link&amp;anchor=H25#H25\">",
"       \"Causes and diagnosis of anemia due to iron deficiency\", section on 'Oral iron absorption test'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The patient has an inherited condition associated with iron deficiency anemia and a failure to respond to treatment with oral iron (IRIDA). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link&amp;anchor=H18#H18\">",
"       \"Regulation of iron balance\", section on 'Iron-refractory iron deficiency anemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The appropriate treatment depends upon the cause for failure to respond.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard treatment of iron deficiency in pregnancy is the same as that in nonpregnant, postpartum, premenopausal, and postmenopausal women. However, in the pregnant patient, bloating and constipation are common problems due to high progesterone levels and the increasing pressure of the gravid uterus on the rectum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/60/9160?source=see_link&amp;anchor=H15#H15\">",
"     \"Maternal gastrointestinal tract adaptation to pregnancy\", section on 'Bloating and constipation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Such side effects can be exacerbated by treatment with oral iron, and can be partially managed by reducing the amount of iron given",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    modifying the patient's diet, both of which require patient adherence. Furthermore, up to 70 percent of pregnant women to whom oral iron is prescribed report adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/17\">",
"     17",
"    </a>",
"    ]. While numerous publications have shown the safety and efficacy of parenteral iron in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/18-27\">",
"     18-27",
"    </a>",
"    ], its use in pregnancy is sporadic at best and is hindered by the fact that no parenteral iron preparation has been given an FDA category &ldquo;A&rdquo; rating for use in pregnancy (ie, controlled human studies show no risk) (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Nevertheless, a number of observations suggest the safety of intravenous iron in pregnant women:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 1266 infusions of low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/46/21222?source=see_link\">",
"       iron dextran",
"      </a>",
"      (1 gram infused over one hour) given to 888 patients, 162 of whom were pregnant, no severe adverse events were noted [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In our practice, we routinely administer 1000 mg of low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/46/21222?source=see_link\">",
"       iron dextran",
"      </a>",
"      in one hour to iron deficient pregnant women whether or not they are oral iron intolerant [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/24\">",
"       24",
"      </a>",
"      ]. Although this agent has an FDA category &ldquo;C&rdquo; rating in pregnancy (",
"      <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"       table 3",
"      </a>",
"      ), in over 1000 treated subjects, no serious adverse effects have been observed. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the preponderance of published evidence on the safety of intravenous iron in the pregnant patient, we believe that the failure to use intravenous iron in this population appears to represent an unmet clinical need. From the standpoint of the developing fetus, a more liberal use of IV iron in pregnancy will likely minimize the chance that the neonate of an iron deficient woman will also be iron deficient, especially in view of evidence that iron deficient neonates not only have delayed growth and development, but also an increase in behavioral problems later in childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PARENTERAL IRON THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of indications for the use of parenteral, rather than oral, iron preparations. These are discussed below. Given the safety and efficacy of IV iron in a broad spectrum of diseases associated with iron deficiency, the current paradigm that oral iron is first line therapy should be reconsidered [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1484809\">",
"    <span class=\"h3\">",
"     Excessive continuing blood loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Currently, parenteral iron is most often used in iron deficient patients whose level of continued bleeding, usually gastrointestinal or menstrual, exceeds the ability of the gastrointestinal tract to absorb iron. As an example, in one study the maximum amount of iron capable of being absorbed from oral iron preparations was found to be 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/10\">",
"     10",
"    </a>",
"    ], the amount of iron in 25 mL of packed red cells or approximately 60 mL of whole blood. Accordingly, oral iron therapy alone would not expected to be able to keep up with chronic blood loss averaging &ge;25",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    of packed red cells or a transfusion requirement of one unit of packed red cells every 8 to 10 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1484816\">",
"    <span class=\"h3\">",
"     Inflammatory bowel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with inflammatory bowel disease (IBD) and iron deficiency have severe intolerance to oral iron preparations, which may also worsen IBD disease activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43113?source=see_link&amp;anchor=H14#H14\">",
"     \"Nutrient deficiencies in inflammatory bowel disease\", section on 'Iron'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further, unlike oral iron, IV iron is able to partially overcome the iron restricted erythropoiesis associated with inflammation. Numerous studies in the United States and other countries have demonstrated the safety and efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/31/41461?source=see_link\">",
"     iron sucrose",
"    </a>",
"    , LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/46/27364?source=see_link\">",
"     ferumoxytol",
"    </a>",
"    , and ferric carboxymaltose in patients with inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/2,31,32\">",
"     2,31,32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Treatment issues'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    It has therefore been suggested that intravenous, rather than oral, iron should be considered in patients with IBD for the following scenarios [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anemia and unresponsiveness to or intolerance of oral iron",
"     </li>",
"     <li>",
"      Need for a quick recovery from anemia",
"     </li>",
"     <li>",
"      Adjuvant use of erythropoietin",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1484823\">",
"    <span class=\"h3\">",
"     Chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;IV iron is the current standard in both dialysis and non-dialysis associated chronic kidney disease patients for multiple reasons, including ongoing blood loss associated with the procedure, the need for adequate iron to respond to the administration of erythropoietic stimulating agents, as well as the frequent inability of these patients to utilize iron administered orally [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=see_link&amp;anchor=H8#H8\">",
"     \"Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients\", section on 'Indications for oral versus intravenous iron therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1484830\">",
"    <span class=\"h3\">",
"     Use in cancer patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of prospective studies support the observation that IV iron, unlike oral iron, synergizes with erythropoiesis-stimulating agents (eg, erythropoietin, darbepoetin) therapy in anemic cancer patients both on and off chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/7\">",
"     7",
"    </a>",
"    ]. This subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link&amp;anchor=H34#H34\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\", section on 'Iron monitoring and supplementation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is limited information on the efficacy of IV iron in anemic cancer patients receiving chemotherapy in the absence of treatment with erythropoiesis-stimulating agents [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/7,34,35\">",
"     7,34,35",
"    </a>",
"    ]. An observational study in anemic cancer patients receiving IV iron (ferric carboxymaltose, median dose 1000 mg of elemental iron) indicated that patients with baseline hemoglobin levels up to 11.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and serum ferritin levels up to 500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    responded to treatment with an increase in hemoglobin and a reduction in the need for red cell transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/36\">",
"     36",
"    </a>",
"    ]. Benefit was also noted for those with ferritin levels &gt;500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    if transferrin saturation was &lt;20 percent (mean baseline saturation 14 percent). IV iron was well tolerated, with adverse drug reactions, mainly nausea and diarrhea, reported in 2.3 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Available preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of parenteral iron formulations approved for use in various countries (",
"    <a class=\"graphic graphic_table graphicRef88303 \" href=\"UTD.htm?25/3/25661\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Iron dextran",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/46/21222?source=see_link\">",
"     Iron dextran",
"    </a>",
"    preparations contain 50 mg of elemental",
"    <span class=\"nowrap\">",
"     iron/mL,",
"    </span>",
"    and can be given either by the intramuscular (IM) or intravenous (IV) route. Both local and systemic side effects can occur following use of iron",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    , with an anticipated frequency of reactions of 4.7 percent in one older study [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/37\">",
"     37",
"    </a>",
"    ]. High molecular weight (HMW) iron dextran preparations (Dexferrum) are associated with a considerably higher incidence of adverse events than are the low molecular weight (LMW) preparations (INFeD, Cosmofer) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/4,38,39\">",
"     4,38,39",
"    </a>",
"    ]. Minor, self-limiting infusion reactions occur in less 1 percent. Importantly, when HMW preparations are avoided, serious adverse events from iron dextran are extremely rare (&lt;1:200,000). (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Prevention and treatment of adverse drug events'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The National Comprehensive Cancer Network (NCCN) and the nursing association of the American Society of Nephrology have proscribed the use of HMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    by brand (Dexferrum); this product has been removed from the formularies of the United States Veterans Administration Medical Centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4372556\">",
"    <span class=\"h4\">",
"     Total dose infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    may be given as a total dose infusion (TDI). However, in that there is no evidence that doses larger than 1000 mg are clinically useful, it has been our policy to routinely administer 1000 mg over one hour [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Calculation of the dose'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    TDI of LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    has been shown to be safe and effective in pregnancy, the peripartum period, heavy uterine bleeding, inflammatory bowel disease, gastric bypass, hereditary hemorrhagic telangiectasias, chronic kidney disease, and the restless legs syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/24,40,41\">",
"     24,40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14842750\">",
"    <span class=\"h4\">",
"     Test dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;A test dose of 25 mg given by slow IV push over five minutes is required when giving this agent for the first time. After a 15-minute observation period, the remainder of the dose may be infused. Subsequent dose(s) may be administered by IV bolus at rate of &le;50",
"    <span class=\"nowrap\">",
"     mg/minute",
"    </span>",
"    or diluted in 250 to 1000 mL normal saline and infused over one to six hours. We routinely administer 1000 mg of LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    in 250 mL of normal saline over one hour without premedication [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/24\">",
"     24",
"    </a>",
"    ]. The initial 25 mL should be given slowly and patient should be observed for allergic reactions",
"    <strong>",
"     .",
"    </strong>",
"   </p>",
"   <p>",
"    In those with more than one drug allergy or asthma we premedicate with corticosteroids (125 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    IV).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Ferric gluconate complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/53/31573?source=see_link\">",
"     Ferric gluconate",
"    </a>",
"    complex (Ferrlecit) is only approved for IV use. Data from Europe and the United States indicate that, compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    , sodium ferric gluconate complex in sucrose has a reduced incidence of adverse allergic reactions (3.3 versus 8.7 allergic events per one million doses per year) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/42\">",
"     42",
"    </a>",
"    ]. In prospective and intra-institutional retrospective studies, no difference in adverse event rates with either iron salt (ferric gluconate and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/31/41461?source=see_link\">",
"     iron sucrose",
"    </a>",
"    ) was observed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One group has reported on the efficacy and safety of 125 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/53/31573?source=see_link\">",
"     ferric gluconate",
"    </a>",
"    complex given either undiluted by slow IV push at a rate of 12.5",
"    <span class=\"nowrap\">",
"     mg/minute",
"    </span>",
"    or diluted in 100 mL isotonic saline and infused over 30 to 60 minutes, in 74 patients with iron deficiency anemia and normal levels of serum creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/44\">",
"     44",
"    </a>",
"    ]. Of 639 infusions, 11 reactions (1.7 percent) were documented; no reaction was considered severe or anaphylactic. Two reactions were moderately severe (eg, dyspnea, severe urticaria, neck and back spasm), causing the infusion to be stopped. All other reactions were minor (eg, pruritus, palpitations, dizziness), causing the infusion to be temporarily stopped, following which all patients were able to continue the infusion. When measured in 56 of the 74 patients, all efficacy end points (eg, increases in hemoglobin, hematocrit, mean corpuscular volume, serum ferritin) showed significant improvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=see_link\">",
"     \"Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=see_link\">",
"     \"Use of iron preparations in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/53/31573?source=see_link\">",
"     Ferric gluconate",
"    </a>",
"    is approved for a maximum single dose of 125 mg, although published evidence suggests that a dose of 250 mg is well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/53/31573?source=see_link\">",
"     ferric gluconate",
"    </a>",
"    complex is used for this purpose, up to 187.5 mg is administered (15 mL) at any one setting. It may be diluted and infused over 20 to 30 minutes. It can also be administered as a 125 mg two-minute bolus in dialysis patients. Although rarely done, 250 mg infusions over one hour have been reported to be well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/45\">",
"     45",
"    </a>",
"    ]. Larger single doses should not be attempted. The remainder of the calculated dose of iron is given at subsequent treatment sessions at this rate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=see_link&amp;anchor=H8#H8\">",
"     \"Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients\", section on 'Indications for oral versus intravenous iron therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14842757\">",
"    <span class=\"h4\">",
"     Test dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Product labeling for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/53/31573?source=see_link\">",
"     ferric gluconate",
"    </a>",
"    does not indicate the need for a test dose, however in patients with a sensitivity to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    or with other drug allergies a test dose is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Iron sucrose",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/31/41461?source=see_link\">",
"     Iron sucrose",
"    </a>",
"    (Venofer, iron saccharate, 20 mg",
"    <span class=\"nowrap\">",
"     iron/mL)",
"    </span>",
"    is only approved for IV use. The safety and efficacy profile of iron sucrose is similar to that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/53/31573?source=see_link\">",
"     ferric gluconate",
"    </a>",
"    . Iron sucrose has been shown to be safe and efficacious in dialysis, non-dialysis CKD, inflammatory bowel disease, chemotherapy-induced anemia, the peripartum period, gastric bypass, heavy uterine bleeding, and a host of other conditions associated with iron lack. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=see_link\">",
"     \"Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=see_link\">",
"     \"Use of iron preparations in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/46/27364?source=see_link\">",
"     ferumoxytol",
"    </a>",
"    , ferric carboxymaltose, and iron isomaltoside,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/31/41461?source=see_link\">",
"     iron sucrose",
"    </a>",
"    cannot be administered as a total dose infusion and doses above 300 mg are not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommended dose for anemic cancer patients receiving erythropoiesis-stimulating agents is 200 mg infused over 60 minutes, repeated every two to three weeks. It is routinely given as a 200 mg IV bolus over two minutes in dialysis centers. While approved as a 500 mg infusion over longer periods of time (hours), single doses greater than 300 mg are not recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link&amp;anchor=H34#H34\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\", section on 'Iron monitoring and supplementation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14842764\">",
"    <span class=\"h4\">",
"     Test dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Product labeling for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/31/41461?source=see_link\">",
"     iron sucrose",
"    </a>",
"    does not indicate the need for a test dose in product-naive patients, but a test dose is recommended (25 mg by slow IV push) in patients who are sensitive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    or have other drug allergies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Ferumoxytol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/46/27364?source=see_link\">",
"     Ferumoxytol",
"    </a>",
"    (Feraheme) is composed of superparamagnetic iron oxide nanoparticles coated with a low molecular weight semisynthetic carbohydrate. It has been deemed safe and effective when given as a rapid intravenous infusion of up to 510 mg of elemental iron in a volume of 17 mL (infusion rate: up to 1",
"    <span class=\"nowrap\">",
"     mL/second)",
"    </span>",
"    in patients with chronic kidney disease (CKD) and those on dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=see_link&amp;anchor=H18#H18\">",
"     \"Use of iron preparations in hemodialysis patients\", section on 'Ferumoxytol'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, based on both in vitro data and in vivo experience, we strongly recommend that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/46/27364?source=see_link\">",
"     ferumoxytol",
"    </a>",
"    not be infused over a period less than one minute [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. While ferumoxytol has been shown to be safe and efficacious as a 1020 mg infusion over 15 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/50\">",
"     50",
"    </a>",
"    ], ferumoxytol is only approved for a 510 mg injection in patients with CKD.",
"   </p>",
"   <p>",
"    The United States FDA has approved",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/46/27364?source=see_link\">",
"     ferumoxytol",
"    </a>",
"    for the treatment of iron deficiency anemia in adult patients with chronic kidney disease. The most important safety concerns were hypotension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypersensitivity reactions, including anaphylaxis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anaphylactoid reactions. Ferumoxytol administration may transiently affect the diagnostic ability of magnetic resonance imaging. If an MRI is ordered within four weeks of a ferumoxytol injection, the radiologist should be notified. In a prospective randomized study, no significant difference in safety or efficacy was noted between ferumoxytol and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/31/41461?source=see_link\">",
"     iron sucrose",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Currently there are no published data on the safety and efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/46/27364?source=see_link\">",
"     ferumoxytol",
"    </a>",
"    in pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Ferric carboxymaltose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ferric carboxymaltose (Ferinject) is a novel stable iron complex for intravenous use that can be given at single doses of up to 1000 mg of elemental iron per week over a recommended infusion time of 15 minutes. A number of trials have shown efficacy and safety of this agent in iron deficient patients in a number of different settings (eg, heavy uterine bleeding, postpartum women, chronic renal failure, inflammatory bowel disease, heart failure) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/52-56\">",
"     52-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ferric carboxymaltose was shown to be effective in alleviating symptoms of congestive heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/55\">",
"     55",
"    </a>",
"    ] and was the first agent to demonstrate efficacy in chemotherapy-associated anemia when administered without concomitant use of an erythropoiesis-stimulating agent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/36\">",
"     36",
"    </a>",
"    ]. This agent is currently licensed for use in Europe, Asia, and New Zealand, but not in the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1705?source=see_link&amp;anchor=H16#H16\">",
"     \"Impact of anemia in patients with heart failure\", section on 'Intravenous iron'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The United States FDA has delayed approval of this agent due to hypophosphatemia observed at two weeks and an imbalance of cardiovascular events and deaths (none of which was attributed to the drug) in the treatment arm compared with controls. No clinical sequelae secondary to the hypophosphatemia associated with ferric carboxymaltose infusions have been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14842561\">",
"    <span class=\"h3\">",
"     Iron isomaltoside",
"    </span>",
"    &nbsp;&mdash;&nbsp;This formulation is available only in Europe. It can be safely administered as a 15-minute infusion at a dose of 20",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Intramuscular iron",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mobilization",
"    of iron from intramuscular (IM) sites is slow. As a result, the rise in the hemoglobin concentration following IM administration is only slightly faster than that which occurs following the use of oral iron preparations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parenteral iron, when given by IM injection, is painful, stains the buttocks, has been associated with the development of gluteal sarcomas, and may be poorly absorbed [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/57,58\">",
"       57,58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients who have very brisk continuing bleeding (as with gastrointestinal angiodysplasia) are difficult to treat with an IM regimen because repeated courses of IM iron are painful, and the utilization of iron given via this route is variable.",
"     </li>",
"     <li>",
"      Patients with severe malabsorption",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      malnutrition may not be candidates for IM treatment if they have a markedly reduced muscle mass into which the iron preparation can be injected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For all of the above reasons, including the fact that IM administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    has not been shown to be safer or less toxic than the intravenous (IV) route, the most appropriate parenteral route is the IV one [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Prevention and treatment of adverse drug events",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following sections should be",
"    <strong>",
"     required reading",
"    </strong>",
"    for all clinicians contemplating the use of an intravenous iron preparation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14842743\">",
"    <span class=\"h3\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each of the available formulations of IV iron has been associated with reports of life-threatening adverse drug events (ADEs) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/39,60,61\">",
"     39,60,61",
"    </a>",
"    ]. While the Food and Drug Administration&rsquo;s Adverse Event Reporting System (AERS) has been employed for comparing such rates [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/39,62\">",
"     39,62",
"    </a>",
"    ], it is not possible to draw valid conclusions about comparative risks from the AERS database and other voluntarily submitted reports [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/60,63\">",
"     60,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There exist only a small number of randomized, prospective trials comparing the relative safety of the various intravenous iron preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/64\">",
"     64",
"    </a>",
"    ]: three have shown relatively equal safety for low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/31/41461?source=see_link\">",
"     iron sucrose",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/61,65,66\">",
"     61,65,66",
"    </a>",
"    ]; one has shown relatively equal safety for iron sucrose and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/53/31573?source=see_link\">",
"     ferric gluconate",
"    </a>",
"    complex [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/67\">",
"     67",
"    </a>",
"    ]; while one, in abstract form, has shown comparability of safety between iron sucrose and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/46/27364?source=see_link\">",
"     ferumoxytol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/68\">",
"     68",
"    </a>",
"    ]. While the preponderance of published evidence indicates that low molecular iron",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    preparations are associated with fewer adverse reactions than high molecular weight iron dextran preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/69\">",
"     69",
"    </a>",
"    ], it is not otherwise possible at this time to conclude that any one intravenous iron preparation is safer than another [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/30,60\">",
"     30,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with a history of drug allergy or multiple drug allergies may be at increased risk of anaphylactic-type reactions. It is an FDA recommendation that resuscitation equipment and personnel trained in the detection and treatment of anaphylactic-type reactions be readily available during administration of all",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/70\">",
"     70",
"    </a>",
"    ]. However, while we have seen such anaphylactic-type reactions to high molecular weight iron",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    , we have not seen such reactions after infusions of low molecular weight iron dextran preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/59\">",
"     59",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/46/27364?source=see_link\">",
"     ferumoxytol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/31/41461?source=see_link\">",
"     iron sucrose",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/53/31573?source=see_link\">",
"     ferric gluconate",
"    </a>",
"    complex.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic effects of IV iron include self-limiting fever, arthralgias, and myalgias, usually within 24 hours of infusions. These resolve without therapy but a small clinical benefit is obtained from the use of nonsteroidal anti-inflammatory agents.",
"     </li>",
"     <li>",
"      A flare of arthritis in patients with inflammatory arthritis, such as rheumatoid arthritis, commonly occurs. This can usually be abated by the use of 125 mg of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      immediately before the iron infusion and 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      for four days thereafter. The cause of these reactions is unknown as tryptase levels, a marker of mast cell degranulation, have been normal following these reactions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=see_link&amp;anchor=H14#H14\">",
"       \"Allergic reactions to vaccines\", section on 'Dextran'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/27/442?source=see_link&amp;anchor=H28#H28\">",
"       \"Perioperative anaphylaxis: Evaluation and prevention of recurrent reactions\", section on 'Colloids'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Approximately 0.5 to 1 percent of patients may complain of arthralgias, myalgias, or flushing",
"      <strong>",
"       without",
"      </strong>",
"      associated hypotension, tachypnea, tachycardia, wheezing, stridor, or periorbital edema [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/30,59\">",
"       30,59",
"      </a>",
"      ]. After symptoms abate, rechallenge is appropriate and symptoms rarely recur. The empiric use of steroids prior to rechallenge may be beneficial, but is untested. In the rare patient who reacts in this manner twice, the IV formulation should be changed. No intervention for these complaints is necessary. Specifically, the use of antihistamines for prevention or treatment is inappropriate. (See",
"      <a class=\"local\" href=\"#H14842780\">",
"       'Need for premedication'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14842780\">",
"    <span class=\"h3\">",
"     Need for premedication",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reluctance to use intravenous iron is at least in part due to misunderstanding and misinterpretation of the clinical nature of adverse events with IV iron. As an example, myalgias, when they include chest and back discomfort, are mistakenly described as anaphylaxis, prompting unnecessary interventions with antihistamines and pressors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/59\">",
"     59",
"    </a>",
"    ]. Accordingly, we employ the following guidelines in patients about to receive intravenous iron preparations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is published evidence suggesting that the majority of reactions attributed to IV iron are actually due to premedication with antihistamines, particularly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/71\">",
"       71",
"      </a>",
"      ]. Such use of antihistamines can cause hypotension, somnolence, flushing, and supraventricular tachycardia, prompting inappropriate intervention with pressor agents and the conversion of a minor reaction to a severe one. Accordingly, the use of antihistamines for prevention or treatment of these reactions is inappropriate.",
"     </li>",
"     <li>",
"      Those with asthma or more than one drug allergy are more likely to experience a minor infusion reaction. We routinely premedicate these patients with 125 mg of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      . This recommendation applies to all of the intravenous iron formulations.",
"     </li>",
"     <li>",
"      In the absence of a history of asthma or more than one drug allergy, we strongly recommend that premedication not be given.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the above tenets are followed and the use of high molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    is avoided, serious adverse events with IV iron are extremely rare, with an estimated frequency of less than 1:200,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Calculation of the dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;In selecting the dose of parenteral iron required, one calculates the iron deficit based upon the fact that 1 g of hemoglobin contains 3.3 mg of elemental iron (",
"    <a class=\"graphic graphic_table graphicRef54677 \" href=\"UTD.htm?34/55/35708\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Iron dextran'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Correction of anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assume, for example, that a 60 kg woman with a hemoglobin concentration of 8",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    due to iron deficiency needs parenteral iron replacement, which will be given intravenously in the form of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/31/41461?source=see_link\">",
"     iron sucrose",
"    </a>",
"    (20 mg",
"    <span class=\"nowrap\">",
"     iron/mL).",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      normal blood volume is approximately 65",
"      <span class=\"nowrap\">",
"       mL/kg.",
"      </span>",
"      Thus, her total blood volume is approximately 3900 mL or 39 deciliters (65",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      x 60 kg).",
"     </li>",
"     <li>",
"      A normal hemoglobin concentration would be 14",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      Thus, her hemoglobin deficit is 6",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      with a total deficit of 234 g (6",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      x 39 dL).",
"     </li>",
"     <li>",
"      Each gram of hemoglobin contains 3.3 mg of iron. Thus, her total red cell iron deficit is 772 mg (234 g of hemoglobin x 3.3 mg Fe per gram of hemoglobin).",
"     </li>",
"     <li>",
"      At an iron concentration of 20",
"      <span class=\"nowrap\">",
"       mg/mL,",
"      </span>",
"      this would require a total of 38.6 mL of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/31/41461?source=see_link\">",
"       iron sucrose",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      In preparing to infuse this or any other amount of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/31/41461?source=see_link\">",
"       iron sucrose",
"      </a>",
"      , the product information sheet, as well as institutional guidelines, should be consulted for the need for a test dose, proper dilution, rate of infusion, and maximal allowable dose per infusion.",
"      <br/>",
"      <br/>",
"      However, in that there is no evidence that doses larger than 1000 mg are clinically useful, it has been our policy to routinely administer a fixed 1000 mg dose over one hour to iron deficient patients receiving intravenous low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/46/21222?source=see_link\">",
"       iron dextran",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Repletion of iron stores",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issue of whether to replete iron stores in the patient with iron deficiency anemia is discussed above. Iron stores in most normal men and women are in the range of 10 and 5",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    respectively. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Duration of treatment'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link&amp;anchor=H13#H13\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\", section on 'Normal body iron content'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     BLOOD TRANSFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the patient who is hemodynamically unstable because of active bleeding,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    who shows evidence for end-organ ischemia secondary to severe iron deficiency anemia, packed red blood cell transfusion can be life saving. Each unit of packed cells with a volume of 300 mL contains approximately 200 mL of red cells and 200 mg of iron in the form of hemoglobin heme. Transfusion of one such unit to an adult will raise the hematocrit by roughly 3 percentage points (and the hemoglobin by approximately 1",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    unless there is continued bleeding.",
"   </p>",
"   <p>",
"    While blood transfusion therapy should be individualized, transfusion is not recommended in hemodynamically stable patients without end-organ ischemia. This subject is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=see_link\">",
"     \"Indications for red cell transfusion in the adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21263646\">",
"    <span class=\"h1\">",
"     TREATMENT OF FATIGUE IN NONANEMIC SUBJECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized, double-blind study evaluated the efficacy and safety of intravenous iron (cumulative dose: 800 mg of iron as iron (III)-hydroxide sucrose given in four infusions over a two-week period) versus placebo (0.9 percent saline) for the treatment of fatigue in 90 nonanemic (hemoglobin &ge;12.0",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    premenopausal women with serum ferritin levels &le;50",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    Results included [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant improvement in the fatigue score at six weeks, as evaluated by the Brief Fatigue Inventory questionnaire, was noted only in the subgroup of women with serum ferritins &le;15",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (82 percent with intravenous iron versus 47 percent of those treated with placebo).",
"     </li>",
"     <li>",
"      Treatment with intravenous iron significantly increased serum ferritin levels and transferrin saturation, but did not increase hemoglobin values. Drug-associated adverse events were observed in 21 percent of those treated with intravenous iron versus 7 percent in the placebo-treated group; none of these events was serious.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The iron in the above-noted study was given intravenously. However, other studies have shown that iron given orally can also improve fatigue in similar patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/73-76\">",
"     73-76",
"    </a>",
"    ], can improve exercise capacity in nonanemic adolescent runners with serum ferritin levels &lt;20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/77\">",
"     77",
"    </a>",
"    ], and can improve symptoms of fatigue in nonanemic female blood donors with serum ferritins &lt;10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/62/25578/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/53/19281?source=see_link\">",
"       \"Patient information: Anemia caused by low iron (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30484?source=see_link\">",
"       \"Patient information: Anemia caused by low iron (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Indications for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;While some patients with iron deficiency anemia will be asymptomatic, most will have symptoms. In any case, all should receive treatment. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Management overview'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Importantly, the cause for the iron deficiency should be sought in every patient, as the iron deficiency may be secondary to a treatable condition (eg, colonic malignancy)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    may make the patient liable for recurrence of the iron deficient state (eg, bleeding gastrointestinal telangiectasias in hereditary hemorrhagic telangiectasia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link&amp;anchor=H37#H37\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\", section on 'Search for source of blood and iron loss'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Initial treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because of ease of treatment, we recommend that patients with uncomplicated iron deficiency anemia be treated with oral iron rather than an intravenous (IV) iron formulation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      An appropriate daily dose for the treatment of iron deficiency in adults is in the range of 150 to 200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of elemental iron. While there is insufficient information to select one oral iron preparation over another, one 325 mg tablet of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37046?source=see_link\">",
"       ferrous sulfate",
"      </a>",
"      (iron content 65 mg) taken three times per day contains this amount of iron. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Oral iron therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have a history of intolerance to oral iron therapy, published evidence supports a larger and earlier role for intravenous iron. Intramuscular iron preparations should not be used for this purpose. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'General principles'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Intramuscular iron'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      High molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/46/21222?source=see_link\">",
"       iron dextran",
"      </a>",
"      preparations are associated with a considerably higher incidence of adverse events than are the low molecular weight preparations, and should not be employed. Otherwise, there is insufficient evidence for the superiority of one parenteral iron preparation over another (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/31/41461?source=see_link\">",
"       iron sucrose",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/53/31573?source=see_link\">",
"       ferric gluconate",
"      </a>",
"      complex, low molecular weight iron",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"       dextran",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/46/27364?source=see_link\">",
"       ferumoxytol",
"      </a>",
"      ) (",
"      <a class=\"graphic graphic_table graphicRef88303 \" href=\"UTD.htm?25/3/25661\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Available preparations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Prevention and treatment of adverse drug events'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Clinicians contemplating the use of intravenous iron preparations should be fully conversant with requirements for a test dose, rates of infusion, maximum allowed doses, and the need, if any, for premedication.",
"      </strong>",
"      <strong>",
"       The use of antihistamines for premedication or treatment of infusional side effects is to be avoided.",
"      </strong>",
"      (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Prevention and treatment of adverse drug events'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice of the length of treatment with iron depends upon whether the treatment goal is to restore hemoglobin levels to normal or to restore both hemoglobin levels and iron stores to normal. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Duration of treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Resistant or relapsed disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have failed to respond to oral or parenteral iron therapy, the cause for this failure should be determined and appropriate action undertaken. The table outlines the various steps that should be taken when this occurs (",
"      <a class=\"graphic graphic_table graphicRef56310 \" href=\"UTD.htm?21/33/22044\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Failure to respond to oral iron therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Relapsed disease (ie, recurrence of iron deficiency following successful treatment) is most often due to persistence or relapse of the initial inciting cause (eg, recurrent gastrointestinal or uterine bleeding), and should be treated appropriately.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/1\">",
"      Kruske SG, Ruben AR, Brewster DR. An iron treatment trial in an aboriginal community: improving non-adherence. J Paediatr Child Health 1999; 35:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/2\">",
"      Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007; 13:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/3\">",
"      Brugnara C, Chambers LA, Malynn E, et al. Red blood cell regeneration induced by subcutaneous recombinant erythropoietin: iron-deficient erythropoiesis in iron-replete subjects. Blood 1993; 81:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/4\">",
"      Auerbach M, Goodnough LT, Picard D, Maniatis A. The role of intravenous iron in anemia management and transfusion avoidance. Transfusion 2008; 48:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/5\">",
"      Macdougall IC. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous? Curr Med Res Opin 2010; 26:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/6\">",
"      Auerbach M, Liang AS, Glaspy J. Intravenous iron in chemotherapy and cancer-related anemia. Community Oncol 2012; 9:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/7\">",
"      Gafter-Gvili A, Rozen-Zvi B, Vidal L, et al. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia - systematic review and meta-analysis of randomised controlled trials. Acta Oncol 2013; 52:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/8\">",
"      Bregman DB, Morris D, Koch TA, et al. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am J Hematol 2013; 88:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/9\">",
"      Pasricha SR, Drakesmith H, Black J, et al. Control of iron deficiency anemia in low and middle-income countries. Blood 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/10\">",
"      Werner E, Kaltwasser JP, Ihm P. [Oral iron treatment: intestinal absorption and the influence of a meal (author's transl)]. Dtsch Med Wochenschr 1977; 102:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/11\">",
"      Crosby WH. The rationale for treating iron deficiency anemia. Arch Intern Med 1984; 144:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/12\">",
"      Alleyne M, Horne MK, Miller JL. Individualized treatment for iron-deficiency anemia in adults. Am J Med 2008; 121:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/13\">",
"      Boggs DR. Fate of a ferrous sulfate prescription. Am J Med 1987; 82:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/14\">",
"      Rimon E, Kagansky N, Kagansky M, et al. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians. Am J Med 2005; 118:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/15\">",
"      Cancelo-Hidalgo MJ, Castelo-Branco C, Palacios S, et al. Tolerability of different oral iron supplements: a systematic review. Curr Med Res Opin 2013; 29:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/16\">",
"      Hershko C, Hoffbrand AV, Keret D, et al. Role of autoimmune gastritis, Helicobacter pylori and celiac disease in refractory or unexplained iron deficiency anemia. Haematologica 2005; 90:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/17\">",
"      Reveiz L, Gyte GM, Cuervo LG, Casasbuenas A. Treatments for iron-deficiency anaemia in pregnancy. Cochrane Database Syst Rev 2011; :CD003094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/18\">",
"      Krayenbuehl PA, Battegay E, Breymann C, et al. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 2011; 118:3222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/19\">",
"      Bencaiova G, von Mandach U, Zimmermann R. Iron prophylaxis in pregnancy: intravenous route versus oral route. Eur J Obstet Gynecol Reprod Biol 2009; 144:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/20\">",
"      Bhandal N, Russell R. Intravenous versus oral iron therapy for postpartum anaemia. BJOG 2006; 113:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/21\">",
"      Al RA, Unlubilgin E, Kandemir O, et al. Intravenous versus oral iron for treatment of anemia in pregnancy: a randomized trial. Obstet Gynecol 2005; 106:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/22\">",
"      Bayoumeu F, Subiran-Buisset C, Baka NE, et al. Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route. Am J Obstet Gynecol 2002; 186:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/23\">",
"      Souza AI, Batista Filho M, Bresani CC, et al. Adherence and side effects of three ferrous sulfate treatment regimens on anemic pregnant women in clinical trials. Cad Saude Publica 2009; 25:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/24\">",
"      Auerbach M, Pappadakis JA, Bahrain H, et al. Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. Am J Hematol 2011; 86:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/25\">",
"      Khalafallah A, Dennis A, Bates J, et al. A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy. J Intern Med 2010; 268:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/26\">",
"      Kanakaraddi VP, Hoskatti CG, Nadig VS, et al. Comparative therapeutic study of T.D.I. and I.M. injections of iron dextran complex in anaemia. J Assoc Physicians India 1973; 21:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/27\">",
"      Khalafallah AA, Dennis AE, Ogden K, et al. Three-year follow-up of a randomised clinical trial of intravenous versus oral iron for anaemia in pregnancy. BMJ Open 2012; 2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/28\">",
"      Henry DH, Dahl NV, Auerbach MA. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. Am J Hematol 2012; 87:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/29\">",
"      Congdon EL, Westerlund A, Algarin CR, et al. Iron deficiency in infancy is associated with altered neural correlates of recognition memory at 10 years. J Pediatr 2012; 160:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/30\">",
"      Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program 2010; 2010:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/31\">",
"      Gasch&eacute; C, Dejaco C, Waldhoer T, et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial. Ann Intern Med 1997; 126:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/32\">",
"      Schreiber S, Howaldt S, Schnoor M, et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med 1996; 334:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/33\">",
"      Gomoll&oacute;n F, Gisbert JP. Intravenous iron in inflammatory bowel diseases. Curr Opin Gastroenterol 2013; 29:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/34\">",
"      Kim YT, Kim SW, Yoon BS, et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 2007; 105:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/35\">",
"      Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 2010; 116:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/36\">",
"      Steinmetz T, Tschechne B, Harlin O, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol 2013; 24:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/37\">",
"      Fishbane S, Ungureanu VD, Maesaka JK, et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996; 28:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/38\">",
"      Auerbach M, Rodgers GM. Intravenous iron. N Engl J Med 2007; 357:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/39\">",
"      Chertow GM, Mason PD, Vaage-Nilsen O, Ahlm&eacute;n J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/40\">",
"      Auerbach M, Winchester J, Wahab A, et al. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. Am J Kidney Dis 1998; 31:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/41\">",
"      Ondo WG. Intravenous iron dextran for severe refractory restless legs syndrome. Sleep Med 2010; 11:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/42\">",
"      Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 1999; 33:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/43\">",
"      Okam MM, Mandell E, Hevelone N, et al. Comparative rates of adverse events with different formulations of intravenous iron. Am J Hematol 2012; 87:E123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/44\">",
"      Miller HJ, Hu J, Valentine JK, Gable PS. Efficacy and tolerability of intravenous ferric gluconate in the treatment of iron deficiency anemia in patients without kidney disease. Arch Intern Med 2007; 167:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/45\">",
"      Folkert VW, Michael B, Agarwal R, et al. Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (&gt; or =250 mg) administration. Am J Kidney Dis 2003; 41:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/46\">",
"      Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000; 96:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/47\">",
"      Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis 2001; 38:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/48\">",
"      Rosner MH, Auerbach M. Ferumoxytol for the treatment of iron deficiency. Expert Rev Hematol 2011; 4:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/49\">",
"      Jahn MR, Andreasen HB, F&uuml;tterer S, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 2011; 78:480.",
"     </a>",
"    </li>",
"    <li>",
"     Auerbach M, Strauss W, Auerbach S, et al. Efficacy of total dose administration (TDI) of 1012 mg of ferumoxytol over 15 minutes for the treatment of iron deficient anemia. Presented at the 54th Annual meeting of the American Society of Hematology, Atlanta, GA, 2012. Abstract 3204.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/51\">",
"      Macdougall IC, Mclaughlin J, Fortin GS, et al. The FIRST head-to-head comparison study (ferumoxytol compared to iron sucrose trial) of the safety and efficacy of ferumoxytol with iron sucrose for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD) (poster abstract). J Am Soc Nephrol 2011; 22:LBPO3156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/52\">",
"      Van Wyck DB, Martens MG, Seid MH, et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol 2007; 110:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/53\">",
"      Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet 2008; 101:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/54\">",
"      Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008; 103:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/55\">",
"      Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361:2436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/56\">",
"      Van Wyck DB, Mangione A, Morrison J, et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009; 49:2719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/57\">",
"      Grasso P. Sarcoma after intramuscular iron injection. Br Med J 1973; 2:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/58\">",
"      Greenberg G. Sarcoma after intramuscular iron injection. Br Med J 1976; 1:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/59\">",
"      Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet 2007; 369:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/60\">",
"      Wysowski DK, Swartz L, Borders-Hemphill BV, et al. Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol 2010; 85:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/61\">",
"      Critchley J, Dundar Y. Adverse events associated with intravenous iron infusion (low-molecular-weight iron dextran and iron sucrose): a systematic review. Transfusion Alternatives in Transfusion Medicine 2007; 9:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/62\">",
"      Bailie GR. Comparison of rates of reported adverse events associated with i.v. iron products in the United States. Am J Health Syst Pharm 2012; 69:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/63\">",
"      Auerbach M, Kane RC. Caution in making inferences from FDA's Adverse Event Reporting System. Am J Health Syst Pharm 2012; 69:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/64\">",
"      Critchley J, Dundar Y. Adverse events associated with intravenous iron infusion (low-molecular-weight iron dextran and iron sucrose). Transfusion Alternatives inTransfusion Med 2007; 9:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/65\">",
"      Sav T, Tokgoz B, Sipahioglu MH, et al. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? Ren Fail 2007; 29:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/66\">",
"      Moniem KA, Bhandari S. Tolerability and efficacy of parenteral iron therapy in hemodialysis patients, a comparison of preparations. Transfus Altern Transfus Med 2007; 9:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/67\">",
"      Kosch M, Bahner U, Bettger H, et al. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant 2001; 16:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/68\">",
"      MacDougall IC, McGlaughlin J, Fortin GS, et al. FIRST: head-to-head comparison study (Ferumoxytol compared to IRon Sucrose Trial) of the safety and efficacy of ferumoxytol with iron sucrose for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD). Abstract. J Am Soc Nephrol 2011; 22:6B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/69\">",
"      Rodgers GM, Auerbach M, Cella D, et al. High-molecular weight iron dextran: a wolf in sheep's clothing? J Am Soc Nephrol 2008; 19:833.",
"     </a>",
"    </li>",
"    <li>",
"     Alert available on the United States FDA website at: file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm186899.htm (Accessed on October 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/71\">",
"      Barton JC, Barton EH, Bertoli LF, et al. Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. Am J Med 2000; 109:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/72\">",
"      Chertow GM, Mason PD, Vaage-Nilsen O, Ahlm&eacute;n J. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004; 19:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/73\">",
"      BEUTLER E, LARSH SE, GURNEY CW. Iron therapy in chronically fatigued, nonanemic women: a double-blind study. Ann Intern Med 1960; 52:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/74\">",
"      Patterson AJ, Brown WJ, Roberts DC. Dietary and supplement treatment of iron deficiency results in improvements in general health and fatigue in Australian women of childbearing age. J Am Coll Nutr 2001; 20:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/75\">",
"      Verdon F, Burnand B, Stubi CL, et al. Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. BMJ 2003; 326:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/76\">",
"      Vaucher P, Druais PL, Waldvogel S, Favrat B. Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: a randomized controlled trial. CMAJ 2012; 184:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/77\">",
"      Rowland TW, Deisroth MB, Green GM, Kelleher JF. The effect of iron therapy on the exercise capacity of nonanemic iron-deficient adolescent runners. Am J Dis Child 1988; 142:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/62/25578/abstract/78\">",
"      Pittori C, Buser A, Gasser UE, et al. A pilot iron substitution programme in female blood donors with iron deficiency without anaemia. Vox Sang 2011; 100:303.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7148 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-110.170.48.130-F96105F60D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_62_25578=[""].join("\n");
var outline_f24_62_25578=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MANAGEMENT OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Diagnostic issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Treatment issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ORAL IRON THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Choice of preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Dosing in older adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Expected response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Duration of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Failure to respond to oral iron therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PARENTERAL IRON THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1484809\">",
"      - Excessive continuing blood loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1484816\">",
"      - Inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1484823\">",
"      - Chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1484830\">",
"      - Use in cancer patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Available preparations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Iron dextran",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4372556\">",
"      Total dose infusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14842750\">",
"      Test dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Ferric gluconate complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14842757\">",
"      Test dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Iron sucrose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14842764\">",
"      Test dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Ferumoxytol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Ferric carboxymaltose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14842561\">",
"      - Iron isomaltoside",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Intramuscular iron",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Prevention and treatment of adverse drug events",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14842743\">",
"      - Overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14842780\">",
"      - Need for premedication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Calculation of the dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Correction of anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Repletion of iron stores",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      BLOOD TRANSFUSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21263646\">",
"      TREATMENT OF FATIGUE IN NONANEMIC SUBJECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Indications for treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Initial treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Resistant or relapsed disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7148\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7148|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/5/26715\" title=\"table 1\">",
"      Iron bioavailability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/33/22044\" title=\"table 2\">",
"      Failure to respond to iron",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\" title=\"table 3\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/3/25661\" title=\"table 4\">",
"      IV iron preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/55/35708\" title=\"table 5\">",
"      Parenteral iron dose",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=related_link\">",
"      Allergic reactions to vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=related_link\">",
"      Causes and diagnosis of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28005?source=related_link\">",
"      Diagnosis of iron deficiency in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=related_link\">",
"      Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12089?source=related_link\">",
"      Idiopathic pulmonary hemosiderosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1705?source=related_link\">",
"      Impact of anemia in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=related_link\">",
"      Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38949?source=related_link\">",
"      Iron deficiency in infants and young children: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/60/9160?source=related_link\">",
"      Maternal gastrointestinal tract adaptation to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24185?source=related_link\">",
"      Metaplastic (chronic) atrophic gastritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43113?source=related_link\">",
"      Nutrient deficiencies in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30484?source=related_link\">",
"      Patient information: Anemia caused by low iron (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/53/19281?source=related_link\">",
"      Patient information: Anemia caused by low iron (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/27/442?source=related_link\">",
"      Perioperative anaphylaxis: Evaluation and prevention of recurrent reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=related_link\">",
"      Regulation of iron balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=related_link\">",
"      Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=related_link\">",
"      Use of iron preparations in hemodialysis patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_62_25579="Workers comp reqs AMA Guide";
var content_f24_62_25579=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Workers' compensation requirements using the AMA 'Guides to the Evaluation of Permanent Impairment' or state-specific guidelines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Workers' compensation requirement",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of states",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific states",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AMA Guides 6th",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        AK, AZ, LA, MT, NM, OK, PA, RI, TN, WY",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AMA Guides 5th",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        CA, GA, HI, IA, KY, MA, NH, ND, RI, VT, WA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AMA Guides 4th",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        AL, AR, KS, ME, MD, SD, TX, WV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AMA Guides 3rd",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        CO, OR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        State-specific guideline",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        CT, DE, FL, ID,IL, IN, MI, MN, MS, MO, NE, NJ, NY, NC, OH, SC, UT, VA, WI",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: State-by-state Use of AMA Guides, updated June 2010. Available at: file://www.lexisnexis.com/community/workerscompensationlaw/blogs/freedownloads/archive/2009/06/14/free-download_3a00_-state_2d00_by_2d00_state-use-of-ama-guides-_2800_revised-7_2f00_1_2f00_2009_2900_.aspx.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_62_25579=[""].join("\n");
var outline_f24_62_25579=null;
var title_f24_62_25580="Secondary hypogonadism male";
var content_f24_62_25580=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F53205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F53205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of secondary hypogonadism in males",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Congenital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Isolated gonadotropin deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Kallmann's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        DAX 1 mutation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        GPR54 mutation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leptin or leptin receptor mutation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prader Willi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gonadotropin subunit mutation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Idiopathic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Deficiencies of multiple pituitary hormones",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pituicyte differentiation gene mutations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Acquired",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Suppression of gonadotropins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hyperprolactinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gonadal steroid administration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glucocorticoid treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Critical illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic systemic illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Opiates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Idiopathic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        GnRH analogs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Damage to gonadotroph cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Benign tumors and cysts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Malignant tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Infiltrative diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pituitary apoplexy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Surgery in the sellar region",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Radiation to the sellar region",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_62_25580=[""].join("\n");
var outline_f24_62_25580=null;
var title_f24_62_25581="Antidepressants PI";
var content_f24_62_25581=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F68418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F68418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    2007 Revised Medication Guide",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"2\">",
"       Medication Guide",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"2\">",
"       Antidepressant medicines, depression and other serious mental illnesses, and suicidal thoughts or actions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"2\">",
"       Read the Medication Guide that comes with you or your family member's antidepressant medicine. This Medication Guide is only about the risk of suicidal thoughts and actions with antidepressant medicines.",
"       <strong>",
"        Talk to your, or your family member's, healthcare provider about:",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" colspan=\"2\">",
"       &bull; All risks and benefits of treatment with antidepressant medicines",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" colspan=\"2\">",
"       &bull; All treatment choices for depression or other serious mental illness",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"2\">",
"       What is the most important information I should know about antidepressant medicines, depression and other serious mental illnesses, and suicidal thoughts or actions?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\" colspan=\"2\">",
"       1. Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults when the medicine is first started.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\" colspan=\"2\">",
"       2. Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a particularly high risk of having suicidal thoughts or actions. These include people who have (or have a family history of) bipolar illness (also called manic-depressive illness) or suicidal thoughts or actions.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\" colspan=\"2\">",
"       3. How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" colspan=\"2\">",
"       &bull; Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is first started or when the dose is changed.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" colspan=\"2\">",
"       &bull; Call the healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" colspan=\"2\">",
"       &bull; Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider between visits as needed, especially if you have concerns about symptoms.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\" colspan=\"2\">",
"       4. Call a healthcare provider right away if you or your family member has any of the following symptoms, especially if they are new, worse, or worry you:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       &bull; Thoughts about suicide or dying",
"      </td>",
"      <td>",
"       &bull; Trouble sleeping (insomnia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       &bull; Attempts to commit suicide",
"      </td>",
"      <td>",
"       &bull; New or worse irritability",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       &bull; New or worse depression",
"      </td>",
"      <td>",
"       &bull; Acting aggressive, being angry, or violent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       &bull; New or worse anxiety",
"      </td>",
"      <td>",
"       &bull; Acting on dangerous impulses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       &bull; Feeling very agitated or restless",
"      </td>",
"      <td>",
"       &bull; An extreme increase in activity and talking (mania)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       &bull; Panic attacks",
"      </td>",
"      <td>",
"       &bull; Other unusual changes in behavior or mood",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\" colspan=\"2\">",
"       5. What else do I need to know about antidepressant medicines?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" colspan=\"2\">",
"       &bull;",
"       <strong>",
"        Never stop an antidepressant medicine without first talking to a healthcare provider.",
"       </strong>",
"       Stopping an antidepressant medicine suddenly can cause other symptoms.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" colspan=\"2\">",
"       &bull;",
"       <strong>",
"        Antidepressants are medicines used to treat depression and other illnesses.",
"       </strong>",
"       It is important to discuss all the risks of treating depression and also the risks of not treating it. Patients and their families or other caregivers should discuss all treatment choices with the healthcare provider, not just the use of antidepressants.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" colspan=\"2\">",
"       &bull;",
"       <strong>",
"        Antidepressant medicines have other side effects.",
"       </strong>",
"       Talk to the healthcare provider about the side effects of the medicine prescribed for you or your family member.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" colspan=\"2\">",
"       &bull;",
"       <strong>",
"        Antidepressant medicines can interact with other medicines.",
"       </strong>",
"       Know all of the medicines that you or your family member takes. Keep a list of all medicines to show the healthcare provider. Do not start new medicines without first checking with your healthcare provider.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\" colspan=\"2\">",
"       &bull;",
"       <strong>",
"        Not all antidepressant medicines prescribed for children are FDA approved for use in children.",
"       </strong>",
"       Talk to your child's healthcare provider for more information.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This Medication Guide has been approved by the US Food and Drug Administration for all antidepressants.",
"    <br>",
"     Revised 2007.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Data from: US Food and Drug Administration, Center for Drug Evaluation and Research. Medication Guide for Antidepressant Drugs. Available at: www.fda.gov/Cder/drug/antidepressants (Accessed on August 1, 2008).",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_62_25581=[""].join("\n");
var outline_f24_62_25581=null;
var title_f24_62_25582="Auto PEEP effect";
var content_f24_62_25582=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Quantification of the auto-PEEP effect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 323px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During mechanical ventilation of the patient with airflow obstruction, expiratory flow is too slow to allow complete deflation of the lung to its normal relaxed state before the ventilator delivers another breath. Slow flow continues until interrupted by the next inflation. Upper panel: Alveolar pressure remains positive at end exhalation (15 cmH2O) but is not measured by the ventilator manometer (0 cmH2O) located downstream from the site of increased airway resistance. Lower panel: Alveolar pressure at end-exhalation can be quantified by stopping flow transiently at the end of a set exhalation period, thereby allowing equilibration of pressures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from O'Quinn, R, Marini, JJ, Am Rev Respir Dis 1983; 128:319.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_62_25582=[""].join("\n");
var outline_f24_62_25582=null;
var title_f24_62_25583="Operative approach to the left cervical esophagus - positioning";
var content_f24_62_25583=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F55814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F55814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Operative approach to the left cervical esophagus - position and skin incision",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the skin incision in the left neck, as the preferred approach to the perforated cervical esophagus. The patient is positioned supine, with a support under the head and the back. The head is extended to enhance exposure of the esophagus. The incision is made medial to the left sternocleidomastoid muscle. If the perforation occurs in the right cervical esophagus, the approach is through the right side of the neck.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_62_25583=[""].join("\n");
var outline_f24_62_25583=null;
